cid	atc	pert_iname	pert_id	pert_count	cell_id_count	inst_id	cell_id	det_plate	det_well	pert_mfc_id	pert_dose	pert_dose_unit	pert_type	pert_time	pert_time_unit	cell_type	base_cell_id	precursor_cell_id	modification	sample_type	primary_site	subtype	original_growth_pattern	provider_catalog_id	original_source_vendor	donor_age	donor_sex	donor_ethnicity
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F01	A375	REP.A011_A375_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F02	A375	REP.A011_A375_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F03	A375	REP.A011_A375_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F04	A375	REP.A011_A375_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F05	A375	REP.A011_A375_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X1_B24:F06	A375	REP.A011_A375_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F01	A375	REP.A011_A375_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F02	A375	REP.A011_A375_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F03	A375	REP.A011_A375_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F04	A375	REP.A011_A375_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F05	A375	REP.A011_A375_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X2_B24:F06	A375	REP.A011_A375_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F01	A375	REP.A011_A375_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F02	A375	REP.A011_A375_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F03	A375	REP.A011_A375_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F04	A375	REP.A011_A375_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F05	A375	REP.A011_A375_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_A375_24H_X3_B24:F06	A375	REP.A011_A375_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L01	A375	REP.A007_A375_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L02	A375	REP.A007_A375_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L03	A375	REP.A007_A375_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L04	A375	REP.A007_A375_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L05	A375	REP.A007_A375_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X1_B22:L06	A375	REP.A007_A375_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L01	A375	REP.A007_A375_24H_X2_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L02	A375	REP.A007_A375_24H_X2_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L03	A375	REP.A007_A375_24H_X2_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L04	A375	REP.A007_A375_24H_X2_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L05	A375	REP.A007_A375_24H_X2_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X2_B22:L06	A375	REP.A007_A375_24H_X2_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L01	A375	REP.A007_A375_24H_X3_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L02	A375	REP.A007_A375_24H_X3_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L03	A375	REP.A007_A375_24H_X3_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L04	A375	REP.A007_A375_24H_X3_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L05	A375	REP.A007_A375_24H_X3_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_A375_24H_X3_B22:L06	A375	REP.A007_A375_24H_X3_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I13	A375	REP.A012_A375_24H_X1_B24	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I14	A375	REP.A012_A375_24H_X1_B24	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I15	A375	REP.A012_A375_24H_X1_B24	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I16	A375	REP.A012_A375_24H_X1_B24	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I17	A375	REP.A012_A375_24H_X1_B24	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X1_B24:I18	A375	REP.A012_A375_24H_X1_B24	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I13	A375	REP.A012_A375_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I14	A375	REP.A012_A375_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I15	A375	REP.A012_A375_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I16	A375	REP.A012_A375_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I17	A375	REP.A012_A375_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X2_B22:I18	A375	REP.A012_A375_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I13	A375	REP.A012_A375_24H_X3_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I14	A375	REP.A012_A375_24H_X3_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I15	A375	REP.A012_A375_24H_X3_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I16	A375	REP.A012_A375_24H_X3_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I17	A375	REP.A012_A375_24H_X3_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_A375_24H_X3_B22:I18	A375	REP.A012_A375_24H_X3_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C13	A375	REP.A017_A375_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C14	A375	REP.A017_A375_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C15	A375	REP.A017_A375_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C16	A375	REP.A017_A375_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C17	A375	REP.A017_A375_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C18	A375	REP.A017_A375_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C13	A375	REP.A017_A375_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C14	A375	REP.A017_A375_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C15	A375	REP.A017_A375_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C16	A375	REP.A017_A375_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C17	A375	REP.A017_A375_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C18	A375	REP.A017_A375_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C14	A375	REP.A017_A375_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C15	A375	REP.A017_A375_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C16	A375	REP.A017_A375_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C17	A375	REP.A017_A375_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C18	A375	REP.A017_A375_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C13	A375	REP.A017_A375_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C14	A375	REP.A017_A375_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C15	A375	REP.A017_A375_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C16	A375	REP.A017_A375_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C17	A375	REP.A017_A375_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X1_B23:C18	A375	REP.A017_A375_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C13	A375	REP.A017_A375_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C14	A375	REP.A017_A375_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C15	A375	REP.A017_A375_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C16	A375	REP.A017_A375_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C17	A375	REP.A017_A375_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X2_B23:C18	A375	REP.A017_A375_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C14	A375	REP.A017_A375_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C15	A375	REP.A017_A375_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C16	A375	REP.A017_A375_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C17	A375	REP.A017_A375_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_A375_24H_X3_B23:C18	A375	REP.A017_A375_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I19	A375	REP.A007_A375_24H_X1_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I20	A375	REP.A007_A375_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I21	A375	REP.A007_A375_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I22	A375	REP.A007_A375_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I23	A375	REP.A007_A375_24H_X1_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X1_B22:I24	A375	REP.A007_A375_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I19	A375	REP.A007_A375_24H_X2_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I20	A375	REP.A007_A375_24H_X2_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I21	A375	REP.A007_A375_24H_X2_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I22	A375	REP.A007_A375_24H_X2_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I23	A375	REP.A007_A375_24H_X2_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X2_B22:I24	A375	REP.A007_A375_24H_X2_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I19	A375	REP.A007_A375_24H_X3_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I20	A375	REP.A007_A375_24H_X3_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I21	A375	REP.A007_A375_24H_X3_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I22	A375	REP.A007_A375_24H_X3_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I23	A375	REP.A007_A375_24H_X3_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_A375_24H_X3_B22:I24	A375	REP.A007_A375_24H_X3_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N01	A375	REP.A014_A375_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N02	A375	REP.A014_A375_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N03	A375	REP.A014_A375_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N04	A375	REP.A014_A375_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N05	A375	REP.A014_A375_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X1_B23:N06	A375	REP.A014_A375_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N01	A375	REP.A014_A375_24H_X2.A2_B25	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N02	A375	REP.A014_A375_24H_X2.A2_B25	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N03	A375	REP.A014_A375_24H_X2.A2_B25	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N04	A375	REP.A014_A375_24H_X2.A2_B25	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N05	A375	REP.A014_A375_24H_X2.A2_B25	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X2.A2_B25:N06	A375	REP.A014_A375_24H_X2.A2_B25	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N01	A375	REP.A014_A375_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N02	A375	REP.A014_A375_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N03	A375	REP.A014_A375_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N04	A375	REP.A014_A375_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N05	A375	REP.A014_A375_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_A375_24H_X3_B23:N06	A375	REP.A014_A375_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A13	A375	REP.A003_A375_24H_X1_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A14	A375	REP.A003_A375_24H_X1_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A15	A375	REP.A003_A375_24H_X1_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A16	A375	REP.A003_A375_24H_X1_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A17	A375	REP.A003_A375_24H_X1_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X1_B22:A18	A375	REP.A003_A375_24H_X1_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A13	A375	REP.A003_A375_24H_X2_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A14	A375	REP.A003_A375_24H_X2_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A15	A375	REP.A003_A375_24H_X2_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A16	A375	REP.A003_A375_24H_X2_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A17	A375	REP.A003_A375_24H_X2_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X2_B22:A18	A375	REP.A003_A375_24H_X2_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A13	A375	REP.A003_A375_24H_X3_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A14	A375	REP.A003_A375_24H_X3_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A15	A375	REP.A003_A375_24H_X3_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A16	A375	REP.A003_A375_24H_X3_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A17	A375	REP.A003_A375_24H_X3_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_A375_24H_X3_B22:A18	A375	REP.A003_A375_24H_X3_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H13	A375	REP.A016_A375_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H14	A375	REP.A016_A375_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H15	A375	REP.A016_A375_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H16	A375	REP.A016_A375_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H17	A375	REP.A016_A375_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X1_B23:H18	A375	REP.A016_A375_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H13	A375	REP.A016_A375_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H14	A375	REP.A016_A375_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H15	A375	REP.A016_A375_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H16	A375	REP.A016_A375_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H17	A375	REP.A016_A375_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X2_B23:H18	A375	REP.A016_A375_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H13	A375	REP.A016_A375_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H14	A375	REP.A016_A375_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H15	A375	REP.A016_A375_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H16	A375	REP.A016_A375_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H17	A375	REP.A016_A375_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_A375_24H_X3_B23:H18	A375	REP.A016_A375_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E01	A375	REP.A013_A375_24H_X1_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E02	A375	REP.A013_A375_24H_X1_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E03	A375	REP.A013_A375_24H_X1_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E04	A375	REP.A013_A375_24H_X1_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E05	A375	REP.A013_A375_24H_X1_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X1_B24:E06	A375	REP.A013_A375_24H_X1_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E01	A375	REP.A013_A375_24H_X2_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E02	A375	REP.A013_A375_24H_X2_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E03	A375	REP.A013_A375_24H_X2_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E04	A375	REP.A013_A375_24H_X2_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E05	A375	REP.A013_A375_24H_X2_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X2_B24:E06	A375	REP.A013_A375_24H_X2_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E01	A375	REP.A013_A375_24H_X3_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E02	A375	REP.A013_A375_24H_X3_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E03	A375	REP.A013_A375_24H_X3_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E04	A375	REP.A013_A375_24H_X3_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E05	A375	REP.A013_A375_24H_X3_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_A375_24H_X3_B24:E06	A375	REP.A013_A375_24H_X3_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X1_B22:N20	A375	REP.A004_A375_24H_X1_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X1_B22:N21	A375	REP.A004_A375_24H_X1_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X1_B22:N22	A375	REP.A004_A375_24H_X1_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X1_B22:N23	A375	REP.A004_A375_24H_X1_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X1_B22:N24	A375	REP.A004_A375_24H_X1_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N19	A375	REP.A004_A375_24H_X2_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N20	A375	REP.A004_A375_24H_X2_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N21	A375	REP.A004_A375_24H_X2_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N22	A375	REP.A004_A375_24H_X2_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N23	A375	REP.A004_A375_24H_X2_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X2_B22:N24	A375	REP.A004_A375_24H_X2_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N19	A375	REP.A004_A375_24H_X3_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N20	A375	REP.A004_A375_24H_X3_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N21	A375	REP.A004_A375_24H_X3_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N22	A375	REP.A004_A375_24H_X3_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N23	A375	REP.A004_A375_24H_X3_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_A375_24H_X3_B22:N24	A375	REP.A004_A375_24H_X3_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C07	A375	REP.A004_A375_24H_X1_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C08	A375	REP.A004_A375_24H_X1_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C09	A375	REP.A004_A375_24H_X1_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C10	A375	REP.A004_A375_24H_X1_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C11	A375	REP.A004_A375_24H_X1_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X1_B22:C12	A375	REP.A004_A375_24H_X1_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X2_B22:C07	A375	REP.A004_A375_24H_X2_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X2_B22:C09	A375	REP.A004_A375_24H_X2_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X2_B22:C10	A375	REP.A004_A375_24H_X2_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X2_B22:C11	A375	REP.A004_A375_24H_X2_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X2_B22:C12	A375	REP.A004_A375_24H_X2_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C07	A375	REP.A004_A375_24H_X3_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C08	A375	REP.A004_A375_24H_X3_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C09	A375	REP.A004_A375_24H_X3_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C10	A375	REP.A004_A375_24H_X3_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C11	A375	REP.A004_A375_24H_X3_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_A375_24H_X3_B22:C12	A375	REP.A004_A375_24H_X3_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I13	A375	REP.A017_A375_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I14	A375	REP.A017_A375_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I15	A375	REP.A017_A375_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I16	A375	REP.A017_A375_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I17	A375	REP.A017_A375_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X1_B23:I18	A375	REP.A017_A375_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I13	A375	REP.A017_A375_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I14	A375	REP.A017_A375_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I15	A375	REP.A017_A375_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I16	A375	REP.A017_A375_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I17	A375	REP.A017_A375_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X2_B23:I18	A375	REP.A017_A375_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I13	A375	REP.A017_A375_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I14	A375	REP.A017_A375_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I15	A375	REP.A017_A375_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I16	A375	REP.A017_A375_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I17	A375	REP.A017_A375_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_A375_24H_X3_B23:I18	A375	REP.A017_A375_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M07	A375	REP.A011_A375_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M08	A375	REP.A011_A375_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M09	A375	REP.A011_A375_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M10	A375	REP.A011_A375_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M11	A375	REP.A011_A375_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X1_B24:M12	A375	REP.A011_A375_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X2_B24:M07	A375	REP.A011_A375_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X2_B24:M08	A375	REP.A011_A375_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X2_B24:M09	A375	REP.A011_A375_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X2_B24:M10	A375	REP.A011_A375_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X2_B24:M11	A375	REP.A011_A375_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M07	A375	REP.A011_A375_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M08	A375	REP.A011_A375_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M09	A375	REP.A011_A375_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M10	A375	REP.A011_A375_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M11	A375	REP.A011_A375_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_A375_24H_X3_B24:M12	A375	REP.A011_A375_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P19	A375	REP.A008_A375_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P20	A375	REP.A008_A375_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P21	A375	REP.A008_A375_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P22	A375	REP.A008_A375_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P23	A375	REP.A008_A375_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X1_B24:P24	A375	REP.A008_A375_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P19	A375	REP.A008_A375_24H_X2_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P20	A375	REP.A008_A375_24H_X2_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P21	A375	REP.A008_A375_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P22	A375	REP.A008_A375_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P23	A375	REP.A008_A375_24H_X2_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X2_B24:P24	A375	REP.A008_A375_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X3_B24:P20	A375	REP.A008_A375_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X3_B24:P21	A375	REP.A008_A375_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X3_B24:P22	A375	REP.A008_A375_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_A375_24H_X3_B24:P23	A375	REP.A008_A375_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J07	A375	REP.A026_A375_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J08	A375	REP.A026_A375_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J09	A375	REP.A026_A375_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J10	A375	REP.A026_A375_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J11	A375	REP.A026_A375_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X1_B25:J12	A375	REP.A026_A375_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J07	A375	REP.A026_A375_24H_X2_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J08	A375	REP.A026_A375_24H_X2_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J09	A375	REP.A026_A375_24H_X2_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J10	A375	REP.A026_A375_24H_X2_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J11	A375	REP.A026_A375_24H_X2_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X2_B25:J12	A375	REP.A026_A375_24H_X2_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J07	A375	REP.A026_A375_24H_X3_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J08	A375	REP.A026_A375_24H_X3_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J09	A375	REP.A026_A375_24H_X3_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J10	A375	REP.A026_A375_24H_X3_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J11	A375	REP.A026_A375_24H_X3_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_A375_24H_X3_B25:J12	A375	REP.A026_A375_24H_X3_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D13	A375	REP.A013_A375_24H_X1_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D14	A375	REP.A013_A375_24H_X1_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D15	A375	REP.A013_A375_24H_X1_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D16	A375	REP.A013_A375_24H_X1_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D17	A375	REP.A013_A375_24H_X1_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X1_B24:D18	A375	REP.A013_A375_24H_X1_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D13	A375	REP.A013_A375_24H_X2_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D14	A375	REP.A013_A375_24H_X2_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D15	A375	REP.A013_A375_24H_X2_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D16	A375	REP.A013_A375_24H_X2_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D17	A375	REP.A013_A375_24H_X2_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X2_B24:D18	A375	REP.A013_A375_24H_X2_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D13	A375	REP.A013_A375_24H_X3_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D14	A375	REP.A013_A375_24H_X3_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D15	A375	REP.A013_A375_24H_X3_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D16	A375	REP.A013_A375_24H_X3_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D17	A375	REP.A013_A375_24H_X3_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_A375_24H_X3_B24:D18	A375	REP.A013_A375_24H_X3_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L01	A375	REP.A013_A375_24H_X1_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L02	A375	REP.A013_A375_24H_X1_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L03	A375	REP.A013_A375_24H_X1_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L04	A375	REP.A013_A375_24H_X1_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L05	A375	REP.A013_A375_24H_X1_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X1_B24:L06	A375	REP.A013_A375_24H_X1_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L01	A375	REP.A013_A375_24H_X2_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L02	A375	REP.A013_A375_24H_X2_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L03	A375	REP.A013_A375_24H_X2_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L04	A375	REP.A013_A375_24H_X2_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L05	A375	REP.A013_A375_24H_X2_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X2_B24:L06	A375	REP.A013_A375_24H_X2_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L01	A375	REP.A013_A375_24H_X3_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L02	A375	REP.A013_A375_24H_X3_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L03	A375	REP.A013_A375_24H_X3_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L04	A375	REP.A013_A375_24H_X3_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L05	A375	REP.A013_A375_24H_X3_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_A375_24H_X3_B24:L06	A375	REP.A013_A375_24H_X3_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I01	A375	REP.A023_A375_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I02	A375	REP.A023_A375_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I03	A375	REP.A023_A375_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I04	A375	REP.A023_A375_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I05	A375	REP.A023_A375_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X1_B23:I06	A375	REP.A023_A375_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I01	A375	REP.A023_A375_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I02	A375	REP.A023_A375_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I03	A375	REP.A023_A375_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I04	A375	REP.A023_A375_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I05	A375	REP.A023_A375_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X2_B23:I06	A375	REP.A023_A375_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I01	A375	REP.A023_A375_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I02	A375	REP.A023_A375_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I03	A375	REP.A023_A375_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I04	A375	REP.A023_A375_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I05	A375	REP.A023_A375_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_A375_24H_X3_B23:I06	A375	REP.A023_A375_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N07	A375	LJP008_A375_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N08	A375	LJP008_A375_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N09	A375	LJP008_A375_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N10	A375	LJP008_A375_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N11	A375	LJP008_A375_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X1_B20:N12	A375	LJP008_A375_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N07	A375	LJP008_A375_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N08	A375	LJP008_A375_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N09	A375	LJP008_A375_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N10	A375	LJP008_A375_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N11	A375	LJP008_A375_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X2_B20:N12	A375	LJP008_A375_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N07	A375	LJP008_A375_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N08	A375	LJP008_A375_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N09	A375	LJP008_A375_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N10	A375	LJP008_A375_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N11	A375	LJP008_A375_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A375_24H_X3_B20:N12	A375	LJP008_A375_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G07	A375	REP.A022_A375_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G08	A375	REP.A022_A375_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G09	A375	REP.A022_A375_24H_X1_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G10	A375	REP.A022_A375_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G11	A375	REP.A022_A375_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X1_B23:G12	A375	REP.A022_A375_24H_X1_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G07	A375	REP.A022_A375_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G08	A375	REP.A022_A375_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G09	A375	REP.A022_A375_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G10	A375	REP.A022_A375_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G11	A375	REP.A022_A375_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X2_B23:G12	A375	REP.A022_A375_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G07	A375	REP.A022_A375_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G08	A375	REP.A022_A375_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G09	A375	REP.A022_A375_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G10	A375	REP.A022_A375_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G11	A375	REP.A022_A375_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_A375_24H_X3_B23:G12	A375	REP.A022_A375_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A19	A375	REP.A004_A375_24H_X1_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A20	A375	REP.A004_A375_24H_X1_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A21	A375	REP.A004_A375_24H_X1_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A22	A375	REP.A004_A375_24H_X1_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A23	A375	REP.A004_A375_24H_X1_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X1_B22:A24	A375	REP.A004_A375_24H_X1_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A19	A375	REP.A004_A375_24H_X2_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A20	A375	REP.A004_A375_24H_X2_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A21	A375	REP.A004_A375_24H_X2_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A22	A375	REP.A004_A375_24H_X2_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A23	A375	REP.A004_A375_24H_X2_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X2_B22:A24	A375	REP.A004_A375_24H_X2_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A19	A375	REP.A004_A375_24H_X3_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A20	A375	REP.A004_A375_24H_X3_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A21	A375	REP.A004_A375_24H_X3_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A22	A375	REP.A004_A375_24H_X3_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A23	A375	REP.A004_A375_24H_X3_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_A375_24H_X3_B22:A24	A375	REP.A004_A375_24H_X3_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D07	A375	REP.A016_A375_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D08	A375	REP.A016_A375_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D09	A375	REP.A016_A375_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D10	A375	REP.A016_A375_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D11	A375	REP.A016_A375_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X1_B23:D12	A375	REP.A016_A375_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D07	A375	REP.A016_A375_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D08	A375	REP.A016_A375_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D09	A375	REP.A016_A375_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D10	A375	REP.A016_A375_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D11	A375	REP.A016_A375_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X2_B23:D12	A375	REP.A016_A375_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D07	A375	REP.A016_A375_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D08	A375	REP.A016_A375_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D09	A375	REP.A016_A375_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D10	A375	REP.A016_A375_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D11	A375	REP.A016_A375_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_A375_24H_X3_B23:D12	A375	REP.A016_A375_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O07	A375	REP.A010_A375_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O08	A375	REP.A010_A375_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O09	A375	REP.A010_A375_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O10	A375	REP.A010_A375_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O11	A375	REP.A010_A375_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X1_B24:O12	A375	REP.A010_A375_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O07	A375	REP.A010_A375_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O08	A375	REP.A010_A375_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O09	A375	REP.A010_A375_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O10	A375	REP.A010_A375_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O11	A375	REP.A010_A375_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X2_B24:O12	A375	REP.A010_A375_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O07	A375	REP.A010_A375_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O08	A375	REP.A010_A375_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O09	A375	REP.A010_A375_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O10	A375	REP.A010_A375_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O11	A375	REP.A010_A375_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_A375_24H_X3_B24:O12	A375	REP.A010_A375_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L13	A375	REP.A023_A375_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L14	A375	REP.A023_A375_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L15	A375	REP.A023_A375_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L16	A375	REP.A023_A375_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L17	A375	REP.A023_A375_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X1_B23:L18	A375	REP.A023_A375_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L13	A375	REP.A023_A375_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L14	A375	REP.A023_A375_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L15	A375	REP.A023_A375_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L16	A375	REP.A023_A375_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L17	A375	REP.A023_A375_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X2_B23:L18	A375	REP.A023_A375_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L13	A375	REP.A023_A375_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L14	A375	REP.A023_A375_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L15	A375	REP.A023_A375_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L16	A375	REP.A023_A375_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L17	A375	REP.A023_A375_24H_X3_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_A375_24H_X3_B23:L18	A375	REP.A023_A375_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F19	A375	REP.A013_A375_24H_X1_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F20	A375	REP.A013_A375_24H_X1_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F21	A375	REP.A013_A375_24H_X1_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F22	A375	REP.A013_A375_24H_X1_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F23	A375	REP.A013_A375_24H_X1_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X1_B24:F24	A375	REP.A013_A375_24H_X1_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X2_B24:F19	A375	REP.A013_A375_24H_X2_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X2_B24:F20	A375	REP.A013_A375_24H_X2_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X2_B24:F22	A375	REP.A013_A375_24H_X2_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X2_B24:F23	A375	REP.A013_A375_24H_X2_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X2_B24:F24	A375	REP.A013_A375_24H_X2_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F19	A375	REP.A013_A375_24H_X3_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F20	A375	REP.A013_A375_24H_X3_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F21	A375	REP.A013_A375_24H_X3_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F22	A375	REP.A013_A375_24H_X3_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F23	A375	REP.A013_A375_24H_X3_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_A375_24H_X3_B24:F24	A375	REP.A013_A375_24H_X3_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L01	A375	REP.A021_A375_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L02	A375	REP.A021_A375_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L03	A375	REP.A021_A375_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L04	A375	REP.A021_A375_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L05	A375	REP.A021_A375_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X1_B23:L06	A375	REP.A021_A375_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L01	A375	REP.A021_A375_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L02	A375	REP.A021_A375_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L03	A375	REP.A021_A375_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L04	A375	REP.A021_A375_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L05	A375	REP.A021_A375_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X2_B23:L06	A375	REP.A021_A375_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L01	A375	REP.A021_A375_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L02	A375	REP.A021_A375_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L03	A375	REP.A021_A375_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L04	A375	REP.A021_A375_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L05	A375	REP.A021_A375_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_A375_24H_X3_B23:L06	A375	REP.A021_A375_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N01	A375	REP.A026_A375_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N02	A375	REP.A026_A375_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N03	A375	REP.A026_A375_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N04	A375	REP.A026_A375_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N05	A375	REP.A026_A375_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X1_B25:N06	A375	REP.A026_A375_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N01	A375	REP.A026_A375_24H_X2_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N02	A375	REP.A026_A375_24H_X2_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N03	A375	REP.A026_A375_24H_X2_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N04	A375	REP.A026_A375_24H_X2_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N05	A375	REP.A026_A375_24H_X2_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X2_B25:N06	A375	REP.A026_A375_24H_X2_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N01	A375	REP.A026_A375_24H_X3_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N02	A375	REP.A026_A375_24H_X3_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N03	A375	REP.A026_A375_24H_X3_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N04	A375	REP.A026_A375_24H_X3_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N05	A375	REP.A026_A375_24H_X3_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_A375_24H_X3_B25:N06	A375	REP.A026_A375_24H_X3_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	A375	-666	-666	tumor	skin	malignant melanoma	adherent	CRL-1619	ATCC	54	F	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F01	HA1E	REP.A011_HA1E_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F02	HA1E	REP.A011_HA1E_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F03	HA1E	REP.A011_HA1E_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F04	HA1E	REP.A011_HA1E_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F05	HA1E	REP.A011_HA1E_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X1_B24:F06	HA1E	REP.A011_HA1E_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F01	HA1E	REP.A011_HA1E_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F02	HA1E	REP.A011_HA1E_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F03	HA1E	REP.A011_HA1E_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F04	HA1E	REP.A011_HA1E_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F05	HA1E	REP.A011_HA1E_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X2_B24:F06	HA1E	REP.A011_HA1E_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F01	HA1E	REP.A011_HA1E_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F02	HA1E	REP.A011_HA1E_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F03	HA1E	REP.A011_HA1E_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F04	HA1E	REP.A011_HA1E_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F05	HA1E	REP.A011_HA1E_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HA1E_24H_X3_B24:F06	HA1E	REP.A011_HA1E_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L01	HA1E	REP.A007_HA1E_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L02	HA1E	REP.A007_HA1E_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L03	HA1E	REP.A007_HA1E_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L04	HA1E	REP.A007_HA1E_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L05	HA1E	REP.A007_HA1E_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X1_B22:L06	HA1E	REP.A007_HA1E_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L01	HA1E	REP.A007_HA1E_24H_X2_B24	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L02	HA1E	REP.A007_HA1E_24H_X2_B24	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L03	HA1E	REP.A007_HA1E_24H_X2_B24	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L04	HA1E	REP.A007_HA1E_24H_X2_B24	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L05	HA1E	REP.A007_HA1E_24H_X2_B24	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X2_B24:L06	HA1E	REP.A007_HA1E_24H_X2_B24	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L01	HA1E	REP.A007_HA1E_24H_X3_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L02	HA1E	REP.A007_HA1E_24H_X3_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L03	HA1E	REP.A007_HA1E_24H_X3_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L04	HA1E	REP.A007_HA1E_24H_X3_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L05	HA1E	REP.A007_HA1E_24H_X3_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HA1E_24H_X3_B22:L06	HA1E	REP.A007_HA1E_24H_X3_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X1_B22:I14	HA1E	REP.A012_HA1E_24H_X1_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X1_B22:I15	HA1E	REP.A012_HA1E_24H_X1_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X1_B22:I16	HA1E	REP.A012_HA1E_24H_X1_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X1_B22:I17	HA1E	REP.A012_HA1E_24H_X1_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X1_B22:I18	HA1E	REP.A012_HA1E_24H_X1_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I13	HA1E	REP.A012_HA1E_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I14	HA1E	REP.A012_HA1E_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I15	HA1E	REP.A012_HA1E_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I16	HA1E	REP.A012_HA1E_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I17	HA1E	REP.A012_HA1E_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X2_B22:I18	HA1E	REP.A012_HA1E_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X3_B22:I14	HA1E	REP.A012_HA1E_24H_X3_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X3_B22:I15	HA1E	REP.A012_HA1E_24H_X3_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X3_B22:I16	HA1E	REP.A012_HA1E_24H_X3_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X3_B22:I17	HA1E	REP.A012_HA1E_24H_X3_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HA1E_24H_X3_B22:I18	HA1E	REP.A012_HA1E_24H_X3_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C13	HA1E	REP.A017_HA1E_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C14	HA1E	REP.A017_HA1E_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C15	HA1E	REP.A017_HA1E_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C16	HA1E	REP.A017_HA1E_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C17	HA1E	REP.A017_HA1E_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C18	HA1E	REP.A017_HA1E_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C13	HA1E	REP.A017_HA1E_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C14	HA1E	REP.A017_HA1E_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C15	HA1E	REP.A017_HA1E_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C16	HA1E	REP.A017_HA1E_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C17	HA1E	REP.A017_HA1E_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C18	HA1E	REP.A017_HA1E_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C13	HA1E	REP.A017_HA1E_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C14	HA1E	REP.A017_HA1E_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C15	HA1E	REP.A017_HA1E_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C16	HA1E	REP.A017_HA1E_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C17	HA1E	REP.A017_HA1E_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C18	HA1E	REP.A017_HA1E_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C13	HA1E	REP.A017_HA1E_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C14	HA1E	REP.A017_HA1E_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C15	HA1E	REP.A017_HA1E_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C16	HA1E	REP.A017_HA1E_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C17	HA1E	REP.A017_HA1E_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X1_B23:C18	HA1E	REP.A017_HA1E_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C13	HA1E	REP.A017_HA1E_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C14	HA1E	REP.A017_HA1E_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C15	HA1E	REP.A017_HA1E_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C16	HA1E	REP.A017_HA1E_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C17	HA1E	REP.A017_HA1E_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X2_B23:C18	HA1E	REP.A017_HA1E_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C13	HA1E	REP.A017_HA1E_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C14	HA1E	REP.A017_HA1E_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C15	HA1E	REP.A017_HA1E_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C16	HA1E	REP.A017_HA1E_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C17	HA1E	REP.A017_HA1E_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HA1E_24H_X3_B23:C18	HA1E	REP.A017_HA1E_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I19	HA1E	REP.A007_HA1E_24H_X1_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I20	HA1E	REP.A007_HA1E_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I21	HA1E	REP.A007_HA1E_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I22	HA1E	REP.A007_HA1E_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I23	HA1E	REP.A007_HA1E_24H_X1_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X1_B22:I24	HA1E	REP.A007_HA1E_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I19	HA1E	REP.A007_HA1E_24H_X2_B24	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I20	HA1E	REP.A007_HA1E_24H_X2_B24	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I21	HA1E	REP.A007_HA1E_24H_X2_B24	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I22	HA1E	REP.A007_HA1E_24H_X2_B24	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I23	HA1E	REP.A007_HA1E_24H_X2_B24	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X2_B24:I24	HA1E	REP.A007_HA1E_24H_X2_B24	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I19	HA1E	REP.A007_HA1E_24H_X3_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I20	HA1E	REP.A007_HA1E_24H_X3_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I21	HA1E	REP.A007_HA1E_24H_X3_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I22	HA1E	REP.A007_HA1E_24H_X3_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I23	HA1E	REP.A007_HA1E_24H_X3_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HA1E_24H_X3_B22:I24	HA1E	REP.A007_HA1E_24H_X3_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N01	HA1E	REP.A014_HA1E_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N02	HA1E	REP.A014_HA1E_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N03	HA1E	REP.A014_HA1E_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N04	HA1E	REP.A014_HA1E_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N05	HA1E	REP.A014_HA1E_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X1_B23:N06	HA1E	REP.A014_HA1E_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N01	HA1E	REP.A014_HA1E_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N02	HA1E	REP.A014_HA1E_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N03	HA1E	REP.A014_HA1E_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N04	HA1E	REP.A014_HA1E_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N05	HA1E	REP.A014_HA1E_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X2_B23:N06	HA1E	REP.A014_HA1E_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N01	HA1E	REP.A014_HA1E_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N02	HA1E	REP.A014_HA1E_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N03	HA1E	REP.A014_HA1E_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N04	HA1E	REP.A014_HA1E_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N05	HA1E	REP.A014_HA1E_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HA1E_24H_X3_B23:N06	HA1E	REP.A014_HA1E_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A13	HA1E	REP.A003_HA1E_24H_X1_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A14	HA1E	REP.A003_HA1E_24H_X1_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A15	HA1E	REP.A003_HA1E_24H_X1_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A16	HA1E	REP.A003_HA1E_24H_X1_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A17	HA1E	REP.A003_HA1E_24H_X1_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X1_B22:A18	HA1E	REP.A003_HA1E_24H_X1_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A13	HA1E	REP.A003_HA1E_24H_X2_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A14	HA1E	REP.A003_HA1E_24H_X2_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A15	HA1E	REP.A003_HA1E_24H_X2_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A16	HA1E	REP.A003_HA1E_24H_X2_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A17	HA1E	REP.A003_HA1E_24H_X2_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X2_B22:A18	HA1E	REP.A003_HA1E_24H_X2_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A13	HA1E	REP.A003_HA1E_24H_X3_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A14	HA1E	REP.A003_HA1E_24H_X3_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A15	HA1E	REP.A003_HA1E_24H_X3_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A16	HA1E	REP.A003_HA1E_24H_X3_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A17	HA1E	REP.A003_HA1E_24H_X3_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HA1E_24H_X3_B22:A18	HA1E	REP.A003_HA1E_24H_X3_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H13	HA1E	REP.A016_HA1E_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H14	HA1E	REP.A016_HA1E_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H15	HA1E	REP.A016_HA1E_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H16	HA1E	REP.A016_HA1E_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H17	HA1E	REP.A016_HA1E_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X1_B23:H18	HA1E	REP.A016_HA1E_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X2_B23:H14	HA1E	REP.A016_HA1E_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X2_B23:H15	HA1E	REP.A016_HA1E_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X2_B23:H16	HA1E	REP.A016_HA1E_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X2_B23:H17	HA1E	REP.A016_HA1E_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X2_B23:H18	HA1E	REP.A016_HA1E_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H13	HA1E	REP.A016_HA1E_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H14	HA1E	REP.A016_HA1E_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H15	HA1E	REP.A016_HA1E_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H16	HA1E	REP.A016_HA1E_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H17	HA1E	REP.A016_HA1E_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HA1E_24H_X3_B23:H18	HA1E	REP.A016_HA1E_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E01	HA1E	REP.A013_HA1E_24H_X1_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E02	HA1E	REP.A013_HA1E_24H_X1_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E03	HA1E	REP.A013_HA1E_24H_X1_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E04	HA1E	REP.A013_HA1E_24H_X1_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E05	HA1E	REP.A013_HA1E_24H_X1_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X1_B24:E06	HA1E	REP.A013_HA1E_24H_X1_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X2_B24:E02	HA1E	REP.A013_HA1E_24H_X2_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X2_B24:E03	HA1E	REP.A013_HA1E_24H_X2_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X2_B24:E04	HA1E	REP.A013_HA1E_24H_X2_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X2_B24:E05	HA1E	REP.A013_HA1E_24H_X2_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X2_B24:E06	HA1E	REP.A013_HA1E_24H_X2_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E01	HA1E	REP.A013_HA1E_24H_X3_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E02	HA1E	REP.A013_HA1E_24H_X3_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E03	HA1E	REP.A013_HA1E_24H_X3_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E04	HA1E	REP.A013_HA1E_24H_X3_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E05	HA1E	REP.A013_HA1E_24H_X3_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HA1E_24H_X3_B24:E06	HA1E	REP.A013_HA1E_24H_X3_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N19	HA1E	REP.A004_HA1E_24H_X1_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N20	HA1E	REP.A004_HA1E_24H_X1_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N21	HA1E	REP.A004_HA1E_24H_X1_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N22	HA1E	REP.A004_HA1E_24H_X1_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N23	HA1E	REP.A004_HA1E_24H_X1_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X1_B22:N24	HA1E	REP.A004_HA1E_24H_X1_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X2_B22:N19	HA1E	REP.A004_HA1E_24H_X2_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X2_B22:N20	HA1E	REP.A004_HA1E_24H_X2_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X2_B22:N21	HA1E	REP.A004_HA1E_24H_X2_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X2_B22:N22	HA1E	REP.A004_HA1E_24H_X2_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X2_B22:N24	HA1E	REP.A004_HA1E_24H_X2_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N19	HA1E	REP.A004_HA1E_24H_X3_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N20	HA1E	REP.A004_HA1E_24H_X3_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N21	HA1E	REP.A004_HA1E_24H_X3_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N22	HA1E	REP.A004_HA1E_24H_X3_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N23	HA1E	REP.A004_HA1E_24H_X3_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HA1E_24H_X3_B22:N24	HA1E	REP.A004_HA1E_24H_X3_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C07	HA1E	REP.A004_HA1E_24H_X1_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C08	HA1E	REP.A004_HA1E_24H_X1_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C09	HA1E	REP.A004_HA1E_24H_X1_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C10	HA1E	REP.A004_HA1E_24H_X1_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C11	HA1E	REP.A004_HA1E_24H_X1_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X1_B22:C12	HA1E	REP.A004_HA1E_24H_X1_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C07	HA1E	REP.A004_HA1E_24H_X2_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C08	HA1E	REP.A004_HA1E_24H_X2_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C09	HA1E	REP.A004_HA1E_24H_X2_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C10	HA1E	REP.A004_HA1E_24H_X2_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C11	HA1E	REP.A004_HA1E_24H_X2_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X2_B22:C12	HA1E	REP.A004_HA1E_24H_X2_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C07	HA1E	REP.A004_HA1E_24H_X3_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C08	HA1E	REP.A004_HA1E_24H_X3_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C09	HA1E	REP.A004_HA1E_24H_X3_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C10	HA1E	REP.A004_HA1E_24H_X3_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C11	HA1E	REP.A004_HA1E_24H_X3_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HA1E_24H_X3_B22:C12	HA1E	REP.A004_HA1E_24H_X3_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I13	HA1E	REP.A017_HA1E_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I14	HA1E	REP.A017_HA1E_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I15	HA1E	REP.A017_HA1E_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I16	HA1E	REP.A017_HA1E_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I17	HA1E	REP.A017_HA1E_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X1_B23:I18	HA1E	REP.A017_HA1E_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X2_B23:I13	HA1E	REP.A017_HA1E_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X2_B23:I14	HA1E	REP.A017_HA1E_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X2_B23:I16	HA1E	REP.A017_HA1E_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X2_B23:I17	HA1E	REP.A017_HA1E_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X2_B23:I18	HA1E	REP.A017_HA1E_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I13	HA1E	REP.A017_HA1E_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I14	HA1E	REP.A017_HA1E_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I15	HA1E	REP.A017_HA1E_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I16	HA1E	REP.A017_HA1E_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I17	HA1E	REP.A017_HA1E_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HA1E_24H_X3_B23:I18	HA1E	REP.A017_HA1E_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M07	HA1E	REP.A011_HA1E_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M08	HA1E	REP.A011_HA1E_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M09	HA1E	REP.A011_HA1E_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M10	HA1E	REP.A011_HA1E_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M11	HA1E	REP.A011_HA1E_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X1_B24:M12	HA1E	REP.A011_HA1E_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M07	HA1E	REP.A011_HA1E_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M08	HA1E	REP.A011_HA1E_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M09	HA1E	REP.A011_HA1E_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M10	HA1E	REP.A011_HA1E_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M11	HA1E	REP.A011_HA1E_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X2_B24:M12	HA1E	REP.A011_HA1E_24H_X2_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X3_B24:M07	HA1E	REP.A011_HA1E_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X3_B24:M08	HA1E	REP.A011_HA1E_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X3_B24:M09	HA1E	REP.A011_HA1E_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X3_B24:M10	HA1E	REP.A011_HA1E_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HA1E_24H_X3_B24:M11	HA1E	REP.A011_HA1E_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P19	HA1E	REP.A008_HA1E_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P20	HA1E	REP.A008_HA1E_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P21	HA1E	REP.A008_HA1E_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P22	HA1E	REP.A008_HA1E_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P23	HA1E	REP.A008_HA1E_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X1_B24:P24	HA1E	REP.A008_HA1E_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P19	HA1E	REP.A008_HA1E_24H_X2_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P20	HA1E	REP.A008_HA1E_24H_X2_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P21	HA1E	REP.A008_HA1E_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P22	HA1E	REP.A008_HA1E_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P23	HA1E	REP.A008_HA1E_24H_X2_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X2_B24:P24	HA1E	REP.A008_HA1E_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P19	HA1E	REP.A008_HA1E_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P20	HA1E	REP.A008_HA1E_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P21	HA1E	REP.A008_HA1E_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P22	HA1E	REP.A008_HA1E_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P23	HA1E	REP.A008_HA1E_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HA1E_24H_X3_B24:P24	HA1E	REP.A008_HA1E_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J07	HA1E	REP.A026_HA1E_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J08	HA1E	REP.A026_HA1E_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J09	HA1E	REP.A026_HA1E_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J10	HA1E	REP.A026_HA1E_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J11	HA1E	REP.A026_HA1E_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X1_B25:J12	HA1E	REP.A026_HA1E_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J07	HA1E	REP.A026_HA1E_24H_X2_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J08	HA1E	REP.A026_HA1E_24H_X2_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J09	HA1E	REP.A026_HA1E_24H_X2_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J10	HA1E	REP.A026_HA1E_24H_X2_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J11	HA1E	REP.A026_HA1E_24H_X2_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X2_B25:J12	HA1E	REP.A026_HA1E_24H_X2_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J07	HA1E	REP.A026_HA1E_24H_X3_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J08	HA1E	REP.A026_HA1E_24H_X3_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J09	HA1E	REP.A026_HA1E_24H_X3_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J10	HA1E	REP.A026_HA1E_24H_X3_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J11	HA1E	REP.A026_HA1E_24H_X3_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HA1E_24H_X3_B25:J12	HA1E	REP.A026_HA1E_24H_X3_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D13	HA1E	REP.A013_HA1E_24H_X1_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D14	HA1E	REP.A013_HA1E_24H_X1_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D15	HA1E	REP.A013_HA1E_24H_X1_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D16	HA1E	REP.A013_HA1E_24H_X1_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D17	HA1E	REP.A013_HA1E_24H_X1_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X1_B24:D18	HA1E	REP.A013_HA1E_24H_X1_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D13	HA1E	REP.A013_HA1E_24H_X2_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D14	HA1E	REP.A013_HA1E_24H_X2_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D15	HA1E	REP.A013_HA1E_24H_X2_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D16	HA1E	REP.A013_HA1E_24H_X2_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D17	HA1E	REP.A013_HA1E_24H_X2_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X2_B24:D18	HA1E	REP.A013_HA1E_24H_X2_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D13	HA1E	REP.A013_HA1E_24H_X3_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D14	HA1E	REP.A013_HA1E_24H_X3_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D15	HA1E	REP.A013_HA1E_24H_X3_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D16	HA1E	REP.A013_HA1E_24H_X3_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D17	HA1E	REP.A013_HA1E_24H_X3_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HA1E_24H_X3_B24:D18	HA1E	REP.A013_HA1E_24H_X3_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L01	HA1E	REP.A013_HA1E_24H_X1_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L02	HA1E	REP.A013_HA1E_24H_X1_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L03	HA1E	REP.A013_HA1E_24H_X1_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L04	HA1E	REP.A013_HA1E_24H_X1_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L05	HA1E	REP.A013_HA1E_24H_X1_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X1_B24:L06	HA1E	REP.A013_HA1E_24H_X1_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L01	HA1E	REP.A013_HA1E_24H_X2_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L02	HA1E	REP.A013_HA1E_24H_X2_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L03	HA1E	REP.A013_HA1E_24H_X2_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L04	HA1E	REP.A013_HA1E_24H_X2_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L05	HA1E	REP.A013_HA1E_24H_X2_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X2_B24:L06	HA1E	REP.A013_HA1E_24H_X2_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L01	HA1E	REP.A013_HA1E_24H_X3_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L02	HA1E	REP.A013_HA1E_24H_X3_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L03	HA1E	REP.A013_HA1E_24H_X3_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L04	HA1E	REP.A013_HA1E_24H_X3_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L05	HA1E	REP.A013_HA1E_24H_X3_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HA1E_24H_X3_B24:L06	HA1E	REP.A013_HA1E_24H_X3_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I01	HA1E	REP.A023_HA1E_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I02	HA1E	REP.A023_HA1E_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I03	HA1E	REP.A023_HA1E_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I04	HA1E	REP.A023_HA1E_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I05	HA1E	REP.A023_HA1E_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X1_B23:I06	HA1E	REP.A023_HA1E_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I01	HA1E	REP.A023_HA1E_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I02	HA1E	REP.A023_HA1E_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I03	HA1E	REP.A023_HA1E_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I04	HA1E	REP.A023_HA1E_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I05	HA1E	REP.A023_HA1E_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X2_B23:I06	HA1E	REP.A023_HA1E_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I01	HA1E	REP.A023_HA1E_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I02	HA1E	REP.A023_HA1E_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I03	HA1E	REP.A023_HA1E_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I04	HA1E	REP.A023_HA1E_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I05	HA1E	REP.A023_HA1E_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HA1E_24H_X3_B23:I06	HA1E	REP.A023_HA1E_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N07	HA1E	LJP008_HA1E_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N08	HA1E	LJP008_HA1E_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N09	HA1E	LJP008_HA1E_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N10	HA1E	LJP008_HA1E_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N11	HA1E	LJP008_HA1E_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X1_B20:N12	HA1E	LJP008_HA1E_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N07	HA1E	LJP008_HA1E_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N08	HA1E	LJP008_HA1E_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N09	HA1E	LJP008_HA1E_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N10	HA1E	LJP008_HA1E_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N11	HA1E	LJP008_HA1E_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X2_B20:N12	HA1E	LJP008_HA1E_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N07	HA1E	LJP008_HA1E_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N08	HA1E	LJP008_HA1E_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N09	HA1E	LJP008_HA1E_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N10	HA1E	LJP008_HA1E_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N11	HA1E	LJP008_HA1E_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HA1E_24H_X3_B20:N12	HA1E	LJP008_HA1E_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G07	HA1E	REP.A022_HA1E_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G08	HA1E	REP.A022_HA1E_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G09	HA1E	REP.A022_HA1E_24H_X1_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G10	HA1E	REP.A022_HA1E_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G11	HA1E	REP.A022_HA1E_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X1_B23:G12	HA1E	REP.A022_HA1E_24H_X1_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G07	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G08	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G09	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G10	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G11	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X2.L2.A2_B23:G12	HA1E	REP.A022_HA1E_24H_X2.L2.A2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G07	HA1E	REP.A022_HA1E_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G08	HA1E	REP.A022_HA1E_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G09	HA1E	REP.A022_HA1E_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G10	HA1E	REP.A022_HA1E_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G11	HA1E	REP.A022_HA1E_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HA1E_24H_X3_B23:G12	HA1E	REP.A022_HA1E_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A19	HA1E	REP.A004_HA1E_24H_X1_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A20	HA1E	REP.A004_HA1E_24H_X1_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A21	HA1E	REP.A004_HA1E_24H_X1_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A22	HA1E	REP.A004_HA1E_24H_X1_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A23	HA1E	REP.A004_HA1E_24H_X1_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X1_B22:A24	HA1E	REP.A004_HA1E_24H_X1_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A19	HA1E	REP.A004_HA1E_24H_X2_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A20	HA1E	REP.A004_HA1E_24H_X2_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A21	HA1E	REP.A004_HA1E_24H_X2_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A22	HA1E	REP.A004_HA1E_24H_X2_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A23	HA1E	REP.A004_HA1E_24H_X2_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X2_B22:A24	HA1E	REP.A004_HA1E_24H_X2_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A19	HA1E	REP.A004_HA1E_24H_X3_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A20	HA1E	REP.A004_HA1E_24H_X3_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A21	HA1E	REP.A004_HA1E_24H_X3_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A22	HA1E	REP.A004_HA1E_24H_X3_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A23	HA1E	REP.A004_HA1E_24H_X3_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HA1E_24H_X3_B22:A24	HA1E	REP.A004_HA1E_24H_X3_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D07	HA1E	REP.A016_HA1E_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D08	HA1E	REP.A016_HA1E_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D09	HA1E	REP.A016_HA1E_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D10	HA1E	REP.A016_HA1E_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D11	HA1E	REP.A016_HA1E_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X1_B23:D12	HA1E	REP.A016_HA1E_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D07	HA1E	REP.A016_HA1E_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D08	HA1E	REP.A016_HA1E_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D09	HA1E	REP.A016_HA1E_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D10	HA1E	REP.A016_HA1E_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D11	HA1E	REP.A016_HA1E_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X2_B23:D12	HA1E	REP.A016_HA1E_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D07	HA1E	REP.A016_HA1E_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D08	HA1E	REP.A016_HA1E_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D09	HA1E	REP.A016_HA1E_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D10	HA1E	REP.A016_HA1E_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D11	HA1E	REP.A016_HA1E_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HA1E_24H_X3_B23:D12	HA1E	REP.A016_HA1E_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O07	HA1E	REP.A010_HA1E_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O08	HA1E	REP.A010_HA1E_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O09	HA1E	REP.A010_HA1E_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O10	HA1E	REP.A010_HA1E_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O11	HA1E	REP.A010_HA1E_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X1_B24:O12	HA1E	REP.A010_HA1E_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O07	HA1E	REP.A010_HA1E_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O08	HA1E	REP.A010_HA1E_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O09	HA1E	REP.A010_HA1E_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O10	HA1E	REP.A010_HA1E_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O11	HA1E	REP.A010_HA1E_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X2_B24:O12	HA1E	REP.A010_HA1E_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X3_B24:O07	HA1E	REP.A010_HA1E_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X3_B24:O09	HA1E	REP.A010_HA1E_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X3_B24:O10	HA1E	REP.A010_HA1E_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HA1E_24H_X3_B24:O12	HA1E	REP.A010_HA1E_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L13	HA1E	REP.A023_HA1E_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L14	HA1E	REP.A023_HA1E_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L15	HA1E	REP.A023_HA1E_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L16	HA1E	REP.A023_HA1E_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L17	HA1E	REP.A023_HA1E_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X1_B23:L18	HA1E	REP.A023_HA1E_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X2_B23:L13	HA1E	REP.A023_HA1E_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X2_B23:L14	HA1E	REP.A023_HA1E_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X2_B23:L15	HA1E	REP.A023_HA1E_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X2_B23:L16	HA1E	REP.A023_HA1E_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X2_B23:L18	HA1E	REP.A023_HA1E_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L13	HA1E	REP.A023_HA1E_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L14	HA1E	REP.A023_HA1E_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L15	HA1E	REP.A023_HA1E_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L16	HA1E	REP.A023_HA1E_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L17	HA1E	REP.A023_HA1E_24H_X3_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HA1E_24H_X3_B23:L18	HA1E	REP.A023_HA1E_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F19	HA1E	REP.A013_HA1E_24H_X1_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F20	HA1E	REP.A013_HA1E_24H_X1_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F21	HA1E	REP.A013_HA1E_24H_X1_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F22	HA1E	REP.A013_HA1E_24H_X1_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F23	HA1E	REP.A013_HA1E_24H_X1_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X1_B24:F24	HA1E	REP.A013_HA1E_24H_X1_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F19	HA1E	REP.A013_HA1E_24H_X2_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F20	HA1E	REP.A013_HA1E_24H_X2_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F21	HA1E	REP.A013_HA1E_24H_X2_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F22	HA1E	REP.A013_HA1E_24H_X2_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F23	HA1E	REP.A013_HA1E_24H_X2_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X2_B24:F24	HA1E	REP.A013_HA1E_24H_X2_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F19	HA1E	REP.A013_HA1E_24H_X3_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F20	HA1E	REP.A013_HA1E_24H_X3_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F21	HA1E	REP.A013_HA1E_24H_X3_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F22	HA1E	REP.A013_HA1E_24H_X3_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F23	HA1E	REP.A013_HA1E_24H_X3_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HA1E_24H_X3_B24:F24	HA1E	REP.A013_HA1E_24H_X3_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L01	HA1E	REP.A021_HA1E_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L02	HA1E	REP.A021_HA1E_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L03	HA1E	REP.A021_HA1E_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L04	HA1E	REP.A021_HA1E_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L05	HA1E	REP.A021_HA1E_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X1_B23:L06	HA1E	REP.A021_HA1E_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L01	HA1E	REP.A021_HA1E_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L02	HA1E	REP.A021_HA1E_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L03	HA1E	REP.A021_HA1E_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L04	HA1E	REP.A021_HA1E_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L05	HA1E	REP.A021_HA1E_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X2_B23:L06	HA1E	REP.A021_HA1E_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L01	HA1E	REP.A021_HA1E_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L02	HA1E	REP.A021_HA1E_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L03	HA1E	REP.A021_HA1E_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L04	HA1E	REP.A021_HA1E_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L05	HA1E	REP.A021_HA1E_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HA1E_24H_X3_B23:L06	HA1E	REP.A021_HA1E_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N01	HA1E	REP.A026_HA1E_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N02	HA1E	REP.A026_HA1E_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N03	HA1E	REP.A026_HA1E_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N04	HA1E	REP.A026_HA1E_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N05	HA1E	REP.A026_HA1E_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X1_B25:N06	HA1E	REP.A026_HA1E_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N01	HA1E	REP.A026_HA1E_24H_X2_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N02	HA1E	REP.A026_HA1E_24H_X2_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N03	HA1E	REP.A026_HA1E_24H_X2_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N04	HA1E	REP.A026_HA1E_24H_X2_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N05	HA1E	REP.A026_HA1E_24H_X2_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X2_B25:N06	HA1E	REP.A026_HA1E_24H_X2_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N01	HA1E	REP.A026_HA1E_24H_X3_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N02	HA1E	REP.A026_HA1E_24H_X3_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N03	HA1E	REP.A026_HA1E_24H_X3_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N04	HA1E	REP.A026_HA1E_24H_X3_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N05	HA1E	REP.A026_HA1E_24H_X3_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HA1E_24H_X3_B25:N06	HA1E	REP.A026_HA1E_24H_X3_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HA1E	-666	immortalized normal	normal	kidney	normal kidney	adherent	-666	-666	-666	-666	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F01	HELA	REP.A011_HELA_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F02	HELA	REP.A011_HELA_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F03	HELA	REP.A011_HELA_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F04	HELA	REP.A011_HELA_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F05	HELA	REP.A011_HELA_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X1_B24:F06	HELA	REP.A011_HELA_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F01	HELA	REP.A011_HELA_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F02	HELA	REP.A011_HELA_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F03	HELA	REP.A011_HELA_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F04	HELA	REP.A011_HELA_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F05	HELA	REP.A011_HELA_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X2_B24:F06	HELA	REP.A011_HELA_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F01	HELA	REP.A011_HELA_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F02	HELA	REP.A011_HELA_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F03	HELA	REP.A011_HELA_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F04	HELA	REP.A011_HELA_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F05	HELA	REP.A011_HELA_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HELA_24H_X3_B24:F06	HELA	REP.A011_HELA_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L01	HELA	REP.A007_HELA_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L02	HELA	REP.A007_HELA_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L03	HELA	REP.A007_HELA_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L04	HELA	REP.A007_HELA_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L05	HELA	REP.A007_HELA_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X1_B22:L06	HELA	REP.A007_HELA_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L01	HELA	REP.A007_HELA_24H_X2_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L02	HELA	REP.A007_HELA_24H_X2_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L03	HELA	REP.A007_HELA_24H_X2_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L04	HELA	REP.A007_HELA_24H_X2_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L05	HELA	REP.A007_HELA_24H_X2_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X2_B22:L06	HELA	REP.A007_HELA_24H_X2_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L01	HELA	REP.A007_HELA_24H_X3_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L02	HELA	REP.A007_HELA_24H_X3_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L03	HELA	REP.A007_HELA_24H_X3_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L04	HELA	REP.A007_HELA_24H_X3_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L05	HELA	REP.A007_HELA_24H_X3_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HELA_24H_X3_B22:L06	HELA	REP.A007_HELA_24H_X3_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I13	HELA	REP.A012_HELA_24H_X1_B23	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I14	HELA	REP.A012_HELA_24H_X1_B23	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I15	HELA	REP.A012_HELA_24H_X1_B23	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I16	HELA	REP.A012_HELA_24H_X1_B23	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I17	HELA	REP.A012_HELA_24H_X1_B23	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X1_B23:I18	HELA	REP.A012_HELA_24H_X1_B23	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I13	HELA	REP.A012_HELA_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I14	HELA	REP.A012_HELA_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I15	HELA	REP.A012_HELA_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I16	HELA	REP.A012_HELA_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I17	HELA	REP.A012_HELA_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X2_B22:I18	HELA	REP.A012_HELA_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X3_B22:I14	HELA	REP.A012_HELA_24H_X3_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X3_B22:I15	HELA	REP.A012_HELA_24H_X3_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X3_B22:I16	HELA	REP.A012_HELA_24H_X3_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X3_B22:I17	HELA	REP.A012_HELA_24H_X3_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HELA_24H_X3_B22:I18	HELA	REP.A012_HELA_24H_X3_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C13	HELA	REP.A017_HELA_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C14	HELA	REP.A017_HELA_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C15	HELA	REP.A017_HELA_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C16	HELA	REP.A017_HELA_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C17	HELA	REP.A017_HELA_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C18	HELA	REP.A017_HELA_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C13	HELA	REP.A017_HELA_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C14	HELA	REP.A017_HELA_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C15	HELA	REP.A017_HELA_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C16	HELA	REP.A017_HELA_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C17	HELA	REP.A017_HELA_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C18	HELA	REP.A017_HELA_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C13	HELA	REP.A017_HELA_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C14	HELA	REP.A017_HELA_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C15	HELA	REP.A017_HELA_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C16	HELA	REP.A017_HELA_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C17	HELA	REP.A017_HELA_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C18	HELA	REP.A017_HELA_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C13	HELA	REP.A017_HELA_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C14	HELA	REP.A017_HELA_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C15	HELA	REP.A017_HELA_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C16	HELA	REP.A017_HELA_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C17	HELA	REP.A017_HELA_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X1_B23:C18	HELA	REP.A017_HELA_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C13	HELA	REP.A017_HELA_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C14	HELA	REP.A017_HELA_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C15	HELA	REP.A017_HELA_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C16	HELA	REP.A017_HELA_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C17	HELA	REP.A017_HELA_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X2_B23:C18	HELA	REP.A017_HELA_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C13	HELA	REP.A017_HELA_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C14	HELA	REP.A017_HELA_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C15	HELA	REP.A017_HELA_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C16	HELA	REP.A017_HELA_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C17	HELA	REP.A017_HELA_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HELA_24H_X3_B23:C18	HELA	REP.A017_HELA_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X1_B22:I20	HELA	REP.A007_HELA_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X1_B22:I21	HELA	REP.A007_HELA_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X1_B22:I22	HELA	REP.A007_HELA_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X1_B22:I23	HELA	REP.A007_HELA_24H_X1_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X1_B22:I24	HELA	REP.A007_HELA_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I19	HELA	REP.A007_HELA_24H_X2_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I20	HELA	REP.A007_HELA_24H_X2_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I21	HELA	REP.A007_HELA_24H_X2_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I22	HELA	REP.A007_HELA_24H_X2_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I23	HELA	REP.A007_HELA_24H_X2_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X2_B22:I24	HELA	REP.A007_HELA_24H_X2_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I19	HELA	REP.A007_HELA_24H_X3_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I20	HELA	REP.A007_HELA_24H_X3_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I21	HELA	REP.A007_HELA_24H_X3_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I22	HELA	REP.A007_HELA_24H_X3_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I23	HELA	REP.A007_HELA_24H_X3_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HELA_24H_X3_B22:I24	HELA	REP.A007_HELA_24H_X3_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N01	HELA	REP.A014_HELA_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N02	HELA	REP.A014_HELA_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N03	HELA	REP.A014_HELA_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N04	HELA	REP.A014_HELA_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N05	HELA	REP.A014_HELA_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X1_B23:N06	HELA	REP.A014_HELA_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N01	HELA	REP.A014_HELA_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N02	HELA	REP.A014_HELA_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N03	HELA	REP.A014_HELA_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N04	HELA	REP.A014_HELA_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N05	HELA	REP.A014_HELA_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X2_B23:N06	HELA	REP.A014_HELA_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N01	HELA	REP.A014_HELA_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N02	HELA	REP.A014_HELA_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N03	HELA	REP.A014_HELA_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N04	HELA	REP.A014_HELA_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N05	HELA	REP.A014_HELA_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HELA_24H_X3_B23:N06	HELA	REP.A014_HELA_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A13	HELA	REP.A003_HELA_24H_X1_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A14	HELA	REP.A003_HELA_24H_X1_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A15	HELA	REP.A003_HELA_24H_X1_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A16	HELA	REP.A003_HELA_24H_X1_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A17	HELA	REP.A003_HELA_24H_X1_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X1_B22:A18	HELA	REP.A003_HELA_24H_X1_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A13	HELA	REP.A003_HELA_24H_X2_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A14	HELA	REP.A003_HELA_24H_X2_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A15	HELA	REP.A003_HELA_24H_X2_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A16	HELA	REP.A003_HELA_24H_X2_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A17	HELA	REP.A003_HELA_24H_X2_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X2_B22:A18	HELA	REP.A003_HELA_24H_X2_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A13	HELA	REP.A003_HELA_24H_X3_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A14	HELA	REP.A003_HELA_24H_X3_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A15	HELA	REP.A003_HELA_24H_X3_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A16	HELA	REP.A003_HELA_24H_X3_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A17	HELA	REP.A003_HELA_24H_X3_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HELA_24H_X3_B22:A18	HELA	REP.A003_HELA_24H_X3_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H13	HELA	REP.A016_HELA_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H14	HELA	REP.A016_HELA_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H15	HELA	REP.A016_HELA_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H16	HELA	REP.A016_HELA_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H17	HELA	REP.A016_HELA_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X1_B23:H18	HELA	REP.A016_HELA_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X2_B23:H13	HELA	REP.A016_HELA_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X2_B23:H14	HELA	REP.A016_HELA_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X2_B23:H15	HELA	REP.A016_HELA_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X2_B23:H16	HELA	REP.A016_HELA_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X2_B23:H18	HELA	REP.A016_HELA_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H13	HELA	REP.A016_HELA_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H14	HELA	REP.A016_HELA_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H15	HELA	REP.A016_HELA_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H16	HELA	REP.A016_HELA_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H17	HELA	REP.A016_HELA_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HELA_24H_X3_B23:H18	HELA	REP.A016_HELA_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E01	HELA	REP.A013_HELA_24H_X1_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E02	HELA	REP.A013_HELA_24H_X1_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E03	HELA	REP.A013_HELA_24H_X1_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E04	HELA	REP.A013_HELA_24H_X1_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E05	HELA	REP.A013_HELA_24H_X1_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X1_B24:E06	HELA	REP.A013_HELA_24H_X1_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E01	HELA	REP.A013_HELA_24H_X2_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E02	HELA	REP.A013_HELA_24H_X2_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E03	HELA	REP.A013_HELA_24H_X2_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E04	HELA	REP.A013_HELA_24H_X2_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E05	HELA	REP.A013_HELA_24H_X2_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X2_B24:E06	HELA	REP.A013_HELA_24H_X2_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E01	HELA	REP.A013_HELA_24H_X3_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E02	HELA	REP.A013_HELA_24H_X3_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E03	HELA	REP.A013_HELA_24H_X3_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E04	HELA	REP.A013_HELA_24H_X3_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E05	HELA	REP.A013_HELA_24H_X3_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HELA_24H_X3_B24:E06	HELA	REP.A013_HELA_24H_X3_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N19	HELA	REP.A004_HELA_24H_X1_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N20	HELA	REP.A004_HELA_24H_X1_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N21	HELA	REP.A004_HELA_24H_X1_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N22	HELA	REP.A004_HELA_24H_X1_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N23	HELA	REP.A004_HELA_24H_X1_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X1_B22:N24	HELA	REP.A004_HELA_24H_X1_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N19	HELA	REP.A004_HELA_24H_X2_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N20	HELA	REP.A004_HELA_24H_X2_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N21	HELA	REP.A004_HELA_24H_X2_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N22	HELA	REP.A004_HELA_24H_X2_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N23	HELA	REP.A004_HELA_24H_X2_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X2_B22:N24	HELA	REP.A004_HELA_24H_X2_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N19	HELA	REP.A004_HELA_24H_X3_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N20	HELA	REP.A004_HELA_24H_X3_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N21	HELA	REP.A004_HELA_24H_X3_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N22	HELA	REP.A004_HELA_24H_X3_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N23	HELA	REP.A004_HELA_24H_X3_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HELA_24H_X3_B22:N24	HELA	REP.A004_HELA_24H_X3_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X1_B22:C07	HELA	REP.A004_HELA_24H_X1_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X1_B22:C08	HELA	REP.A004_HELA_24H_X1_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X1_B22:C09	HELA	REP.A004_HELA_24H_X1_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X1_B22:C10	HELA	REP.A004_HELA_24H_X1_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X1_B22:C12	HELA	REP.A004_HELA_24H_X1_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C07	HELA	REP.A004_HELA_24H_X2_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C08	HELA	REP.A004_HELA_24H_X2_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C09	HELA	REP.A004_HELA_24H_X2_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C10	HELA	REP.A004_HELA_24H_X2_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C11	HELA	REP.A004_HELA_24H_X2_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X2_B22:C12	HELA	REP.A004_HELA_24H_X2_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C07	HELA	REP.A004_HELA_24H_X3_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C08	HELA	REP.A004_HELA_24H_X3_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C09	HELA	REP.A004_HELA_24H_X3_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C10	HELA	REP.A004_HELA_24H_X3_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C11	HELA	REP.A004_HELA_24H_X3_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HELA_24H_X3_B22:C12	HELA	REP.A004_HELA_24H_X3_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I13	HELA	REP.A017_HELA_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I14	HELA	REP.A017_HELA_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I15	HELA	REP.A017_HELA_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I16	HELA	REP.A017_HELA_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I17	HELA	REP.A017_HELA_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X1_B23:I18	HELA	REP.A017_HELA_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I13	HELA	REP.A017_HELA_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I14	HELA	REP.A017_HELA_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I15	HELA	REP.A017_HELA_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I16	HELA	REP.A017_HELA_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I17	HELA	REP.A017_HELA_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X2_B23:I18	HELA	REP.A017_HELA_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I13	HELA	REP.A017_HELA_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I14	HELA	REP.A017_HELA_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I15	HELA	REP.A017_HELA_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I16	HELA	REP.A017_HELA_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I17	HELA	REP.A017_HELA_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HELA_24H_X3_B23:I18	HELA	REP.A017_HELA_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M07	HELA	REP.A011_HELA_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M08	HELA	REP.A011_HELA_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M09	HELA	REP.A011_HELA_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M10	HELA	REP.A011_HELA_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M11	HELA	REP.A011_HELA_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X1_B24:M12	HELA	REP.A011_HELA_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X2_B24:M07	HELA	REP.A011_HELA_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X2_B24:M08	HELA	REP.A011_HELA_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X2_B24:M09	HELA	REP.A011_HELA_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X2_B24:M10	HELA	REP.A011_HELA_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X2_B24:M11	HELA	REP.A011_HELA_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M07	HELA	REP.A011_HELA_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M08	HELA	REP.A011_HELA_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M09	HELA	REP.A011_HELA_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M10	HELA	REP.A011_HELA_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M11	HELA	REP.A011_HELA_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HELA_24H_X3_B24:M12	HELA	REP.A011_HELA_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P19	HELA	REP.A008_HELA_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P20	HELA	REP.A008_HELA_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P21	HELA	REP.A008_HELA_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P22	HELA	REP.A008_HELA_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P23	HELA	REP.A008_HELA_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X1_B24:P24	HELA	REP.A008_HELA_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P19	HELA	REP.A008_HELA_24H_X2_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P20	HELA	REP.A008_HELA_24H_X2_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P21	HELA	REP.A008_HELA_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P22	HELA	REP.A008_HELA_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P23	HELA	REP.A008_HELA_24H_X2_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X2_B24:P24	HELA	REP.A008_HELA_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P19	HELA	REP.A008_HELA_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P20	HELA	REP.A008_HELA_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P21	HELA	REP.A008_HELA_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P22	HELA	REP.A008_HELA_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P23	HELA	REP.A008_HELA_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HELA_24H_X3_B24:P24	HELA	REP.A008_HELA_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J07	HELA	REP.A026_HELA_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J08	HELA	REP.A026_HELA_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J09	HELA	REP.A026_HELA_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J10	HELA	REP.A026_HELA_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J11	HELA	REP.A026_HELA_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X1_B25:J12	HELA	REP.A026_HELA_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X2_B25:J08	HELA	REP.A026_HELA_24H_X2_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X2_B25:J09	HELA	REP.A026_HELA_24H_X2_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X2_B25:J10	HELA	REP.A026_HELA_24H_X2_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X2_B25:J11	HELA	REP.A026_HELA_24H_X2_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X2_B25:J12	HELA	REP.A026_HELA_24H_X2_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J07	HELA	REP.A026_HELA_24H_X3_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J08	HELA	REP.A026_HELA_24H_X3_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J09	HELA	REP.A026_HELA_24H_X3_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J10	HELA	REP.A026_HELA_24H_X3_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J11	HELA	REP.A026_HELA_24H_X3_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HELA_24H_X3_B25:J12	HELA	REP.A026_HELA_24H_X3_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D13	HELA	REP.A013_HELA_24H_X1_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D14	HELA	REP.A013_HELA_24H_X1_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D15	HELA	REP.A013_HELA_24H_X1_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D16	HELA	REP.A013_HELA_24H_X1_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D17	HELA	REP.A013_HELA_24H_X1_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X1_B24:D18	HELA	REP.A013_HELA_24H_X1_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D13	HELA	REP.A013_HELA_24H_X2_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D14	HELA	REP.A013_HELA_24H_X2_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D15	HELA	REP.A013_HELA_24H_X2_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D16	HELA	REP.A013_HELA_24H_X2_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D17	HELA	REP.A013_HELA_24H_X2_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X2_B24:D18	HELA	REP.A013_HELA_24H_X2_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D13	HELA	REP.A013_HELA_24H_X3_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D14	HELA	REP.A013_HELA_24H_X3_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D15	HELA	REP.A013_HELA_24H_X3_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D16	HELA	REP.A013_HELA_24H_X3_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D17	HELA	REP.A013_HELA_24H_X3_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HELA_24H_X3_B24:D18	HELA	REP.A013_HELA_24H_X3_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L01	HELA	REP.A013_HELA_24H_X1_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L02	HELA	REP.A013_HELA_24H_X1_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L03	HELA	REP.A013_HELA_24H_X1_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L04	HELA	REP.A013_HELA_24H_X1_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L05	HELA	REP.A013_HELA_24H_X1_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X1_B24:L06	HELA	REP.A013_HELA_24H_X1_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L01	HELA	REP.A013_HELA_24H_X2_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L02	HELA	REP.A013_HELA_24H_X2_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L03	HELA	REP.A013_HELA_24H_X2_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L04	HELA	REP.A013_HELA_24H_X2_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L05	HELA	REP.A013_HELA_24H_X2_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X2_B24:L06	HELA	REP.A013_HELA_24H_X2_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L01	HELA	REP.A013_HELA_24H_X3_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L02	HELA	REP.A013_HELA_24H_X3_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L03	HELA	REP.A013_HELA_24H_X3_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L04	HELA	REP.A013_HELA_24H_X3_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L05	HELA	REP.A013_HELA_24H_X3_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HELA_24H_X3_B24:L06	HELA	REP.A013_HELA_24H_X3_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I01	HELA	REP.A023_HELA_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I02	HELA	REP.A023_HELA_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I03	HELA	REP.A023_HELA_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I04	HELA	REP.A023_HELA_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I05	HELA	REP.A023_HELA_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X1_B23:I06	HELA	REP.A023_HELA_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I01	HELA	REP.A023_HELA_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I02	HELA	REP.A023_HELA_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I03	HELA	REP.A023_HELA_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I04	HELA	REP.A023_HELA_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I05	HELA	REP.A023_HELA_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X2_B23:I06	HELA	REP.A023_HELA_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I01	HELA	REP.A023_HELA_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I02	HELA	REP.A023_HELA_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I03	HELA	REP.A023_HELA_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I04	HELA	REP.A023_HELA_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I05	HELA	REP.A023_HELA_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HELA_24H_X3_B23:I06	HELA	REP.A023_HELA_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X1_B23:G07	HELA	REP.A022_HELA_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X1_B23:G08	HELA	REP.A022_HELA_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X1_B23:G10	HELA	REP.A022_HELA_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X1_B23:G11	HELA	REP.A022_HELA_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X1_B23:G12	HELA	REP.A022_HELA_24H_X1_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G07	HELA	REP.A022_HELA_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G08	HELA	REP.A022_HELA_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G09	HELA	REP.A022_HELA_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G10	HELA	REP.A022_HELA_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G11	HELA	REP.A022_HELA_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X2_B23:G12	HELA	REP.A022_HELA_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G07	HELA	REP.A022_HELA_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G08	HELA	REP.A022_HELA_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G09	HELA	REP.A022_HELA_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G10	HELA	REP.A022_HELA_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G11	HELA	REP.A022_HELA_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HELA_24H_X3_B23:G12	HELA	REP.A022_HELA_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A19	HELA	REP.A004_HELA_24H_X1_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A20	HELA	REP.A004_HELA_24H_X1_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A21	HELA	REP.A004_HELA_24H_X1_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A22	HELA	REP.A004_HELA_24H_X1_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A23	HELA	REP.A004_HELA_24H_X1_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X1_B22:A24	HELA	REP.A004_HELA_24H_X1_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A19	HELA	REP.A004_HELA_24H_X2_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A20	HELA	REP.A004_HELA_24H_X2_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A21	HELA	REP.A004_HELA_24H_X2_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A22	HELA	REP.A004_HELA_24H_X2_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A23	HELA	REP.A004_HELA_24H_X2_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X2_B22:A24	HELA	REP.A004_HELA_24H_X2_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X3_B22:A19	HELA	REP.A004_HELA_24H_X3_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X3_B22:A20	HELA	REP.A004_HELA_24H_X3_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X3_B22:A21	HELA	REP.A004_HELA_24H_X3_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X3_B22:A23	HELA	REP.A004_HELA_24H_X3_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HELA_24H_X3_B22:A24	HELA	REP.A004_HELA_24H_X3_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D07	HELA	REP.A016_HELA_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D08	HELA	REP.A016_HELA_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D09	HELA	REP.A016_HELA_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D10	HELA	REP.A016_HELA_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D11	HELA	REP.A016_HELA_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X1_B23:D12	HELA	REP.A016_HELA_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D07	HELA	REP.A016_HELA_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D08	HELA	REP.A016_HELA_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D09	HELA	REP.A016_HELA_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D10	HELA	REP.A016_HELA_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D11	HELA	REP.A016_HELA_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X2_B23:D12	HELA	REP.A016_HELA_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D07	HELA	REP.A016_HELA_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D08	HELA	REP.A016_HELA_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D09	HELA	REP.A016_HELA_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D10	HELA	REP.A016_HELA_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D11	HELA	REP.A016_HELA_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HELA_24H_X3_B23:D12	HELA	REP.A016_HELA_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O07	HELA	REP.A010_HELA_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O08	HELA	REP.A010_HELA_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O09	HELA	REP.A010_HELA_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O10	HELA	REP.A010_HELA_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O11	HELA	REP.A010_HELA_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X1_B24:O12	HELA	REP.A010_HELA_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O07	HELA	REP.A010_HELA_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O08	HELA	REP.A010_HELA_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O09	HELA	REP.A010_HELA_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O10	HELA	REP.A010_HELA_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O11	HELA	REP.A010_HELA_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X2_B24:O12	HELA	REP.A010_HELA_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O07	HELA	REP.A010_HELA_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O08	HELA	REP.A010_HELA_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O09	HELA	REP.A010_HELA_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O10	HELA	REP.A010_HELA_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O11	HELA	REP.A010_HELA_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HELA_24H_X3_B24:O12	HELA	REP.A010_HELA_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L13	HELA	REP.A023_HELA_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L14	HELA	REP.A023_HELA_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L15	HELA	REP.A023_HELA_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L16	HELA	REP.A023_HELA_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L17	HELA	REP.A023_HELA_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X1_B23:L18	HELA	REP.A023_HELA_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L13	HELA	REP.A023_HELA_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L14	HELA	REP.A023_HELA_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L15	HELA	REP.A023_HELA_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L16	HELA	REP.A023_HELA_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L17	HELA	REP.A023_HELA_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X2_B23:L18	HELA	REP.A023_HELA_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L13	HELA	REP.A023_HELA_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L14	HELA	REP.A023_HELA_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L15	HELA	REP.A023_HELA_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L16	HELA	REP.A023_HELA_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L17	HELA	REP.A023_HELA_24H_X3_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HELA_24H_X3_B23:L18	HELA	REP.A023_HELA_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F19	HELA	REP.A013_HELA_24H_X1_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F20	HELA	REP.A013_HELA_24H_X1_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F21	HELA	REP.A013_HELA_24H_X1_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F22	HELA	REP.A013_HELA_24H_X1_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F23	HELA	REP.A013_HELA_24H_X1_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X1_B24:F24	HELA	REP.A013_HELA_24H_X1_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F19	HELA	REP.A013_HELA_24H_X2_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F20	HELA	REP.A013_HELA_24H_X2_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F21	HELA	REP.A013_HELA_24H_X2_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F22	HELA	REP.A013_HELA_24H_X2_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F23	HELA	REP.A013_HELA_24H_X2_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X2_B24:F24	HELA	REP.A013_HELA_24H_X2_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F19	HELA	REP.A013_HELA_24H_X3_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F20	HELA	REP.A013_HELA_24H_X3_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F21	HELA	REP.A013_HELA_24H_X3_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F22	HELA	REP.A013_HELA_24H_X3_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F23	HELA	REP.A013_HELA_24H_X3_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HELA_24H_X3_B24:F24	HELA	REP.A013_HELA_24H_X3_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L01	HELA	REP.A021_HELA_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L02	HELA	REP.A021_HELA_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L03	HELA	REP.A021_HELA_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L04	HELA	REP.A021_HELA_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L05	HELA	REP.A021_HELA_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X1_B23:L06	HELA	REP.A021_HELA_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L01	HELA	REP.A021_HELA_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L02	HELA	REP.A021_HELA_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L03	HELA	REP.A021_HELA_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L04	HELA	REP.A021_HELA_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L05	HELA	REP.A021_HELA_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X2_B23:L06	HELA	REP.A021_HELA_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L01	HELA	REP.A021_HELA_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L02	HELA	REP.A021_HELA_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L03	HELA	REP.A021_HELA_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L04	HELA	REP.A021_HELA_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L05	HELA	REP.A021_HELA_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HELA_24H_X3_B23:L06	HELA	REP.A021_HELA_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N01	HELA	REP.A026_HELA_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N02	HELA	REP.A026_HELA_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N03	HELA	REP.A026_HELA_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N04	HELA	REP.A026_HELA_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N05	HELA	REP.A026_HELA_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X1_B25:N06	HELA	REP.A026_HELA_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N01	HELA	REP.A026_HELA_24H_X2_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N02	HELA	REP.A026_HELA_24H_X2_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N03	HELA	REP.A026_HELA_24H_X2_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N04	HELA	REP.A026_HELA_24H_X2_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N05	HELA	REP.A026_HELA_24H_X2_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X2_B25:N06	HELA	REP.A026_HELA_24H_X2_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N01	HELA	REP.A026_HELA_24H_X3_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N02	HELA	REP.A026_HELA_24H_X3_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N03	HELA	REP.A026_HELA_24H_X3_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N04	HELA	REP.A026_HELA_24H_X3_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N05	HELA	REP.A026_HELA_24H_X3_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HELA_24H_X3_B25:N06	HELA	REP.A026_HELA_24H_X3_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HELA	-666	-666	tumor	large intestine	adenocarcinoma	adherent	CCL-2	ATCC	31	F	Black
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X1_B24:F01	HT29	REP.A011_HT29_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X1_B24:F03	HT29	REP.A011_HT29_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X1_B24:F04	HT29	REP.A011_HT29_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X1_B24:F05	HT29	REP.A011_HT29_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X1_B24:F06	HT29	REP.A011_HT29_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F01	HT29	REP.A011_HT29_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F02	HT29	REP.A011_HT29_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F03	HT29	REP.A011_HT29_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F04	HT29	REP.A011_HT29_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F05	HT29	REP.A011_HT29_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X2_B24:F06	HT29	REP.A011_HT29_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F01	HT29	REP.A011_HT29_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F02	HT29	REP.A011_HT29_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F03	HT29	REP.A011_HT29_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F04	HT29	REP.A011_HT29_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F05	HT29	REP.A011_HT29_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_HT29_24H_X3_B24:F06	HT29	REP.A011_HT29_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L01	HT29	REP.A007_HT29_24H_X1_B24	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L02	HT29	REP.A007_HT29_24H_X1_B24	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L03	HT29	REP.A007_HT29_24H_X1_B24	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L04	HT29	REP.A007_HT29_24H_X1_B24	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L05	HT29	REP.A007_HT29_24H_X1_B24	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X1_B24:L06	HT29	REP.A007_HT29_24H_X1_B24	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L01	HT29	REP.A007_HT29_24H_X2_B24	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L02	HT29	REP.A007_HT29_24H_X2_B24	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L03	HT29	REP.A007_HT29_24H_X2_B24	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L04	HT29	REP.A007_HT29_24H_X2_B24	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L05	HT29	REP.A007_HT29_24H_X2_B24	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X2_B24:L06	HT29	REP.A007_HT29_24H_X2_B24	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L01	HT29	REP.A007_HT29_24H_X3_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L02	HT29	REP.A007_HT29_24H_X3_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L03	HT29	REP.A007_HT29_24H_X3_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L04	HT29	REP.A007_HT29_24H_X3_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L05	HT29	REP.A007_HT29_24H_X3_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_HT29_24H_X3_B22:L06	HT29	REP.A007_HT29_24H_X3_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I13	HT29	REP.A012_HT29_24H_X1_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I14	HT29	REP.A012_HT29_24H_X1_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I15	HT29	REP.A012_HT29_24H_X1_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I16	HT29	REP.A012_HT29_24H_X1_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I17	HT29	REP.A012_HT29_24H_X1_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X1_B22:I18	HT29	REP.A012_HT29_24H_X1_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I13	HT29	REP.A012_HT29_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I14	HT29	REP.A012_HT29_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I15	HT29	REP.A012_HT29_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I16	HT29	REP.A012_HT29_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I17	HT29	REP.A012_HT29_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X2_B22:I18	HT29	REP.A012_HT29_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I13	HT29	REP.A012_HT29_24H_X3_B24	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I14	HT29	REP.A012_HT29_24H_X3_B24	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I15	HT29	REP.A012_HT29_24H_X3_B24	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I16	HT29	REP.A012_HT29_24H_X3_B24	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I17	HT29	REP.A012_HT29_24H_X3_B24	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_HT29_24H_X3_B24:I18	HT29	REP.A012_HT29_24H_X3_B24	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C13	HT29	REP.A017_HT29_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C14	HT29	REP.A017_HT29_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C15	HT29	REP.A017_HT29_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C16	HT29	REP.A017_HT29_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C17	HT29	REP.A017_HT29_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C18	HT29	REP.A017_HT29_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C13	HT29	REP.A017_HT29_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C14	HT29	REP.A017_HT29_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C15	HT29	REP.A017_HT29_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C16	HT29	REP.A017_HT29_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C17	HT29	REP.A017_HT29_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C18	HT29	REP.A017_HT29_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C13	HT29	REP.A017_HT29_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C14	HT29	REP.A017_HT29_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C15	HT29	REP.A017_HT29_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C16	HT29	REP.A017_HT29_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C17	HT29	REP.A017_HT29_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C18	HT29	REP.A017_HT29_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C13	HT29	REP.A017_HT29_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C14	HT29	REP.A017_HT29_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C15	HT29	REP.A017_HT29_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C16	HT29	REP.A017_HT29_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C17	HT29	REP.A017_HT29_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X1_B23:C18	HT29	REP.A017_HT29_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C13	HT29	REP.A017_HT29_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C14	HT29	REP.A017_HT29_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C15	HT29	REP.A017_HT29_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C16	HT29	REP.A017_HT29_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C17	HT29	REP.A017_HT29_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X2_B23:C18	HT29	REP.A017_HT29_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C13	HT29	REP.A017_HT29_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C14	HT29	REP.A017_HT29_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C15	HT29	REP.A017_HT29_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C16	HT29	REP.A017_HT29_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C17	HT29	REP.A017_HT29_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_HT29_24H_X3_B23:C18	HT29	REP.A017_HT29_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I19	HT29	REP.A007_HT29_24H_X1_B24	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I20	HT29	REP.A007_HT29_24H_X1_B24	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I21	HT29	REP.A007_HT29_24H_X1_B24	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I22	HT29	REP.A007_HT29_24H_X1_B24	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I23	HT29	REP.A007_HT29_24H_X1_B24	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X1_B24:I24	HT29	REP.A007_HT29_24H_X1_B24	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I19	HT29	REP.A007_HT29_24H_X2_B24	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I20	HT29	REP.A007_HT29_24H_X2_B24	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I21	HT29	REP.A007_HT29_24H_X2_B24	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I22	HT29	REP.A007_HT29_24H_X2_B24	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I23	HT29	REP.A007_HT29_24H_X2_B24	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X2_B24:I24	HT29	REP.A007_HT29_24H_X2_B24	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I19	HT29	REP.A007_HT29_24H_X3_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I20	HT29	REP.A007_HT29_24H_X3_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I21	HT29	REP.A007_HT29_24H_X3_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I22	HT29	REP.A007_HT29_24H_X3_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I23	HT29	REP.A007_HT29_24H_X3_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_HT29_24H_X3_B22:I24	HT29	REP.A007_HT29_24H_X3_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N01	HT29	REP.A014_HT29_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N02	HT29	REP.A014_HT29_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N03	HT29	REP.A014_HT29_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N04	HT29	REP.A014_HT29_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N05	HT29	REP.A014_HT29_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X1_B23:N06	HT29	REP.A014_HT29_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N01	HT29	REP.A014_HT29_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N02	HT29	REP.A014_HT29_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N03	HT29	REP.A014_HT29_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N04	HT29	REP.A014_HT29_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N05	HT29	REP.A014_HT29_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X2_B23:N06	HT29	REP.A014_HT29_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N01	HT29	REP.A014_HT29_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N02	HT29	REP.A014_HT29_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N03	HT29	REP.A014_HT29_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N04	HT29	REP.A014_HT29_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N05	HT29	REP.A014_HT29_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_HT29_24H_X3_B23:N06	HT29	REP.A014_HT29_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A13	HT29	REP.A003_HT29_24H_X1_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A14	HT29	REP.A003_HT29_24H_X1_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A15	HT29	REP.A003_HT29_24H_X1_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A16	HT29	REP.A003_HT29_24H_X1_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A17	HT29	REP.A003_HT29_24H_X1_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X1_B27:A18	HT29	REP.A003_HT29_24H_X1_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A13	HT29	REP.A003_HT29_24H_X2_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A14	HT29	REP.A003_HT29_24H_X2_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A15	HT29	REP.A003_HT29_24H_X2_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A16	HT29	REP.A003_HT29_24H_X2_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A17	HT29	REP.A003_HT29_24H_X2_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X2_B27:A18	HT29	REP.A003_HT29_24H_X2_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A13	HT29	REP.A003_HT29_24H_X3_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A14	HT29	REP.A003_HT29_24H_X3_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A15	HT29	REP.A003_HT29_24H_X3_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A16	HT29	REP.A003_HT29_24H_X3_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A17	HT29	REP.A003_HT29_24H_X3_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_HT29_24H_X3_B27:A18	HT29	REP.A003_HT29_24H_X3_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H13	HT29	REP.A016_HT29_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H14	HT29	REP.A016_HT29_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H15	HT29	REP.A016_HT29_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H16	HT29	REP.A016_HT29_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H17	HT29	REP.A016_HT29_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X1_B23:H18	HT29	REP.A016_HT29_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H13	HT29	REP.A016_HT29_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H14	HT29	REP.A016_HT29_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H15	HT29	REP.A016_HT29_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H16	HT29	REP.A016_HT29_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H17	HT29	REP.A016_HT29_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X2_B23:H18	HT29	REP.A016_HT29_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H13	HT29	REP.A016_HT29_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H14	HT29	REP.A016_HT29_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H15	HT29	REP.A016_HT29_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H16	HT29	REP.A016_HT29_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H17	HT29	REP.A016_HT29_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_HT29_24H_X3_B23:H18	HT29	REP.A016_HT29_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E01	HT29	REP.A013_HT29_24H_X1_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E02	HT29	REP.A013_HT29_24H_X1_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E03	HT29	REP.A013_HT29_24H_X1_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E04	HT29	REP.A013_HT29_24H_X1_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E05	HT29	REP.A013_HT29_24H_X1_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X1_B24:E06	HT29	REP.A013_HT29_24H_X1_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E01	HT29	REP.A013_HT29_24H_X2_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E02	HT29	REP.A013_HT29_24H_X2_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E03	HT29	REP.A013_HT29_24H_X2_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E04	HT29	REP.A013_HT29_24H_X2_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E05	HT29	REP.A013_HT29_24H_X2_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X2_B24:E06	HT29	REP.A013_HT29_24H_X2_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E01	HT29	REP.A013_HT29_24H_X3_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E02	HT29	REP.A013_HT29_24H_X3_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E03	HT29	REP.A013_HT29_24H_X3_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E04	HT29	REP.A013_HT29_24H_X3_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E05	HT29	REP.A013_HT29_24H_X3_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_HT29_24H_X3_B24:E06	HT29	REP.A013_HT29_24H_X3_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N19	HT29	REP.A004_HT29_24H_X1_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N20	HT29	REP.A004_HT29_24H_X1_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N21	HT29	REP.A004_HT29_24H_X1_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N22	HT29	REP.A004_HT29_24H_X1_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N23	HT29	REP.A004_HT29_24H_X1_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X1_B27:N24	HT29	REP.A004_HT29_24H_X1_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N19	HT29	REP.A004_HT29_24H_X3_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N20	HT29	REP.A004_HT29_24H_X3_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N21	HT29	REP.A004_HT29_24H_X3_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N22	HT29	REP.A004_HT29_24H_X3_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N23	HT29	REP.A004_HT29_24H_X3_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_HT29_24H_X3_B27:N24	HT29	REP.A004_HT29_24H_X3_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C07	HT29	REP.A004_HT29_24H_X1_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C08	HT29	REP.A004_HT29_24H_X1_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C09	HT29	REP.A004_HT29_24H_X1_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C10	HT29	REP.A004_HT29_24H_X1_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C11	HT29	REP.A004_HT29_24H_X1_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X1_B27:C12	HT29	REP.A004_HT29_24H_X1_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C07	HT29	REP.A004_HT29_24H_X2_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C08	HT29	REP.A004_HT29_24H_X2_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C09	HT29	REP.A004_HT29_24H_X2_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C10	HT29	REP.A004_HT29_24H_X2_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C11	HT29	REP.A004_HT29_24H_X2_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X2_B27:C12	HT29	REP.A004_HT29_24H_X2_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C07	HT29	REP.A004_HT29_24H_X3_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C08	HT29	REP.A004_HT29_24H_X3_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C09	HT29	REP.A004_HT29_24H_X3_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C10	HT29	REP.A004_HT29_24H_X3_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C11	HT29	REP.A004_HT29_24H_X3_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_HT29_24H_X3_B27:C12	HT29	REP.A004_HT29_24H_X3_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I13	HT29	REP.A017_HT29_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I14	HT29	REP.A017_HT29_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I15	HT29	REP.A017_HT29_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I16	HT29	REP.A017_HT29_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I17	HT29	REP.A017_HT29_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X1_B23:I18	HT29	REP.A017_HT29_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X2_B23:I13	HT29	REP.A017_HT29_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X2_B23:I14	HT29	REP.A017_HT29_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X2_B23:I15	HT29	REP.A017_HT29_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X2_B23:I17	HT29	REP.A017_HT29_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X2_B23:I18	HT29	REP.A017_HT29_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I13	HT29	REP.A017_HT29_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I14	HT29	REP.A017_HT29_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I15	HT29	REP.A017_HT29_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I16	HT29	REP.A017_HT29_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I17	HT29	REP.A017_HT29_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_HT29_24H_X3_B23:I18	HT29	REP.A017_HT29_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M07	HT29	REP.A011_HT29_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M08	HT29	REP.A011_HT29_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M09	HT29	REP.A011_HT29_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M10	HT29	REP.A011_HT29_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M11	HT29	REP.A011_HT29_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X1_B24:M12	HT29	REP.A011_HT29_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M07	HT29	REP.A011_HT29_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M08	HT29	REP.A011_HT29_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M09	HT29	REP.A011_HT29_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M10	HT29	REP.A011_HT29_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M11	HT29	REP.A011_HT29_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X2_B24:M12	HT29	REP.A011_HT29_24H_X2_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M07	HT29	REP.A011_HT29_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M08	HT29	REP.A011_HT29_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M09	HT29	REP.A011_HT29_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M10	HT29	REP.A011_HT29_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M11	HT29	REP.A011_HT29_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_HT29_24H_X3_B24:M12	HT29	REP.A011_HT29_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P19	HT29	REP.A008_HT29_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P20	HT29	REP.A008_HT29_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P21	HT29	REP.A008_HT29_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P22	HT29	REP.A008_HT29_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P23	HT29	REP.A008_HT29_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X1_B24:P24	HT29	REP.A008_HT29_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P19	HT29	REP.A008_HT29_24H_X2_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P20	HT29	REP.A008_HT29_24H_X2_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P21	HT29	REP.A008_HT29_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P22	HT29	REP.A008_HT29_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P23	HT29	REP.A008_HT29_24H_X2_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X2_B24:P24	HT29	REP.A008_HT29_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P19	HT29	REP.A008_HT29_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P20	HT29	REP.A008_HT29_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P21	HT29	REP.A008_HT29_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P22	HT29	REP.A008_HT29_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P23	HT29	REP.A008_HT29_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_HT29_24H_X3_B24:P24	HT29	REP.A008_HT29_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J07	HT29	REP.A026_HT29_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J08	HT29	REP.A026_HT29_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J09	HT29	REP.A026_HT29_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J10	HT29	REP.A026_HT29_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J11	HT29	REP.A026_HT29_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X1_B25:J12	HT29	REP.A026_HT29_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J07	HT29	REP.A026_HT29_24H_X2.A2_B27	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J08	HT29	REP.A026_HT29_24H_X2.A2_B27	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J09	HT29	REP.A026_HT29_24H_X2.A2_B27	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J10	HT29	REP.A026_HT29_24H_X2.A2_B27	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J11	HT29	REP.A026_HT29_24H_X2.A2_B27	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X2.A2_B27:J12	HT29	REP.A026_HT29_24H_X2.A2_B27	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J07	HT29	REP.A026_HT29_24H_X3_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J08	HT29	REP.A026_HT29_24H_X3_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J09	HT29	REP.A026_HT29_24H_X3_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J10	HT29	REP.A026_HT29_24H_X3_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J11	HT29	REP.A026_HT29_24H_X3_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_HT29_24H_X3_B25:J12	HT29	REP.A026_HT29_24H_X3_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D13	HT29	REP.A013_HT29_24H_X1_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D14	HT29	REP.A013_HT29_24H_X1_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D15	HT29	REP.A013_HT29_24H_X1_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D16	HT29	REP.A013_HT29_24H_X1_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D17	HT29	REP.A013_HT29_24H_X1_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X1_B24:D18	HT29	REP.A013_HT29_24H_X1_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D13	HT29	REP.A013_HT29_24H_X2_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D14	HT29	REP.A013_HT29_24H_X2_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D15	HT29	REP.A013_HT29_24H_X2_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D16	HT29	REP.A013_HT29_24H_X2_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D17	HT29	REP.A013_HT29_24H_X2_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X2_B24:D18	HT29	REP.A013_HT29_24H_X2_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D13	HT29	REP.A013_HT29_24H_X3_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D14	HT29	REP.A013_HT29_24H_X3_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D15	HT29	REP.A013_HT29_24H_X3_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D16	HT29	REP.A013_HT29_24H_X3_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D17	HT29	REP.A013_HT29_24H_X3_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_HT29_24H_X3_B24:D18	HT29	REP.A013_HT29_24H_X3_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L01	HT29	REP.A013_HT29_24H_X1_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L02	HT29	REP.A013_HT29_24H_X1_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L03	HT29	REP.A013_HT29_24H_X1_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L04	HT29	REP.A013_HT29_24H_X1_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L05	HT29	REP.A013_HT29_24H_X1_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X1_B24:L06	HT29	REP.A013_HT29_24H_X1_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L01	HT29	REP.A013_HT29_24H_X2_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L02	HT29	REP.A013_HT29_24H_X2_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L03	HT29	REP.A013_HT29_24H_X2_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L04	HT29	REP.A013_HT29_24H_X2_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L05	HT29	REP.A013_HT29_24H_X2_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X2_B24:L06	HT29	REP.A013_HT29_24H_X2_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L01	HT29	REP.A013_HT29_24H_X3_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L02	HT29	REP.A013_HT29_24H_X3_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L03	HT29	REP.A013_HT29_24H_X3_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L04	HT29	REP.A013_HT29_24H_X3_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L05	HT29	REP.A013_HT29_24H_X3_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_HT29_24H_X3_B24:L06	HT29	REP.A013_HT29_24H_X3_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I01	HT29	REP.A023_HT29_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I02	HT29	REP.A023_HT29_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I03	HT29	REP.A023_HT29_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I04	HT29	REP.A023_HT29_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I05	HT29	REP.A023_HT29_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X1_B23:I06	HT29	REP.A023_HT29_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I01	HT29	REP.A023_HT29_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I02	HT29	REP.A023_HT29_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I03	HT29	REP.A023_HT29_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I04	HT29	REP.A023_HT29_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I05	HT29	REP.A023_HT29_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X2_B23:I06	HT29	REP.A023_HT29_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I01	HT29	REP.A023_HT29_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I02	HT29	REP.A023_HT29_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I03	HT29	REP.A023_HT29_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I04	HT29	REP.A023_HT29_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I05	HT29	REP.A023_HT29_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_HT29_24H_X3_B23:I06	HT29	REP.A023_HT29_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N07	HT29	LJP008_HT29_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N08	HT29	LJP008_HT29_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N09	HT29	LJP008_HT29_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N10	HT29	LJP008_HT29_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N11	HT29	LJP008_HT29_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X1_B20:N12	HT29	LJP008_HT29_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N07	HT29	LJP008_HT29_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N08	HT29	LJP008_HT29_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N09	HT29	LJP008_HT29_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N10	HT29	LJP008_HT29_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N11	HT29	LJP008_HT29_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X2_B20:N12	HT29	LJP008_HT29_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N07	HT29	LJP008_HT29_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N08	HT29	LJP008_HT29_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N09	HT29	LJP008_HT29_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N10	HT29	LJP008_HT29_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N11	HT29	LJP008_HT29_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HT29_24H_X3_B20:N12	HT29	LJP008_HT29_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G07	HT29	REP.A022_HT29_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G08	HT29	REP.A022_HT29_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G09	HT29	REP.A022_HT29_24H_X1_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G10	HT29	REP.A022_HT29_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G11	HT29	REP.A022_HT29_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X1_B23:G12	HT29	REP.A022_HT29_24H_X1_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G07	HT29	REP.A022_HT29_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G08	HT29	REP.A022_HT29_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G09	HT29	REP.A022_HT29_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G10	HT29	REP.A022_HT29_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G11	HT29	REP.A022_HT29_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X2_B23:G12	HT29	REP.A022_HT29_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G07	HT29	REP.A022_HT29_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G08	HT29	REP.A022_HT29_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G09	HT29	REP.A022_HT29_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G10	HT29	REP.A022_HT29_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G11	HT29	REP.A022_HT29_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_HT29_24H_X3_B23:G12	HT29	REP.A022_HT29_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A19	HT29	REP.A004_HT29_24H_X1_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A20	HT29	REP.A004_HT29_24H_X1_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A21	HT29	REP.A004_HT29_24H_X1_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A22	HT29	REP.A004_HT29_24H_X1_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A23	HT29	REP.A004_HT29_24H_X1_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X1_B27:A24	HT29	REP.A004_HT29_24H_X1_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X3_B27:A20	HT29	REP.A004_HT29_24H_X3_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X3_B27:A21	HT29	REP.A004_HT29_24H_X3_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X3_B27:A22	HT29	REP.A004_HT29_24H_X3_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X3_B27:A23	HT29	REP.A004_HT29_24H_X3_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_HT29_24H_X3_B27:A24	HT29	REP.A004_HT29_24H_X3_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D07	HT29	REP.A016_HT29_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D08	HT29	REP.A016_HT29_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D09	HT29	REP.A016_HT29_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D10	HT29	REP.A016_HT29_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D11	HT29	REP.A016_HT29_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X1_B23:D12	HT29	REP.A016_HT29_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D07	HT29	REP.A016_HT29_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D08	HT29	REP.A016_HT29_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D09	HT29	REP.A016_HT29_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D10	HT29	REP.A016_HT29_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D11	HT29	REP.A016_HT29_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X2_B23:D12	HT29	REP.A016_HT29_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D07	HT29	REP.A016_HT29_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D08	HT29	REP.A016_HT29_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D09	HT29	REP.A016_HT29_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D10	HT29	REP.A016_HT29_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D11	HT29	REP.A016_HT29_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_HT29_24H_X3_B23:D12	HT29	REP.A016_HT29_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O07	HT29	REP.A010_HT29_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O08	HT29	REP.A010_HT29_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O09	HT29	REP.A010_HT29_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O10	HT29	REP.A010_HT29_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O11	HT29	REP.A010_HT29_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X1_B24:O12	HT29	REP.A010_HT29_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O07	HT29	REP.A010_HT29_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O08	HT29	REP.A010_HT29_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O09	HT29	REP.A010_HT29_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O10	HT29	REP.A010_HT29_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O11	HT29	REP.A010_HT29_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X2_B24:O12	HT29	REP.A010_HT29_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O07	HT29	REP.A010_HT29_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O08	HT29	REP.A010_HT29_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O09	HT29	REP.A010_HT29_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O10	HT29	REP.A010_HT29_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O11	HT29	REP.A010_HT29_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_HT29_24H_X3_B24:O12	HT29	REP.A010_HT29_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L13	HT29	REP.A023_HT29_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L14	HT29	REP.A023_HT29_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L15	HT29	REP.A023_HT29_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L16	HT29	REP.A023_HT29_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L17	HT29	REP.A023_HT29_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X1_B23:L18	HT29	REP.A023_HT29_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L13	HT29	REP.A023_HT29_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L14	HT29	REP.A023_HT29_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L15	HT29	REP.A023_HT29_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L16	HT29	REP.A023_HT29_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L17	HT29	REP.A023_HT29_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X2_B23:L18	HT29	REP.A023_HT29_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L13	HT29	REP.A023_HT29_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L14	HT29	REP.A023_HT29_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L15	HT29	REP.A023_HT29_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L16	HT29	REP.A023_HT29_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L17	HT29	REP.A023_HT29_24H_X3_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_HT29_24H_X3_B23:L18	HT29	REP.A023_HT29_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F19	HT29	REP.A013_HT29_24H_X1_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F20	HT29	REP.A013_HT29_24H_X1_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F21	HT29	REP.A013_HT29_24H_X1_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F22	HT29	REP.A013_HT29_24H_X1_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F23	HT29	REP.A013_HT29_24H_X1_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X1_B24:F24	HT29	REP.A013_HT29_24H_X1_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F19	HT29	REP.A013_HT29_24H_X2_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F20	HT29	REP.A013_HT29_24H_X2_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F21	HT29	REP.A013_HT29_24H_X2_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F22	HT29	REP.A013_HT29_24H_X2_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F23	HT29	REP.A013_HT29_24H_X2_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X2_B24:F24	HT29	REP.A013_HT29_24H_X2_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X3_B24:F19	HT29	REP.A013_HT29_24H_X3_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X3_B24:F21	HT29	REP.A013_HT29_24H_X3_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X3_B24:F22	HT29	REP.A013_HT29_24H_X3_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X3_B24:F23	HT29	REP.A013_HT29_24H_X3_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_HT29_24H_X3_B24:F24	HT29	REP.A013_HT29_24H_X3_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L01	HT29	REP.A021_HT29_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L02	HT29	REP.A021_HT29_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L03	HT29	REP.A021_HT29_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L04	HT29	REP.A021_HT29_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L05	HT29	REP.A021_HT29_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X1_B23:L06	HT29	REP.A021_HT29_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L01	HT29	REP.A021_HT29_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L02	HT29	REP.A021_HT29_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L03	HT29	REP.A021_HT29_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L04	HT29	REP.A021_HT29_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L05	HT29	REP.A021_HT29_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X2_B23:L06	HT29	REP.A021_HT29_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L01	HT29	REP.A021_HT29_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L02	HT29	REP.A021_HT29_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L03	HT29	REP.A021_HT29_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L04	HT29	REP.A021_HT29_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L05	HT29	REP.A021_HT29_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_HT29_24H_X3_B23:L06	HT29	REP.A021_HT29_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N01	HT29	REP.A026_HT29_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N02	HT29	REP.A026_HT29_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N03	HT29	REP.A026_HT29_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N04	HT29	REP.A026_HT29_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N05	HT29	REP.A026_HT29_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X1_B25:N06	HT29	REP.A026_HT29_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N01	HT29	REP.A026_HT29_24H_X2.A2_B27	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N02	HT29	REP.A026_HT29_24H_X2.A2_B27	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N03	HT29	REP.A026_HT29_24H_X2.A2_B27	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N04	HT29	REP.A026_HT29_24H_X2.A2_B27	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N05	HT29	REP.A026_HT29_24H_X2.A2_B27	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X2.A2_B27:N06	HT29	REP.A026_HT29_24H_X2.A2_B27	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N01	HT29	REP.A026_HT29_24H_X3_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N02	HT29	REP.A026_HT29_24H_X3_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N03	HT29	REP.A026_HT29_24H_X3_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N04	HT29	REP.A026_HT29_24H_X3_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N05	HT29	REP.A026_HT29_24H_X3_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_HT29_24H_X3_B25:N06	HT29	REP.A026_HT29_24H_X3_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	HT29	-666	-666	tumor	large intestine	colorectal adenocarcinoma	adherent	HTB-38	ATCC	44	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F01	MCF7	REP.A011_MCF7_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F02	MCF7	REP.A011_MCF7_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F03	MCF7	REP.A011_MCF7_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F04	MCF7	REP.A011_MCF7_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F05	MCF7	REP.A011_MCF7_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X1_B24:F06	MCF7	REP.A011_MCF7_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F01	MCF7	REP.A011_MCF7_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F02	MCF7	REP.A011_MCF7_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F03	MCF7	REP.A011_MCF7_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F04	MCF7	REP.A011_MCF7_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F05	MCF7	REP.A011_MCF7_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X2_B24:F06	MCF7	REP.A011_MCF7_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F01	MCF7	REP.A011_MCF7_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F02	MCF7	REP.A011_MCF7_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F03	MCF7	REP.A011_MCF7_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F04	MCF7	REP.A011_MCF7_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F05	MCF7	REP.A011_MCF7_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_MCF7_24H_X3_B24:F06	MCF7	REP.A011_MCF7_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L01	MCF7	REP.A007_MCF7_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L02	MCF7	REP.A007_MCF7_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L03	MCF7	REP.A007_MCF7_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L04	MCF7	REP.A007_MCF7_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L05	MCF7	REP.A007_MCF7_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X1_B22:L06	MCF7	REP.A007_MCF7_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L01	MCF7	REP.A007_MCF7_24H_X2_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L02	MCF7	REP.A007_MCF7_24H_X2_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L03	MCF7	REP.A007_MCF7_24H_X2_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L04	MCF7	REP.A007_MCF7_24H_X2_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L05	MCF7	REP.A007_MCF7_24H_X2_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X2_B22:L06	MCF7	REP.A007_MCF7_24H_X2_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X3.A2_B23:L03	MCF7	REP.A007_MCF7_24H_X3.A2_B23	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X3.A2_B23:L04	MCF7	REP.A007_MCF7_24H_X3.A2_B23	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X3.A2_B23:L05	MCF7	REP.A007_MCF7_24H_X3.A2_B23	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_MCF7_24H_X3.A2_B23:L06	MCF7	REP.A007_MCF7_24H_X3.A2_B23	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X1_B22:I13	MCF7	REP.A012_MCF7_24H_X1_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X1_B22:I14	MCF7	REP.A012_MCF7_24H_X1_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X1_B22:I15	MCF7	REP.A012_MCF7_24H_X1_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X1_B22:I16	MCF7	REP.A012_MCF7_24H_X1_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X1_B22:I18	MCF7	REP.A012_MCF7_24H_X1_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I13	MCF7	REP.A012_MCF7_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I14	MCF7	REP.A012_MCF7_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I15	MCF7	REP.A012_MCF7_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I16	MCF7	REP.A012_MCF7_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I17	MCF7	REP.A012_MCF7_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X2_B22:I18	MCF7	REP.A012_MCF7_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X3_B22:I13	MCF7	REP.A012_MCF7_24H_X3_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X3_B22:I14	MCF7	REP.A012_MCF7_24H_X3_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X3_B22:I16	MCF7	REP.A012_MCF7_24H_X3_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X3_B22:I17	MCF7	REP.A012_MCF7_24H_X3_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_MCF7_24H_X3_B22:I18	MCF7	REP.A012_MCF7_24H_X3_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C13	MCF7	REP.A017_MCF7_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C14	MCF7	REP.A017_MCF7_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C15	MCF7	REP.A017_MCF7_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C16	MCF7	REP.A017_MCF7_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C17	MCF7	REP.A017_MCF7_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C18	MCF7	REP.A017_MCF7_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C13	MCF7	REP.A017_MCF7_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C14	MCF7	REP.A017_MCF7_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C15	MCF7	REP.A017_MCF7_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C16	MCF7	REP.A017_MCF7_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C17	MCF7	REP.A017_MCF7_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C18	MCF7	REP.A017_MCF7_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C13	MCF7	REP.A017_MCF7_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C14	MCF7	REP.A017_MCF7_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C15	MCF7	REP.A017_MCF7_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C16	MCF7	REP.A017_MCF7_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C17	MCF7	REP.A017_MCF7_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C18	MCF7	REP.A017_MCF7_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C13	MCF7	REP.A017_MCF7_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C14	MCF7	REP.A017_MCF7_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C15	MCF7	REP.A017_MCF7_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C16	MCF7	REP.A017_MCF7_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C17	MCF7	REP.A017_MCF7_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X1_B23:C18	MCF7	REP.A017_MCF7_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C13	MCF7	REP.A017_MCF7_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C14	MCF7	REP.A017_MCF7_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C15	MCF7	REP.A017_MCF7_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C16	MCF7	REP.A017_MCF7_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C17	MCF7	REP.A017_MCF7_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X2_B23:C18	MCF7	REP.A017_MCF7_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C13	MCF7	REP.A017_MCF7_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C14	MCF7	REP.A017_MCF7_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C15	MCF7	REP.A017_MCF7_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C16	MCF7	REP.A017_MCF7_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C17	MCF7	REP.A017_MCF7_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_MCF7_24H_X3_B23:C18	MCF7	REP.A017_MCF7_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I19	MCF7	REP.A007_MCF7_24H_X1_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I20	MCF7	REP.A007_MCF7_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I21	MCF7	REP.A007_MCF7_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I22	MCF7	REP.A007_MCF7_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I23	MCF7	REP.A007_MCF7_24H_X1_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X1_B22:I24	MCF7	REP.A007_MCF7_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I19	MCF7	REP.A007_MCF7_24H_X2_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I20	MCF7	REP.A007_MCF7_24H_X2_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I21	MCF7	REP.A007_MCF7_24H_X2_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I22	MCF7	REP.A007_MCF7_24H_X2_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I23	MCF7	REP.A007_MCF7_24H_X2_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X2_B22:I24	MCF7	REP.A007_MCF7_24H_X2_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I19	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I20	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I21	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I22	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I23	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_MCF7_24H_X3.A2_B23:I24	MCF7	REP.A007_MCF7_24H_X3.A2_B23	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N01	MCF7	REP.A014_MCF7_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N02	MCF7	REP.A014_MCF7_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N03	MCF7	REP.A014_MCF7_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N04	MCF7	REP.A014_MCF7_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N05	MCF7	REP.A014_MCF7_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X1_B23:N06	MCF7	REP.A014_MCF7_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N01	MCF7	REP.A014_MCF7_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N02	MCF7	REP.A014_MCF7_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N03	MCF7	REP.A014_MCF7_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N04	MCF7	REP.A014_MCF7_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N05	MCF7	REP.A014_MCF7_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X2_B23:N06	MCF7	REP.A014_MCF7_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N01	MCF7	REP.A014_MCF7_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N02	MCF7	REP.A014_MCF7_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N03	MCF7	REP.A014_MCF7_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N04	MCF7	REP.A014_MCF7_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N05	MCF7	REP.A014_MCF7_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_MCF7_24H_X3_B23:N06	MCF7	REP.A014_MCF7_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A13	MCF7	REP.A003_MCF7_24H_X1_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A14	MCF7	REP.A003_MCF7_24H_X1_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A15	MCF7	REP.A003_MCF7_24H_X1_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A16	MCF7	REP.A003_MCF7_24H_X1_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A17	MCF7	REP.A003_MCF7_24H_X1_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X1_B27:A18	MCF7	REP.A003_MCF7_24H_X1_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A13	MCF7	REP.A003_MCF7_24H_X2_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A14	MCF7	REP.A003_MCF7_24H_X2_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A15	MCF7	REP.A003_MCF7_24H_X2_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A16	MCF7	REP.A003_MCF7_24H_X2_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A17	MCF7	REP.A003_MCF7_24H_X2_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X2_B27:A18	MCF7	REP.A003_MCF7_24H_X2_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A13	MCF7	REP.A003_MCF7_24H_X3_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A14	MCF7	REP.A003_MCF7_24H_X3_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A15	MCF7	REP.A003_MCF7_24H_X3_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A16	MCF7	REP.A003_MCF7_24H_X3_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A17	MCF7	REP.A003_MCF7_24H_X3_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_MCF7_24H_X3_B27:A18	MCF7	REP.A003_MCF7_24H_X3_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H13	MCF7	REP.A016_MCF7_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H14	MCF7	REP.A016_MCF7_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H15	MCF7	REP.A016_MCF7_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H16	MCF7	REP.A016_MCF7_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H17	MCF7	REP.A016_MCF7_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X1_B23:H18	MCF7	REP.A016_MCF7_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X2_B23:H13	MCF7	REP.A016_MCF7_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X2_B23:H14	MCF7	REP.A016_MCF7_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X2_B23:H15	MCF7	REP.A016_MCF7_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X2_B23:H17	MCF7	REP.A016_MCF7_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X2_B23:H18	MCF7	REP.A016_MCF7_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H13	MCF7	REP.A016_MCF7_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H14	MCF7	REP.A016_MCF7_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H15	MCF7	REP.A016_MCF7_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H16	MCF7	REP.A016_MCF7_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H17	MCF7	REP.A016_MCF7_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_MCF7_24H_X3_B23:H18	MCF7	REP.A016_MCF7_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E01	MCF7	REP.A013_MCF7_24H_X1_B24	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E02	MCF7	REP.A013_MCF7_24H_X1_B24	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E03	MCF7	REP.A013_MCF7_24H_X1_B24	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E04	MCF7	REP.A013_MCF7_24H_X1_B24	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E05	MCF7	REP.A013_MCF7_24H_X1_B24	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X1_B24:E06	MCF7	REP.A013_MCF7_24H_X1_B24	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E01	MCF7	REP.A013_MCF7_24H_X2_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E02	MCF7	REP.A013_MCF7_24H_X2_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E03	MCF7	REP.A013_MCF7_24H_X2_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E04	MCF7	REP.A013_MCF7_24H_X2_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E05	MCF7	REP.A013_MCF7_24H_X2_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X2_B22:E06	MCF7	REP.A013_MCF7_24H_X2_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E01	MCF7	REP.A013_MCF7_24H_X3_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E02	MCF7	REP.A013_MCF7_24H_X3_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E03	MCF7	REP.A013_MCF7_24H_X3_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E04	MCF7	REP.A013_MCF7_24H_X3_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E05	MCF7	REP.A013_MCF7_24H_X3_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_MCF7_24H_X3_B22:E06	MCF7	REP.A013_MCF7_24H_X3_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N19	MCF7	REP.A004_MCF7_24H_X1_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N20	MCF7	REP.A004_MCF7_24H_X1_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N21	MCF7	REP.A004_MCF7_24H_X1_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N22	MCF7	REP.A004_MCF7_24H_X1_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N23	MCF7	REP.A004_MCF7_24H_X1_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X1_B27:N24	MCF7	REP.A004_MCF7_24H_X1_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N19	MCF7	REP.A004_MCF7_24H_X2_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N20	MCF7	REP.A004_MCF7_24H_X2_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N21	MCF7	REP.A004_MCF7_24H_X2_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N22	MCF7	REP.A004_MCF7_24H_X2_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N23	MCF7	REP.A004_MCF7_24H_X2_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X2_B27:N24	MCF7	REP.A004_MCF7_24H_X2_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N19	MCF7	REP.A004_MCF7_24H_X3_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N20	MCF7	REP.A004_MCF7_24H_X3_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N21	MCF7	REP.A004_MCF7_24H_X3_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N22	MCF7	REP.A004_MCF7_24H_X3_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N23	MCF7	REP.A004_MCF7_24H_X3_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_MCF7_24H_X3_B27:N24	MCF7	REP.A004_MCF7_24H_X3_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C07	MCF7	REP.A004_MCF7_24H_X1_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C08	MCF7	REP.A004_MCF7_24H_X1_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C09	MCF7	REP.A004_MCF7_24H_X1_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C10	MCF7	REP.A004_MCF7_24H_X1_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C11	MCF7	REP.A004_MCF7_24H_X1_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X1_B27:C12	MCF7	REP.A004_MCF7_24H_X1_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C07	MCF7	REP.A004_MCF7_24H_X2_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C08	MCF7	REP.A004_MCF7_24H_X2_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C09	MCF7	REP.A004_MCF7_24H_X2_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C10	MCF7	REP.A004_MCF7_24H_X2_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C11	MCF7	REP.A004_MCF7_24H_X2_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X2_B27:C12	MCF7	REP.A004_MCF7_24H_X2_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C07	MCF7	REP.A004_MCF7_24H_X3_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C08	MCF7	REP.A004_MCF7_24H_X3_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C09	MCF7	REP.A004_MCF7_24H_X3_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C10	MCF7	REP.A004_MCF7_24H_X3_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C11	MCF7	REP.A004_MCF7_24H_X3_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_MCF7_24H_X3_B27:C12	MCF7	REP.A004_MCF7_24H_X3_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I13	MCF7	REP.A017_MCF7_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I14	MCF7	REP.A017_MCF7_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I15	MCF7	REP.A017_MCF7_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I16	MCF7	REP.A017_MCF7_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I17	MCF7	REP.A017_MCF7_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X1_B23:I18	MCF7	REP.A017_MCF7_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I13	MCF7	REP.A017_MCF7_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I14	MCF7	REP.A017_MCF7_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I15	MCF7	REP.A017_MCF7_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I16	MCF7	REP.A017_MCF7_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I17	MCF7	REP.A017_MCF7_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X2_B23:I18	MCF7	REP.A017_MCF7_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I13	MCF7	REP.A017_MCF7_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I14	MCF7	REP.A017_MCF7_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I15	MCF7	REP.A017_MCF7_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I16	MCF7	REP.A017_MCF7_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I17	MCF7	REP.A017_MCF7_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_MCF7_24H_X3_B23:I18	MCF7	REP.A017_MCF7_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M07	MCF7	REP.A011_MCF7_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M08	MCF7	REP.A011_MCF7_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M09	MCF7	REP.A011_MCF7_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M10	MCF7	REP.A011_MCF7_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M11	MCF7	REP.A011_MCF7_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X1_B24:M12	MCF7	REP.A011_MCF7_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M07	MCF7	REP.A011_MCF7_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M08	MCF7	REP.A011_MCF7_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M09	MCF7	REP.A011_MCF7_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M10	MCF7	REP.A011_MCF7_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M11	MCF7	REP.A011_MCF7_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X2_B24:M12	MCF7	REP.A011_MCF7_24H_X2_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M07	MCF7	REP.A011_MCF7_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M08	MCF7	REP.A011_MCF7_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M09	MCF7	REP.A011_MCF7_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M10	MCF7	REP.A011_MCF7_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M11	MCF7	REP.A011_MCF7_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_MCF7_24H_X3_B24:M12	MCF7	REP.A011_MCF7_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X1_B24:P19	MCF7	REP.A008_MCF7_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X1_B24:P20	MCF7	REP.A008_MCF7_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X1_B24:P21	MCF7	REP.A008_MCF7_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X1_B24:P23	MCF7	REP.A008_MCF7_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X1_B24:P24	MCF7	REP.A008_MCF7_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P19	MCF7	REP.A008_MCF7_24H_X2_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P20	MCF7	REP.A008_MCF7_24H_X2_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P21	MCF7	REP.A008_MCF7_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P22	MCF7	REP.A008_MCF7_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P23	MCF7	REP.A008_MCF7_24H_X2_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X2_B24:P24	MCF7	REP.A008_MCF7_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P19	MCF7	REP.A008_MCF7_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P20	MCF7	REP.A008_MCF7_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P21	MCF7	REP.A008_MCF7_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P22	MCF7	REP.A008_MCF7_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P23	MCF7	REP.A008_MCF7_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_MCF7_24H_X3_B24:P24	MCF7	REP.A008_MCF7_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X1_B25:J07	MCF7	REP.A026_MCF7_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X1_B25:J09	MCF7	REP.A026_MCF7_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X1_B25:J10	MCF7	REP.A026_MCF7_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X1_B25:J12	MCF7	REP.A026_MCF7_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X2_B25:J07	MCF7	REP.A026_MCF7_24H_X2_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X2_B25:J08	MCF7	REP.A026_MCF7_24H_X2_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X2_B25:J10	MCF7	REP.A026_MCF7_24H_X2_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X2_B25:J11	MCF7	REP.A026_MCF7_24H_X2_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X2_B25:J12	MCF7	REP.A026_MCF7_24H_X2_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J07	MCF7	REP.A026_MCF7_24H_X3_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J08	MCF7	REP.A026_MCF7_24H_X3_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J09	MCF7	REP.A026_MCF7_24H_X3_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J10	MCF7	REP.A026_MCF7_24H_X3_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J11	MCF7	REP.A026_MCF7_24H_X3_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_MCF7_24H_X3_B25:J12	MCF7	REP.A026_MCF7_24H_X3_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D13	MCF7	REP.A013_MCF7_24H_X1_B24	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D14	MCF7	REP.A013_MCF7_24H_X1_B24	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D15	MCF7	REP.A013_MCF7_24H_X1_B24	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D16	MCF7	REP.A013_MCF7_24H_X1_B24	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D17	MCF7	REP.A013_MCF7_24H_X1_B24	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X1_B24:D18	MCF7	REP.A013_MCF7_24H_X1_B24	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X2_B22:D13	MCF7	REP.A013_MCF7_24H_X2_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X2_B22:D15	MCF7	REP.A013_MCF7_24H_X2_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X2_B22:D17	MCF7	REP.A013_MCF7_24H_X2_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X2_B22:D18	MCF7	REP.A013_MCF7_24H_X2_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D13	MCF7	REP.A013_MCF7_24H_X3_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D14	MCF7	REP.A013_MCF7_24H_X3_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D15	MCF7	REP.A013_MCF7_24H_X3_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D16	MCF7	REP.A013_MCF7_24H_X3_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D17	MCF7	REP.A013_MCF7_24H_X3_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_MCF7_24H_X3_B22:D18	MCF7	REP.A013_MCF7_24H_X3_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L01	MCF7	REP.A013_MCF7_24H_X1_B24	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L02	MCF7	REP.A013_MCF7_24H_X1_B24	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L03	MCF7	REP.A013_MCF7_24H_X1_B24	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L04	MCF7	REP.A013_MCF7_24H_X1_B24	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L05	MCF7	REP.A013_MCF7_24H_X1_B24	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X1_B24:L06	MCF7	REP.A013_MCF7_24H_X1_B24	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L01	MCF7	REP.A013_MCF7_24H_X2_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L02	MCF7	REP.A013_MCF7_24H_X2_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L03	MCF7	REP.A013_MCF7_24H_X2_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L04	MCF7	REP.A013_MCF7_24H_X2_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L05	MCF7	REP.A013_MCF7_24H_X2_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X2_B22:L06	MCF7	REP.A013_MCF7_24H_X2_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L01	MCF7	REP.A013_MCF7_24H_X3_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L02	MCF7	REP.A013_MCF7_24H_X3_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L03	MCF7	REP.A013_MCF7_24H_X3_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L04	MCF7	REP.A013_MCF7_24H_X3_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L05	MCF7	REP.A013_MCF7_24H_X3_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_MCF7_24H_X3_B22:L06	MCF7	REP.A013_MCF7_24H_X3_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X1_B23:I01	MCF7	REP.A023_MCF7_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X1_B23:I03	MCF7	REP.A023_MCF7_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X1_B23:I04	MCF7	REP.A023_MCF7_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X1_B23:I05	MCF7	REP.A023_MCF7_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I01	MCF7	REP.A023_MCF7_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I02	MCF7	REP.A023_MCF7_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I03	MCF7	REP.A023_MCF7_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I04	MCF7	REP.A023_MCF7_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I05	MCF7	REP.A023_MCF7_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X2_B23:I06	MCF7	REP.A023_MCF7_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I01	MCF7	REP.A023_MCF7_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I02	MCF7	REP.A023_MCF7_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I03	MCF7	REP.A023_MCF7_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I04	MCF7	REP.A023_MCF7_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I05	MCF7	REP.A023_MCF7_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_MCF7_24H_X3_B23:I06	MCF7	REP.A023_MCF7_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N07	MCF7	LJP008_MCF7_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N08	MCF7	LJP008_MCF7_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N09	MCF7	LJP008_MCF7_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N10	MCF7	LJP008_MCF7_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N11	MCF7	LJP008_MCF7_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X1_B20:N12	MCF7	LJP008_MCF7_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N07	MCF7	LJP008_MCF7_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N08	MCF7	LJP008_MCF7_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N09	MCF7	LJP008_MCF7_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N10	MCF7	LJP008_MCF7_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N11	MCF7	LJP008_MCF7_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X2_B20:N12	MCF7	LJP008_MCF7_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N07	MCF7	LJP008_MCF7_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N08	MCF7	LJP008_MCF7_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N09	MCF7	LJP008_MCF7_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N10	MCF7	LJP008_MCF7_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N11	MCF7	LJP008_MCF7_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_MCF7_24H_X3_B20:N12	MCF7	LJP008_MCF7_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G07	MCF7	REP.A022_MCF7_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G08	MCF7	REP.A022_MCF7_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G09	MCF7	REP.A022_MCF7_24H_X1_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G10	MCF7	REP.A022_MCF7_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G11	MCF7	REP.A022_MCF7_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X1_B23:G12	MCF7	REP.A022_MCF7_24H_X1_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G07	MCF7	REP.A022_MCF7_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G08	MCF7	REP.A022_MCF7_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G09	MCF7	REP.A022_MCF7_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G10	MCF7	REP.A022_MCF7_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G11	MCF7	REP.A022_MCF7_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X2_B23:G12	MCF7	REP.A022_MCF7_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G07	MCF7	REP.A022_MCF7_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G08	MCF7	REP.A022_MCF7_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G09	MCF7	REP.A022_MCF7_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G10	MCF7	REP.A022_MCF7_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G11	MCF7	REP.A022_MCF7_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_MCF7_24H_X3_B23:G12	MCF7	REP.A022_MCF7_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A19	MCF7	REP.A004_MCF7_24H_X1_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A20	MCF7	REP.A004_MCF7_24H_X1_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A21	MCF7	REP.A004_MCF7_24H_X1_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A22	MCF7	REP.A004_MCF7_24H_X1_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A23	MCF7	REP.A004_MCF7_24H_X1_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X1_B27:A24	MCF7	REP.A004_MCF7_24H_X1_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A19	MCF7	REP.A004_MCF7_24H_X2_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A20	MCF7	REP.A004_MCF7_24H_X2_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A21	MCF7	REP.A004_MCF7_24H_X2_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A22	MCF7	REP.A004_MCF7_24H_X2_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A23	MCF7	REP.A004_MCF7_24H_X2_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X2_B27:A24	MCF7	REP.A004_MCF7_24H_X2_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A19	MCF7	REP.A004_MCF7_24H_X3_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A20	MCF7	REP.A004_MCF7_24H_X3_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A21	MCF7	REP.A004_MCF7_24H_X3_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A22	MCF7	REP.A004_MCF7_24H_X3_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A23	MCF7	REP.A004_MCF7_24H_X3_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_MCF7_24H_X3_B27:A24	MCF7	REP.A004_MCF7_24H_X3_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D07	MCF7	REP.A016_MCF7_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D08	MCF7	REP.A016_MCF7_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D09	MCF7	REP.A016_MCF7_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D10	MCF7	REP.A016_MCF7_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D11	MCF7	REP.A016_MCF7_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X1_B23:D12	MCF7	REP.A016_MCF7_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D07	MCF7	REP.A016_MCF7_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D08	MCF7	REP.A016_MCF7_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D09	MCF7	REP.A016_MCF7_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D10	MCF7	REP.A016_MCF7_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D11	MCF7	REP.A016_MCF7_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X2_B23:D12	MCF7	REP.A016_MCF7_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D07	MCF7	REP.A016_MCF7_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D08	MCF7	REP.A016_MCF7_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D09	MCF7	REP.A016_MCF7_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D10	MCF7	REP.A016_MCF7_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D11	MCF7	REP.A016_MCF7_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_MCF7_24H_X3_B23:D12	MCF7	REP.A016_MCF7_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O07	MCF7	REP.A010_MCF7_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O08	MCF7	REP.A010_MCF7_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O09	MCF7	REP.A010_MCF7_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O10	MCF7	REP.A010_MCF7_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O11	MCF7	REP.A010_MCF7_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X1_B24:O12	MCF7	REP.A010_MCF7_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O07	MCF7	REP.A010_MCF7_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O08	MCF7	REP.A010_MCF7_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O09	MCF7	REP.A010_MCF7_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O10	MCF7	REP.A010_MCF7_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O11	MCF7	REP.A010_MCF7_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X2_B24:O12	MCF7	REP.A010_MCF7_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O07	MCF7	REP.A010_MCF7_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O08	MCF7	REP.A010_MCF7_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O09	MCF7	REP.A010_MCF7_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O10	MCF7	REP.A010_MCF7_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O11	MCF7	REP.A010_MCF7_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_MCF7_24H_X3_B24:O12	MCF7	REP.A010_MCF7_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L13	MCF7	REP.A023_MCF7_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L14	MCF7	REP.A023_MCF7_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L15	MCF7	REP.A023_MCF7_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L16	MCF7	REP.A023_MCF7_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L17	MCF7	REP.A023_MCF7_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X1_B23:L18	MCF7	REP.A023_MCF7_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L13	MCF7	REP.A023_MCF7_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L14	MCF7	REP.A023_MCF7_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L15	MCF7	REP.A023_MCF7_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L16	MCF7	REP.A023_MCF7_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L17	MCF7	REP.A023_MCF7_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X2_B23:L18	MCF7	REP.A023_MCF7_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L13	MCF7	REP.A023_MCF7_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L14	MCF7	REP.A023_MCF7_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L15	MCF7	REP.A023_MCF7_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L16	MCF7	REP.A023_MCF7_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L17	MCF7	REP.A023_MCF7_24H_X3_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_MCF7_24H_X3_B23:L18	MCF7	REP.A023_MCF7_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F19	MCF7	REP.A013_MCF7_24H_X1_B24	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F20	MCF7	REP.A013_MCF7_24H_X1_B24	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F21	MCF7	REP.A013_MCF7_24H_X1_B24	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F22	MCF7	REP.A013_MCF7_24H_X1_B24	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F23	MCF7	REP.A013_MCF7_24H_X1_B24	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X1_B24:F24	MCF7	REP.A013_MCF7_24H_X1_B24	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F19	MCF7	REP.A013_MCF7_24H_X2_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F20	MCF7	REP.A013_MCF7_24H_X2_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F21	MCF7	REP.A013_MCF7_24H_X2_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F22	MCF7	REP.A013_MCF7_24H_X2_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F23	MCF7	REP.A013_MCF7_24H_X2_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X2_B22:F24	MCF7	REP.A013_MCF7_24H_X2_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F19	MCF7	REP.A013_MCF7_24H_X3_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F20	MCF7	REP.A013_MCF7_24H_X3_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F21	MCF7	REP.A013_MCF7_24H_X3_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F22	MCF7	REP.A013_MCF7_24H_X3_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F23	MCF7	REP.A013_MCF7_24H_X3_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_MCF7_24H_X3_B22:F24	MCF7	REP.A013_MCF7_24H_X3_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L01	MCF7	REP.A021_MCF7_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L02	MCF7	REP.A021_MCF7_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L03	MCF7	REP.A021_MCF7_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L04	MCF7	REP.A021_MCF7_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L05	MCF7	REP.A021_MCF7_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X1_B23:L06	MCF7	REP.A021_MCF7_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L01	MCF7	REP.A021_MCF7_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L02	MCF7	REP.A021_MCF7_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L03	MCF7	REP.A021_MCF7_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L04	MCF7	REP.A021_MCF7_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L05	MCF7	REP.A021_MCF7_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X2_B23:L06	MCF7	REP.A021_MCF7_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L01	MCF7	REP.A021_MCF7_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L02	MCF7	REP.A021_MCF7_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L03	MCF7	REP.A021_MCF7_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L04	MCF7	REP.A021_MCF7_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L05	MCF7	REP.A021_MCF7_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_MCF7_24H_X3_B23:L06	MCF7	REP.A021_MCF7_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N01	MCF7	REP.A026_MCF7_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N02	MCF7	REP.A026_MCF7_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N03	MCF7	REP.A026_MCF7_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N04	MCF7	REP.A026_MCF7_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N05	MCF7	REP.A026_MCF7_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X1_B25:N06	MCF7	REP.A026_MCF7_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N01	MCF7	REP.A026_MCF7_24H_X2_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N02	MCF7	REP.A026_MCF7_24H_X2_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N03	MCF7	REP.A026_MCF7_24H_X2_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N04	MCF7	REP.A026_MCF7_24H_X2_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N05	MCF7	REP.A026_MCF7_24H_X2_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X2_B25:N06	MCF7	REP.A026_MCF7_24H_X2_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N01	MCF7	REP.A026_MCF7_24H_X3_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N02	MCF7	REP.A026_MCF7_24H_X3_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N03	MCF7	REP.A026_MCF7_24H_X3_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N04	MCF7	REP.A026_MCF7_24H_X3_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N05	MCF7	REP.A026_MCF7_24H_X3_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_MCF7_24H_X3_B25:N06	MCF7	REP.A026_MCF7_24H_X3_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	MCF7	-666	-666	tumor	breast	adenocarcinoma	adherent	HTB-22	ATCC	69	F	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F01	PC3	REP.A011_PC3_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F02	PC3	REP.A011_PC3_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F03	PC3	REP.A011_PC3_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F04	PC3	REP.A011_PC3_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F05	PC3	REP.A011_PC3_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X1_B24:F06	PC3	REP.A011_PC3_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F01	PC3	REP.A011_PC3_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F02	PC3	REP.A011_PC3_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F03	PC3	REP.A011_PC3_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F04	PC3	REP.A011_PC3_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F05	PC3	REP.A011_PC3_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X2_B24:F06	PC3	REP.A011_PC3_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F01	PC3	REP.A011_PC3_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F02	PC3	REP.A011_PC3_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F03	PC3	REP.A011_PC3_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F04	PC3	REP.A011_PC3_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F05	PC3	REP.A011_PC3_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_PC3_24H_X3_B24:F06	PC3	REP.A011_PC3_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L01	PC3	REP.A007_PC3_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L02	PC3	REP.A007_PC3_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L03	PC3	REP.A007_PC3_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L04	PC3	REP.A007_PC3_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L05	PC3	REP.A007_PC3_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X1_B22:L06	PC3	REP.A007_PC3_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L01	PC3	REP.A007_PC3_24H_X2_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L02	PC3	REP.A007_PC3_24H_X2_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L03	PC3	REP.A007_PC3_24H_X2_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L04	PC3	REP.A007_PC3_24H_X2_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L05	PC3	REP.A007_PC3_24H_X2_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X2_B22:L06	PC3	REP.A007_PC3_24H_X2_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L01	PC3	REP.A007_PC3_24H_X3.A2_B23	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L02	PC3	REP.A007_PC3_24H_X3.A2_B23	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L03	PC3	REP.A007_PC3_24H_X3.A2_B23	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L04	PC3	REP.A007_PC3_24H_X3.A2_B23	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L05	PC3	REP.A007_PC3_24H_X3.A2_B23	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_PC3_24H_X3.A2_B23:L06	PC3	REP.A007_PC3_24H_X3.A2_B23	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X1_B22:I14	PC3	REP.A012_PC3_24H_X1_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X1_B22:I15	PC3	REP.A012_PC3_24H_X1_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X1_B22:I16	PC3	REP.A012_PC3_24H_X1_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X1_B22:I17	PC3	REP.A012_PC3_24H_X1_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X1_B22:I18	PC3	REP.A012_PC3_24H_X1_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I13	PC3	REP.A012_PC3_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I14	PC3	REP.A012_PC3_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I15	PC3	REP.A012_PC3_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I16	PC3	REP.A012_PC3_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I17	PC3	REP.A012_PC3_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X2_B22:I18	PC3	REP.A012_PC3_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I13	PC3	REP.A012_PC3_24H_X3_B24	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I14	PC3	REP.A012_PC3_24H_X3_B24	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I15	PC3	REP.A012_PC3_24H_X3_B24	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I16	PC3	REP.A012_PC3_24H_X3_B24	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I17	PC3	REP.A012_PC3_24H_X3_B24	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_PC3_24H_X3_B24:I18	PC3	REP.A012_PC3_24H_X3_B24	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C13	PC3	REP.A017_PC3_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C14	PC3	REP.A017_PC3_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C15	PC3	REP.A017_PC3_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C16	PC3	REP.A017_PC3_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C17	PC3	REP.A017_PC3_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C18	PC3	REP.A017_PC3_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C13	PC3	REP.A017_PC3_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C14	PC3	REP.A017_PC3_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C15	PC3	REP.A017_PC3_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C16	PC3	REP.A017_PC3_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C17	PC3	REP.A017_PC3_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C18	PC3	REP.A017_PC3_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C13	PC3	REP.A017_PC3_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C14	PC3	REP.A017_PC3_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C15	PC3	REP.A017_PC3_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C16	PC3	REP.A017_PC3_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C17	PC3	REP.A017_PC3_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C18	PC3	REP.A017_PC3_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C13	PC3	REP.A017_PC3_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C14	PC3	REP.A017_PC3_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C15	PC3	REP.A017_PC3_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C16	PC3	REP.A017_PC3_24H_X1_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C17	PC3	REP.A017_PC3_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X1_B23:C18	PC3	REP.A017_PC3_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C13	PC3	REP.A017_PC3_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C14	PC3	REP.A017_PC3_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C15	PC3	REP.A017_PC3_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C16	PC3	REP.A017_PC3_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C17	PC3	REP.A017_PC3_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X2_B23:C18	PC3	REP.A017_PC3_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C13	PC3	REP.A017_PC3_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C14	PC3	REP.A017_PC3_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C15	PC3	REP.A017_PC3_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C16	PC3	REP.A017_PC3_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C17	PC3	REP.A017_PC3_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_PC3_24H_X3_B23:C18	PC3	REP.A017_PC3_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X1_B22:I19	PC3	REP.A007_PC3_24H_X1_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X1_B22:I20	PC3	REP.A007_PC3_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X1_B22:I21	PC3	REP.A007_PC3_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X1_B22:I22	PC3	REP.A007_PC3_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X1_B22:I24	PC3	REP.A007_PC3_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I19	PC3	REP.A007_PC3_24H_X2_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I20	PC3	REP.A007_PC3_24H_X2_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I21	PC3	REP.A007_PC3_24H_X2_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I22	PC3	REP.A007_PC3_24H_X2_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I23	PC3	REP.A007_PC3_24H_X2_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_PC3_24H_X2_B22:I24	PC3	REP.A007_PC3_24H_X2_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N01	PC3	REP.A014_PC3_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N02	PC3	REP.A014_PC3_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N03	PC3	REP.A014_PC3_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N04	PC3	REP.A014_PC3_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N05	PC3	REP.A014_PC3_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X1_B23:N06	PC3	REP.A014_PC3_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N01	PC3	REP.A014_PC3_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N02	PC3	REP.A014_PC3_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N03	PC3	REP.A014_PC3_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N04	PC3	REP.A014_PC3_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N05	PC3	REP.A014_PC3_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X2_B23:N06	PC3	REP.A014_PC3_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N01	PC3	REP.A014_PC3_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N02	PC3	REP.A014_PC3_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N03	PC3	REP.A014_PC3_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N04	PC3	REP.A014_PC3_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N05	PC3	REP.A014_PC3_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_PC3_24H_X3_B23:N06	PC3	REP.A014_PC3_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A13	PC3	REP.A003_PC3_24H_X1_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A14	PC3	REP.A003_PC3_24H_X1_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A15	PC3	REP.A003_PC3_24H_X1_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A16	PC3	REP.A003_PC3_24H_X1_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A17	PC3	REP.A003_PC3_24H_X1_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X1_B22:A18	PC3	REP.A003_PC3_24H_X1_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A13	PC3	REP.A003_PC3_24H_X2_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A14	PC3	REP.A003_PC3_24H_X2_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A15	PC3	REP.A003_PC3_24H_X2_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A16	PC3	REP.A003_PC3_24H_X2_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A17	PC3	REP.A003_PC3_24H_X2_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X2_B22:A18	PC3	REP.A003_PC3_24H_X2_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A13	PC3	REP.A003_PC3_24H_X3_B22	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A14	PC3	REP.A003_PC3_24H_X3_B22	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A15	PC3	REP.A003_PC3_24H_X3_B22	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A16	PC3	REP.A003_PC3_24H_X3_B22	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A17	PC3	REP.A003_PC3_24H_X3_B22	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_PC3_24H_X3_B22:A18	PC3	REP.A003_PC3_24H_X3_B22	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H13	PC3	REP.A016_PC3_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H14	PC3	REP.A016_PC3_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H15	PC3	REP.A016_PC3_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H16	PC3	REP.A016_PC3_24H_X1_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H17	PC3	REP.A016_PC3_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X1_B23:H18	PC3	REP.A016_PC3_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H13	PC3	REP.A016_PC3_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H14	PC3	REP.A016_PC3_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H15	PC3	REP.A016_PC3_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H16	PC3	REP.A016_PC3_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H17	PC3	REP.A016_PC3_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X2_B23:H18	PC3	REP.A016_PC3_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X3_B23:H13	PC3	REP.A016_PC3_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X3_B23:H14	PC3	REP.A016_PC3_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X3_B23:H15	PC3	REP.A016_PC3_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X3_B23:H17	PC3	REP.A016_PC3_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_PC3_24H_X3_B23:H18	PC3	REP.A016_PC3_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E01	PC3	REP.A013_PC3_24H_X1_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E02	PC3	REP.A013_PC3_24H_X1_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E03	PC3	REP.A013_PC3_24H_X1_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E04	PC3	REP.A013_PC3_24H_X1_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E05	PC3	REP.A013_PC3_24H_X1_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X1_B22:E06	PC3	REP.A013_PC3_24H_X1_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E01	PC3	REP.A013_PC3_24H_X2_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E02	PC3	REP.A013_PC3_24H_X2_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E03	PC3	REP.A013_PC3_24H_X2_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E04	PC3	REP.A013_PC3_24H_X2_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E05	PC3	REP.A013_PC3_24H_X2_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X2_B22:E06	PC3	REP.A013_PC3_24H_X2_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X3_B22:E01	PC3	REP.A013_PC3_24H_X3_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X3_B22:E02	PC3	REP.A013_PC3_24H_X3_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X3_B22:E03	PC3	REP.A013_PC3_24H_X3_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X3_B22:E05	PC3	REP.A013_PC3_24H_X3_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_PC3_24H_X3_B22:E06	PC3	REP.A013_PC3_24H_X3_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N19	PC3	REP.A004_PC3_24H_X1_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N20	PC3	REP.A004_PC3_24H_X1_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N21	PC3	REP.A004_PC3_24H_X1_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N22	PC3	REP.A004_PC3_24H_X1_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N23	PC3	REP.A004_PC3_24H_X1_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X1_B22:N24	PC3	REP.A004_PC3_24H_X1_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N19	PC3	REP.A004_PC3_24H_X2_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N20	PC3	REP.A004_PC3_24H_X2_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N21	PC3	REP.A004_PC3_24H_X2_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N22	PC3	REP.A004_PC3_24H_X2_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N23	PC3	REP.A004_PC3_24H_X2_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X2_B22:N24	PC3	REP.A004_PC3_24H_X2_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N19	PC3	REP.A004_PC3_24H_X3_B22	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N20	PC3	REP.A004_PC3_24H_X3_B22	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N21	PC3	REP.A004_PC3_24H_X3_B22	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N22	PC3	REP.A004_PC3_24H_X3_B22	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N23	PC3	REP.A004_PC3_24H_X3_B22	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_PC3_24H_X3_B22:N24	PC3	REP.A004_PC3_24H_X3_B22	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C07	PC3	REP.A004_PC3_24H_X1_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C08	PC3	REP.A004_PC3_24H_X1_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C09	PC3	REP.A004_PC3_24H_X1_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C10	PC3	REP.A004_PC3_24H_X1_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C11	PC3	REP.A004_PC3_24H_X1_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X1_B22:C12	PC3	REP.A004_PC3_24H_X1_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C07	PC3	REP.A004_PC3_24H_X2_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C08	PC3	REP.A004_PC3_24H_X2_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C09	PC3	REP.A004_PC3_24H_X2_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C10	PC3	REP.A004_PC3_24H_X2_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C11	PC3	REP.A004_PC3_24H_X2_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X2_B22:C12	PC3	REP.A004_PC3_24H_X2_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C07	PC3	REP.A004_PC3_24H_X3_B22	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C08	PC3	REP.A004_PC3_24H_X3_B22	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C09	PC3	REP.A004_PC3_24H_X3_B22	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C10	PC3	REP.A004_PC3_24H_X3_B22	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C11	PC3	REP.A004_PC3_24H_X3_B22	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_PC3_24H_X3_B22:C12	PC3	REP.A004_PC3_24H_X3_B22	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I13	PC3	REP.A017_PC3_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I14	PC3	REP.A017_PC3_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I15	PC3	REP.A017_PC3_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I16	PC3	REP.A017_PC3_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I17	PC3	REP.A017_PC3_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X1_B23:I18	PC3	REP.A017_PC3_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I13	PC3	REP.A017_PC3_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I14	PC3	REP.A017_PC3_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I15	PC3	REP.A017_PC3_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I16	PC3	REP.A017_PC3_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I17	PC3	REP.A017_PC3_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X2_B23:I18	PC3	REP.A017_PC3_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X3_B23:I13	PC3	REP.A017_PC3_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X3_B23:I14	PC3	REP.A017_PC3_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X3_B23:I15	PC3	REP.A017_PC3_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_PC3_24H_X3_B23:I17	PC3	REP.A017_PC3_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M07	PC3	REP.A011_PC3_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M08	PC3	REP.A011_PC3_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M09	PC3	REP.A011_PC3_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M10	PC3	REP.A011_PC3_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M11	PC3	REP.A011_PC3_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X1_B24:M12	PC3	REP.A011_PC3_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M07	PC3	REP.A011_PC3_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M08	PC3	REP.A011_PC3_24H_X2_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M09	PC3	REP.A011_PC3_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M10	PC3	REP.A011_PC3_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M11	PC3	REP.A011_PC3_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X2_B24:M12	PC3	REP.A011_PC3_24H_X2_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M07	PC3	REP.A011_PC3_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M08	PC3	REP.A011_PC3_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M09	PC3	REP.A011_PC3_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M10	PC3	REP.A011_PC3_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M11	PC3	REP.A011_PC3_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_PC3_24H_X3_B24:M12	PC3	REP.A011_PC3_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P19	PC3	REP.A008_PC3_24H_X1_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P20	PC3	REP.A008_PC3_24H_X1_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P21	PC3	REP.A008_PC3_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P22	PC3	REP.A008_PC3_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P23	PC3	REP.A008_PC3_24H_X1_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X1_B24:P24	PC3	REP.A008_PC3_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X2_B24:P21	PC3	REP.A008_PC3_24H_X2_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X2_B24:P22	PC3	REP.A008_PC3_24H_X2_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X2_B24:P24	PC3	REP.A008_PC3_24H_X2_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P19	PC3	REP.A008_PC3_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P20	PC3	REP.A008_PC3_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P21	PC3	REP.A008_PC3_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P22	PC3	REP.A008_PC3_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P23	PC3	REP.A008_PC3_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_PC3_24H_X3_B24:P24	PC3	REP.A008_PC3_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J07	PC3	REP.A026_PC3_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J08	PC3	REP.A026_PC3_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J09	PC3	REP.A026_PC3_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J10	PC3	REP.A026_PC3_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J11	PC3	REP.A026_PC3_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X1_B25:J12	PC3	REP.A026_PC3_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J07	PC3	REP.A026_PC3_24H_X3.A2_B27	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J08	PC3	REP.A026_PC3_24H_X3.A2_B27	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J09	PC3	REP.A026_PC3_24H_X3.A2_B27	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J10	PC3	REP.A026_PC3_24H_X3.A2_B27	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J11	PC3	REP.A026_PC3_24H_X3.A2_B27	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_PC3_24H_X3.A2_B27:J12	PC3	REP.A026_PC3_24H_X3.A2_B27	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D13	PC3	REP.A013_PC3_24H_X1_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D14	PC3	REP.A013_PC3_24H_X1_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D15	PC3	REP.A013_PC3_24H_X1_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D16	PC3	REP.A013_PC3_24H_X1_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D17	PC3	REP.A013_PC3_24H_X1_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X1_B22:D18	PC3	REP.A013_PC3_24H_X1_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D13	PC3	REP.A013_PC3_24H_X2_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D14	PC3	REP.A013_PC3_24H_X2_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D15	PC3	REP.A013_PC3_24H_X2_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D16	PC3	REP.A013_PC3_24H_X2_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D17	PC3	REP.A013_PC3_24H_X2_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X2_B22:D18	PC3	REP.A013_PC3_24H_X2_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X3_B22:D15	PC3	REP.A013_PC3_24H_X3_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X3_B22:D16	PC3	REP.A013_PC3_24H_X3_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X3_B22:D17	PC3	REP.A013_PC3_24H_X3_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_PC3_24H_X3_B22:D18	PC3	REP.A013_PC3_24H_X3_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L01	PC3	REP.A013_PC3_24H_X1_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L02	PC3	REP.A013_PC3_24H_X1_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L03	PC3	REP.A013_PC3_24H_X1_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L04	PC3	REP.A013_PC3_24H_X1_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L05	PC3	REP.A013_PC3_24H_X1_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X1_B22:L06	PC3	REP.A013_PC3_24H_X1_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L01	PC3	REP.A013_PC3_24H_X2_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L02	PC3	REP.A013_PC3_24H_X2_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L03	PC3	REP.A013_PC3_24H_X2_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L04	PC3	REP.A013_PC3_24H_X2_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L05	PC3	REP.A013_PC3_24H_X2_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X2_B22:L06	PC3	REP.A013_PC3_24H_X2_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L01	PC3	REP.A013_PC3_24H_X3_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L02	PC3	REP.A013_PC3_24H_X3_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L03	PC3	REP.A013_PC3_24H_X3_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L04	PC3	REP.A013_PC3_24H_X3_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L05	PC3	REP.A013_PC3_24H_X3_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_PC3_24H_X3_B22:L06	PC3	REP.A013_PC3_24H_X3_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I01	PC3	REP.A023_PC3_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I02	PC3	REP.A023_PC3_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I03	PC3	REP.A023_PC3_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I04	PC3	REP.A023_PC3_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I05	PC3	REP.A023_PC3_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X1_B23:I06	PC3	REP.A023_PC3_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I01	PC3	REP.A023_PC3_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I02	PC3	REP.A023_PC3_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I03	PC3	REP.A023_PC3_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I04	PC3	REP.A023_PC3_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I05	PC3	REP.A023_PC3_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X2_B23:I06	PC3	REP.A023_PC3_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I01	PC3	REP.A023_PC3_24H_X3.A2_B25	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I02	PC3	REP.A023_PC3_24H_X3.A2_B25	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I03	PC3	REP.A023_PC3_24H_X3.A2_B25	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I04	PC3	REP.A023_PC3_24H_X3.A2_B25	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I05	PC3	REP.A023_PC3_24H_X3.A2_B25	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_PC3_24H_X3.A2_B25:I06	PC3	REP.A023_PC3_24H_X3.A2_B25	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N07	PC3	LJP008_PC3_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N08	PC3	LJP008_PC3_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N09	PC3	LJP008_PC3_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N10	PC3	LJP008_PC3_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N11	PC3	LJP008_PC3_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X1_B20:N12	PC3	LJP008_PC3_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N07	PC3	LJP008_PC3_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N08	PC3	LJP008_PC3_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N09	PC3	LJP008_PC3_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N10	PC3	LJP008_PC3_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N11	PC3	LJP008_PC3_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X2_B20:N12	PC3	LJP008_PC3_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N07	PC3	LJP008_PC3_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N08	PC3	LJP008_PC3_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N09	PC3	LJP008_PC3_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N10	PC3	LJP008_PC3_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N11	PC3	LJP008_PC3_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_PC3_24H_X3_B20:N12	PC3	LJP008_PC3_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G07	PC3	REP.A022_PC3_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G08	PC3	REP.A022_PC3_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G09	PC3	REP.A022_PC3_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G10	PC3	REP.A022_PC3_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G11	PC3	REP.A022_PC3_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X2_B23:G12	PC3	REP.A022_PC3_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G07	PC3	REP.A022_PC3_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G08	PC3	REP.A022_PC3_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G09	PC3	REP.A022_PC3_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G10	PC3	REP.A022_PC3_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G11	PC3	REP.A022_PC3_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_PC3_24H_X3_B23:G12	PC3	REP.A022_PC3_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A19	PC3	REP.A004_PC3_24H_X1_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A20	PC3	REP.A004_PC3_24H_X1_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A21	PC3	REP.A004_PC3_24H_X1_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A22	PC3	REP.A004_PC3_24H_X1_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A23	PC3	REP.A004_PC3_24H_X1_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X1_B22:A24	PC3	REP.A004_PC3_24H_X1_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X2_B22:A19	PC3	REP.A004_PC3_24H_X2_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X2_B22:A20	PC3	REP.A004_PC3_24H_X2_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X2_B22:A21	PC3	REP.A004_PC3_24H_X2_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X2_B22:A22	PC3	REP.A004_PC3_24H_X2_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X2_B22:A24	PC3	REP.A004_PC3_24H_X2_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A19	PC3	REP.A004_PC3_24H_X3_B22	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A20	PC3	REP.A004_PC3_24H_X3_B22	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A21	PC3	REP.A004_PC3_24H_X3_B22	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A22	PC3	REP.A004_PC3_24H_X3_B22	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A23	PC3	REP.A004_PC3_24H_X3_B22	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_PC3_24H_X3_B22:A24	PC3	REP.A004_PC3_24H_X3_B22	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D07	PC3	REP.A016_PC3_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D08	PC3	REP.A016_PC3_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D09	PC3	REP.A016_PC3_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D10	PC3	REP.A016_PC3_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D11	PC3	REP.A016_PC3_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X1_B23:D12	PC3	REP.A016_PC3_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D07	PC3	REP.A016_PC3_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D08	PC3	REP.A016_PC3_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D09	PC3	REP.A016_PC3_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D10	PC3	REP.A016_PC3_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D11	PC3	REP.A016_PC3_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X2_B23:D12	PC3	REP.A016_PC3_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D07	PC3	REP.A016_PC3_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D08	PC3	REP.A016_PC3_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D09	PC3	REP.A016_PC3_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D10	PC3	REP.A016_PC3_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D11	PC3	REP.A016_PC3_24H_X3_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_PC3_24H_X3_B23:D12	PC3	REP.A016_PC3_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O07	PC3	REP.A010_PC3_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O08	PC3	REP.A010_PC3_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O09	PC3	REP.A010_PC3_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O10	PC3	REP.A010_PC3_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O11	PC3	REP.A010_PC3_24H_X1_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X1_B24:O12	PC3	REP.A010_PC3_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O07	PC3	REP.A010_PC3_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O08	PC3	REP.A010_PC3_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O09	PC3	REP.A010_PC3_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O10	PC3	REP.A010_PC3_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O11	PC3	REP.A010_PC3_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X2_B24:O12	PC3	REP.A010_PC3_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O07	PC3	REP.A010_PC3_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O08	PC3	REP.A010_PC3_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O09	PC3	REP.A010_PC3_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O10	PC3	REP.A010_PC3_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O11	PC3	REP.A010_PC3_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_PC3_24H_X3_B24:O12	PC3	REP.A010_PC3_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L13	PC3	REP.A023_PC3_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L14	PC3	REP.A023_PC3_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L15	PC3	REP.A023_PC3_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L16	PC3	REP.A023_PC3_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L17	PC3	REP.A023_PC3_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X1_B23:L18	PC3	REP.A023_PC3_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L13	PC3	REP.A023_PC3_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L14	PC3	REP.A023_PC3_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L15	PC3	REP.A023_PC3_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L16	PC3	REP.A023_PC3_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L17	PC3	REP.A023_PC3_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X2_B23:L18	PC3	REP.A023_PC3_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L13	PC3	REP.A023_PC3_24H_X3.A2_B25	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L14	PC3	REP.A023_PC3_24H_X3.A2_B25	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L15	PC3	REP.A023_PC3_24H_X3.A2_B25	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L16	PC3	REP.A023_PC3_24H_X3.A2_B25	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L17	PC3	REP.A023_PC3_24H_X3.A2_B25	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_PC3_24H_X3.A2_B25:L18	PC3	REP.A023_PC3_24H_X3.A2_B25	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F19	PC3	REP.A013_PC3_24H_X1_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F20	PC3	REP.A013_PC3_24H_X1_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F21	PC3	REP.A013_PC3_24H_X1_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F22	PC3	REP.A013_PC3_24H_X1_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F23	PC3	REP.A013_PC3_24H_X1_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X1_B22:F24	PC3	REP.A013_PC3_24H_X1_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F19	PC3	REP.A013_PC3_24H_X2_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F20	PC3	REP.A013_PC3_24H_X2_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F21	PC3	REP.A013_PC3_24H_X2_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F22	PC3	REP.A013_PC3_24H_X2_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F23	PC3	REP.A013_PC3_24H_X2_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X2_B22:F24	PC3	REP.A013_PC3_24H_X2_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X3_B22:F19	PC3	REP.A013_PC3_24H_X3_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X3_B22:F20	PC3	REP.A013_PC3_24H_X3_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X3_B22:F21	PC3	REP.A013_PC3_24H_X3_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X3_B22:F22	PC3	REP.A013_PC3_24H_X3_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_PC3_24H_X3_B22:F23	PC3	REP.A013_PC3_24H_X3_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L01	PC3	REP.A021_PC3_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L02	PC3	REP.A021_PC3_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L03	PC3	REP.A021_PC3_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L04	PC3	REP.A021_PC3_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L05	PC3	REP.A021_PC3_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X1_B23:L06	PC3	REP.A021_PC3_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L01	PC3	REP.A021_PC3_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L02	PC3	REP.A021_PC3_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L03	PC3	REP.A021_PC3_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L04	PC3	REP.A021_PC3_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L05	PC3	REP.A021_PC3_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X2_B23:L06	PC3	REP.A021_PC3_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L01	PC3	REP.A021_PC3_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L02	PC3	REP.A021_PC3_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L03	PC3	REP.A021_PC3_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L04	PC3	REP.A021_PC3_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L05	PC3	REP.A021_PC3_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_PC3_24H_X3_B23:L06	PC3	REP.A021_PC3_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N01	PC3	REP.A026_PC3_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N02	PC3	REP.A026_PC3_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N03	PC3	REP.A026_PC3_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N04	PC3	REP.A026_PC3_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N05	PC3	REP.A026_PC3_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X1_B25:N06	PC3	REP.A026_PC3_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X3.A2_B27:N01	PC3	REP.A026_PC3_24H_X3.A2_B27	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X3.A2_B27:N02	PC3	REP.A026_PC3_24H_X3.A2_B27	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X3.A2_B27:N03	PC3	REP.A026_PC3_24H_X3.A2_B27	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_PC3_24H_X3.A2_B27:N04	PC3	REP.A026_PC3_24H_X3.A2_B27	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	PC3	-666	-666	tumor	prostate	adenocarcinoma	mix	CRL-1435	ATCC	62	M	Caucasian
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F01	YAPC	REP.A011_YAPC_24H_X1_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F02	YAPC	REP.A011_YAPC_24H_X1_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F03	YAPC	REP.A011_YAPC_24H_X1_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F04	YAPC	REP.A011_YAPC_24H_X1_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F05	YAPC	REP.A011_YAPC_24H_X1_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X1_B24:F06	YAPC	REP.A011_YAPC_24H_X1_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F01	YAPC	REP.A011_YAPC_24H_X2_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F02	YAPC	REP.A011_YAPC_24H_X2_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F03	YAPC	REP.A011_YAPC_24H_X2_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F04	YAPC	REP.A011_YAPC_24H_X2_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F05	YAPC	REP.A011_YAPC_24H_X2_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X2_B24:F06	YAPC	REP.A011_YAPC_24H_X2_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F01	YAPC	REP.A011_YAPC_24H_X3_B24	F01	BRD-A05186015-003-19-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F02	YAPC	REP.A011_YAPC_24H_X3_B24	F02	BRD-A05186015-003-19-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F03	YAPC	REP.A011_YAPC_24H_X3_B24	F03	BRD-A05186015-003-19-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F04	YAPC	REP.A011_YAPC_24H_X3_B24	F04	BRD-A05186015-003-19-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F05	YAPC	REP.A011_YAPC_24H_X3_B24	F05	BRD-A05186015-003-19-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100000444	N06AX12	bupropion	BRD-A05186015	1	7	REP.A011_YAPC_24H_X3_B24:F06	YAPC	REP.A011_YAPC_24H_X3_B24	F06	BRD-A05186015-003-19-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L01	YAPC	REP.A007_YAPC_24H_X1_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L02	YAPC	REP.A007_YAPC_24H_X1_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L03	YAPC	REP.A007_YAPC_24H_X1_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L04	YAPC	REP.A007_YAPC_24H_X1_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L05	YAPC	REP.A007_YAPC_24H_X1_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X1_B22:L06	YAPC	REP.A007_YAPC_24H_X1_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L01	YAPC	REP.A007_YAPC_24H_X2_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L02	YAPC	REP.A007_YAPC_24H_X2_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L03	YAPC	REP.A007_YAPC_24H_X2_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L04	YAPC	REP.A007_YAPC_24H_X2_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L05	YAPC	REP.A007_YAPC_24H_X2_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X2_B22:L06	YAPC	REP.A007_YAPC_24H_X2_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L01	YAPC	REP.A007_YAPC_24H_X3_B22	L01	BRD-K53737926-003-27-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L02	YAPC	REP.A007_YAPC_24H_X3_B22	L02	BRD-K53737926-003-27-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L03	YAPC	REP.A007_YAPC_24H_X3_B22	L03	BRD-K53737926-003-27-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L04	YAPC	REP.A007_YAPC_24H_X3_B22	L04	BRD-K53737926-003-27-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L05	YAPC	REP.A007_YAPC_24H_X3_B22	L05	BRD-K53737926-003-27-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002160	N06AA09	amitriptyline	BRD-K53737926	1	7	REP.A007_YAPC_24H_X3_B22:L06	YAPC	REP.A007_YAPC_24H_X3_B22	L06	BRD-K53737926-003-27-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X1_B24:I14	YAPC	REP.A012_YAPC_24H_X1_B24	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X1_B24:I15	YAPC	REP.A012_YAPC_24H_X1_B24	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X1_B24:I16	YAPC	REP.A012_YAPC_24H_X1_B24	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X1_B24:I17	YAPC	REP.A012_YAPC_24H_X1_B24	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X1_B24:I18	YAPC	REP.A012_YAPC_24H_X1_B24	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I13	YAPC	REP.A012_YAPC_24H_X2_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I14	YAPC	REP.A012_YAPC_24H_X2_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I15	YAPC	REP.A012_YAPC_24H_X2_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I16	YAPC	REP.A012_YAPC_24H_X2_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I17	YAPC	REP.A012_YAPC_24H_X2_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X2_B22:I18	YAPC	REP.A012_YAPC_24H_X2_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I13	YAPC	REP.A012_YAPC_24H_X3_B22	I13	BRD-K02265150-001-26-5	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I14	YAPC	REP.A012_YAPC_24H_X3_B22	I14	BRD-K02265150-001-26-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I15	YAPC	REP.A012_YAPC_24H_X3_B22	I15	BRD-K02265150-001-26-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I16	YAPC	REP.A012_YAPC_24H_X3_B22	I16	BRD-K02265150-001-26-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I17	YAPC	REP.A012_YAPC_24H_X3_B22	I17	BRD-K02265150-001-26-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002170	N06AA17	amoxapine	BRD-K02265150	1	7	REP.A012_YAPC_24H_X3_B22:I18	YAPC	REP.A012_YAPC_24H_X3_B22	I18	BRD-K02265150-001-26-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C13	YAPC	REP.A017_YAPC_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C14	YAPC	REP.A017_YAPC_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C15	YAPC	REP.A017_YAPC_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C17	YAPC	REP.A017_YAPC_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C18	YAPC	REP.A017_YAPC_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C13	YAPC	REP.A017_YAPC_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C14	YAPC	REP.A017_YAPC_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C15	YAPC	REP.A017_YAPC_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C16	YAPC	REP.A017_YAPC_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C17	YAPC	REP.A017_YAPC_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C18	YAPC	REP.A017_YAPC_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C13	YAPC	REP.A017_YAPC_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C14	YAPC	REP.A017_YAPC_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C15	YAPC	REP.A017_YAPC_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C16	YAPC	REP.A017_YAPC_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C17	YAPC	REP.A017_YAPC_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB04	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C18	YAPC	REP.A017_YAPC_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C13	YAPC	REP.A017_YAPC_24H_X1_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C14	YAPC	REP.A017_YAPC_24H_X1_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C15	YAPC	REP.A017_YAPC_24H_X1_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C17	YAPC	REP.A017_YAPC_24H_X1_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X1_B23:C18	YAPC	REP.A017_YAPC_24H_X1_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C13	YAPC	REP.A017_YAPC_24H_X2_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C14	YAPC	REP.A017_YAPC_24H_X2_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C15	YAPC	REP.A017_YAPC_24H_X2_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C16	YAPC	REP.A017_YAPC_24H_X2_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C17	YAPC	REP.A017_YAPC_24H_X2_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X2_B23:C18	YAPC	REP.A017_YAPC_24H_X2_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C13	YAPC	REP.A017_YAPC_24H_X3_B23	C13	BRD-A47598013-004-16-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C14	YAPC	REP.A017_YAPC_24H_X3_B23	C14	BRD-A47598013-004-16-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C15	YAPC	REP.A017_YAPC_24H_X3_B23	C15	BRD-A47598013-004-16-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C16	YAPC	REP.A017_YAPC_24H_X3_B23	C16	BRD-A47598013-004-16-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C17	YAPC	REP.A017_YAPC_24H_X3_B23	C17	BRD-A47598013-004-16-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002771	N06AB10	citalopram	BRD-A47598013	1	7	REP.A017_YAPC_24H_X3_B23:C18	YAPC	REP.A017_YAPC_24H_X3_B23	C18	BRD-A47598013-004-16-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I19	YAPC	REP.A007_YAPC_24H_X1_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I20	YAPC	REP.A007_YAPC_24H_X1_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I21	YAPC	REP.A007_YAPC_24H_X1_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I22	YAPC	REP.A007_YAPC_24H_X1_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I23	YAPC	REP.A007_YAPC_24H_X1_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X1_B22:I24	YAPC	REP.A007_YAPC_24H_X1_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I19	YAPC	REP.A007_YAPC_24H_X2_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I20	YAPC	REP.A007_YAPC_24H_X2_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I21	YAPC	REP.A007_YAPC_24H_X2_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I22	YAPC	REP.A007_YAPC_24H_X2_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I23	YAPC	REP.A007_YAPC_24H_X2_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X2_B22:I24	YAPC	REP.A007_YAPC_24H_X2_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I19	YAPC	REP.A007_YAPC_24H_X3_B22	I19	BRD-K52989797-003-26-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I20	YAPC	REP.A007_YAPC_24H_X3_B22	I20	BRD-K52989797-003-26-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I21	YAPC	REP.A007_YAPC_24H_X3_B22	I21	BRD-K52989797-003-26-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I22	YAPC	REP.A007_YAPC_24H_X3_B22	I22	BRD-K52989797-003-26-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I23	YAPC	REP.A007_YAPC_24H_X3_B22	I23	BRD-K52989797-003-26-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100002801	N06AA04	clomipramine	BRD-K52989797	1	7	REP.A007_YAPC_24H_X3_B22:I24	YAPC	REP.A007_YAPC_24H_X3_B22	I24	BRD-K52989797-003-26-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N01	YAPC	REP.A014_YAPC_24H_X1_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N02	YAPC	REP.A014_YAPC_24H_X1_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N03	YAPC	REP.A014_YAPC_24H_X1_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N04	YAPC	REP.A014_YAPC_24H_X1_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N05	YAPC	REP.A014_YAPC_24H_X1_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X1_B23:N06	YAPC	REP.A014_YAPC_24H_X1_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N01	YAPC	REP.A014_YAPC_24H_X2_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N02	YAPC	REP.A014_YAPC_24H_X2_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N03	YAPC	REP.A014_YAPC_24H_X2_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N04	YAPC	REP.A014_YAPC_24H_X2_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N05	YAPC	REP.A014_YAPC_24H_X2_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X2_B23:N06	YAPC	REP.A014_YAPC_24H_X2_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N01	YAPC	REP.A014_YAPC_24H_X3_B23	N01	BRD-K37694030-003-12-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N02	YAPC	REP.A014_YAPC_24H_X3_B23	N02	BRD-K37694030-003-12-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N03	YAPC	REP.A014_YAPC_24H_X3_B23	N03	BRD-K37694030-003-12-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N04	YAPC	REP.A014_YAPC_24H_X3_B23	N04	BRD-K37694030-003-12-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N05	YAPC	REP.A014_YAPC_24H_X3_B23	N05	BRD-K37694030-003-12-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003158	N06AA12	doxepin	BRD-K37694030	1	7	REP.A014_YAPC_24H_X3_B23:N06	YAPC	REP.A014_YAPC_24H_X3_B23	N06	BRD-K37694030-003-12-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A13	YAPC	REP.A003_YAPC_24H_X1_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A14	YAPC	REP.A003_YAPC_24H_X1_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A15	YAPC	REP.A003_YAPC_24H_X1_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A16	YAPC	REP.A003_YAPC_24H_X1_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A17	YAPC	REP.A003_YAPC_24H_X1_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X1_B27:A18	YAPC	REP.A003_YAPC_24H_X1_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A13	YAPC	REP.A003_YAPC_24H_X2_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A14	YAPC	REP.A003_YAPC_24H_X2_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A15	YAPC	REP.A003_YAPC_24H_X2_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A16	YAPC	REP.A003_YAPC_24H_X2_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A17	YAPC	REP.A003_YAPC_24H_X2_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X2_B27:A18	YAPC	REP.A003_YAPC_24H_X2_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A13	YAPC	REP.A003_YAPC_24H_X3_B27	A13	BRD-A31159102-003-30-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A14	YAPC	REP.A003_YAPC_24H_X3_B27	A14	BRD-A31159102-003-30-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A15	YAPC	REP.A003_YAPC_24H_X3_B27	A15	BRD-A31159102-003-30-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A16	YAPC	REP.A003_YAPC_24H_X3_B27	A16	BRD-A31159102-003-30-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A17	YAPC	REP.A003_YAPC_24H_X3_B27	A17	BRD-A31159102-003-30-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003386	N06AB03	fluoxetine	BRD-A31159102	1	7	REP.A003_YAPC_24H_X3_B27:A18	YAPC	REP.A003_YAPC_24H_X3_B27	A18	BRD-A31159102-003-30-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X1_B23:H13	YAPC	REP.A016_YAPC_24H_X1_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X1_B23:H14	YAPC	REP.A016_YAPC_24H_X1_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X1_B23:H15	YAPC	REP.A016_YAPC_24H_X1_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X1_B23:H17	YAPC	REP.A016_YAPC_24H_X1_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X1_B23:H18	YAPC	REP.A016_YAPC_24H_X1_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H13	YAPC	REP.A016_YAPC_24H_X2_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H14	YAPC	REP.A016_YAPC_24H_X2_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H15	YAPC	REP.A016_YAPC_24H_X2_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H16	YAPC	REP.A016_YAPC_24H_X2_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H17	YAPC	REP.A016_YAPC_24H_X2_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X2_B23:H18	YAPC	REP.A016_YAPC_24H_X2_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H13	YAPC	REP.A016_YAPC_24H_X3_B23	H13	BRD-K53517854-051-01-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H14	YAPC	REP.A016_YAPC_24H_X3_B23	H14	BRD-K53517854-051-01-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H15	YAPC	REP.A016_YAPC_24H_X3_B23	H15	BRD-K53517854-051-01-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H16	YAPC	REP.A016_YAPC_24H_X3_B23	H16	BRD-K53517854-051-01-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H17	YAPC	REP.A016_YAPC_24H_X3_B23	H17	BRD-K53517854-051-01-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003404	N06AB08	fluvoxamine	BRD-K53517854	1	7	REP.A016_YAPC_24H_X3_B23:H18	YAPC	REP.A016_YAPC_24H_X3_B23	H18	BRD-K53517854-051-01-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E01	YAPC	REP.A013_YAPC_24H_X1_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E02	YAPC	REP.A013_YAPC_24H_X1_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E03	YAPC	REP.A013_YAPC_24H_X1_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E04	YAPC	REP.A013_YAPC_24H_X1_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E05	YAPC	REP.A013_YAPC_24H_X1_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X1_B22:E06	YAPC	REP.A013_YAPC_24H_X1_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E01	YAPC	REP.A013_YAPC_24H_X2_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E02	YAPC	REP.A013_YAPC_24H_X2_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E03	YAPC	REP.A013_YAPC_24H_X2_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E04	YAPC	REP.A013_YAPC_24H_X2_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E05	YAPC	REP.A013_YAPC_24H_X2_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X2_B22:E06	YAPC	REP.A013_YAPC_24H_X2_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E01	YAPC	REP.A013_YAPC_24H_X3_B22	E01	BRD-K38436528-003-26-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E02	YAPC	REP.A013_YAPC_24H_X3_B22	E02	BRD-K38436528-003-26-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E03	YAPC	REP.A013_YAPC_24H_X3_B22	E03	BRD-K38436528-003-26-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E04	YAPC	REP.A013_YAPC_24H_X3_B22	E04	BRD-K38436528-003-26-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E05	YAPC	REP.A013_YAPC_24H_X3_B22	E05	BRD-K38436528-003-26-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100003696	N06AA02	imipramine	BRD-K38436528	1	7	REP.A013_YAPC_24H_X3_B22:E06	YAPC	REP.A013_YAPC_24H_X3_B22	E06	BRD-K38436528-003-26-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N19	YAPC	REP.A004_YAPC_24H_X1_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N20	YAPC	REP.A004_YAPC_24H_X1_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N21	YAPC	REP.A004_YAPC_24H_X1_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N22	YAPC	REP.A004_YAPC_24H_X1_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N23	YAPC	REP.A004_YAPC_24H_X1_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X1_B27:N24	YAPC	REP.A004_YAPC_24H_X1_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N19	YAPC	REP.A004_YAPC_24H_X2_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N20	YAPC	REP.A004_YAPC_24H_X2_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N21	YAPC	REP.A004_YAPC_24H_X2_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N22	YAPC	REP.A004_YAPC_24H_X2_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N23	YAPC	REP.A004_YAPC_24H_X2_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X2_B27:N24	YAPC	REP.A004_YAPC_24H_X2_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N19	YAPC	REP.A004_YAPC_24H_X3_B27	N19	BRD-K25433859-003-25-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N20	YAPC	REP.A004_YAPC_24H_X3_B27	N20	BRD-K25433859-003-25-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N21	YAPC	REP.A004_YAPC_24H_X3_B27	N21	BRD-K25433859-003-25-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N22	YAPC	REP.A004_YAPC_24H_X3_B27	N22	BRD-K25433859-003-25-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N23	YAPC	REP.A004_YAPC_24H_X3_B27	N23	BRD-K25433859-003-25-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004011	N06AA21	maprotiline	BRD-K25433859	1	7	REP.A004_YAPC_24H_X3_B27:N24	YAPC	REP.A004_YAPC_24H_X3_B27	N24	BRD-K25433859-003-25-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C07	YAPC	REP.A004_YAPC_24H_X1_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C08	YAPC	REP.A004_YAPC_24H_X1_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C09	YAPC	REP.A004_YAPC_24H_X1_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C10	YAPC	REP.A004_YAPC_24H_X1_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C11	YAPC	REP.A004_YAPC_24H_X1_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X1_B27:C12	YAPC	REP.A004_YAPC_24H_X1_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C07	YAPC	REP.A004_YAPC_24H_X2_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C08	YAPC	REP.A004_YAPC_24H_X2_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C09	YAPC	REP.A004_YAPC_24H_X2_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C10	YAPC	REP.A004_YAPC_24H_X2_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C11	YAPC	REP.A004_YAPC_24H_X2_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X2_B27:C12	YAPC	REP.A004_YAPC_24H_X2_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C07	YAPC	REP.A004_YAPC_24H_X3_B27	C07	BRD-A19661776-003-27-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C08	YAPC	REP.A004_YAPC_24H_X3_B27	C08	BRD-A19661776-003-27-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C09	YAPC	REP.A004_YAPC_24H_X3_B27	C09	BRD-A19661776-003-27-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C10	YAPC	REP.A004_YAPC_24H_X3_B27	C10	BRD-A19661776-003-27-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C11	YAPC	REP.A004_YAPC_24H_X3_B27	C11	BRD-A19661776-003-27-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004184	N06AX03	mianserin	BRD-A19661776	1	7	REP.A004_YAPC_24H_X3_B27:C12	YAPC	REP.A004_YAPC_24H_X3_B27	C12	BRD-A19661776-003-27-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I13	YAPC	REP.A017_YAPC_24H_X1_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I14	YAPC	REP.A017_YAPC_24H_X1_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I15	YAPC	REP.A017_YAPC_24H_X1_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I16	YAPC	REP.A017_YAPC_24H_X1_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I17	YAPC	REP.A017_YAPC_24H_X1_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X1_B23:I18	YAPC	REP.A017_YAPC_24H_X1_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I13	YAPC	REP.A017_YAPC_24H_X2_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I14	YAPC	REP.A017_YAPC_24H_X2_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I15	YAPC	REP.A017_YAPC_24H_X2_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I16	YAPC	REP.A017_YAPC_24H_X2_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I17	YAPC	REP.A017_YAPC_24H_X2_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X2_B23:I18	YAPC	REP.A017_YAPC_24H_X2_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I13	YAPC	REP.A017_YAPC_24H_X3_B23	I13	BRD-A64977602-001-15-9	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I14	YAPC	REP.A017_YAPC_24H_X3_B23	I14	BRD-A64977602-001-15-9	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I15	YAPC	REP.A017_YAPC_24H_X3_B23	I15	BRD-A64977602-001-15-9	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I16	YAPC	REP.A017_YAPC_24H_X3_B23	I16	BRD-A64977602-001-15-9	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I17	YAPC	REP.A017_YAPC_24H_X3_B23	I17	BRD-A64977602-001-15-9	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004205	N06AX11	mirtazapine	BRD-A64977602	1	7	REP.A017_YAPC_24H_X3_B23:I18	YAPC	REP.A017_YAPC_24H_X3_B23	I18	BRD-A64977602-001-15-9	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M07	YAPC	REP.A011_YAPC_24H_X1_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M08	YAPC	REP.A011_YAPC_24H_X1_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M09	YAPC	REP.A011_YAPC_24H_X1_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M10	YAPC	REP.A011_YAPC_24H_X1_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M11	YAPC	REP.A011_YAPC_24H_X1_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X1_B24:M12	YAPC	REP.A011_YAPC_24H_X1_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X2_B24:M07	YAPC	REP.A011_YAPC_24H_X2_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X2_B24:M09	YAPC	REP.A011_YAPC_24H_X2_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X2_B24:M10	YAPC	REP.A011_YAPC_24H_X2_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X2_B24:M11	YAPC	REP.A011_YAPC_24H_X2_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X2_B24:M12	YAPC	REP.A011_YAPC_24H_X2_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M07	YAPC	REP.A011_YAPC_24H_X3_B24	M07	BRD-K07237224-001-19-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M08	YAPC	REP.A011_YAPC_24H_X3_B24	M08	BRD-K07237224-001-19-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M09	YAPC	REP.A011_YAPC_24H_X3_B24	M09	BRD-K07237224-001-19-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M10	YAPC	REP.A011_YAPC_24H_X3_B24	M10	BRD-K07237224-001-19-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M11	YAPC	REP.A011_YAPC_24H_X3_B24	M11	BRD-K07237224-001-19-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004235	N06AG02	moclobemide	BRD-K07237224	1	7	REP.A011_YAPC_24H_X3_B24:M12	YAPC	REP.A011_YAPC_24H_X3_B24	M12	BRD-K07237224-001-19-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X1_B24:P21	YAPC	REP.A008_YAPC_24H_X1_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X1_B24:P22	YAPC	REP.A008_YAPC_24H_X1_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X1_B24:P24	YAPC	REP.A008_YAPC_24H_X1_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P19	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P20	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P21	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P22	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P23	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X2.L2_B25:P24	YAPC	REP.A008_YAPC_24H_X2.L2_B25	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P19	YAPC	REP.A008_YAPC_24H_X3_B24	P19	BRD-K90789829-001-07-8	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P20	YAPC	REP.A008_YAPC_24H_X3_B24	P20	BRD-K90789829-001-07-8	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P21	YAPC	REP.A008_YAPC_24H_X3_B24	P21	BRD-K90789829-001-07-8	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P22	YAPC	REP.A008_YAPC_24H_X3_B24	P22	BRD-K90789829-001-07-8	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P23	YAPC	REP.A008_YAPC_24H_X3_B24	P23	BRD-K90789829-001-07-8	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004449	N06AX06	nefazodone	BRD-K90789829	1	7	REP.A008_YAPC_24H_X3_B24:P24	YAPC	REP.A008_YAPC_24H_X3_B24	P24	BRD-K90789829-001-07-8	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J07	YAPC	REP.A026_YAPC_24H_X1_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J08	YAPC	REP.A026_YAPC_24H_X1_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J09	YAPC	REP.A026_YAPC_24H_X1_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J10	YAPC	REP.A026_YAPC_24H_X1_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J11	YAPC	REP.A026_YAPC_24H_X1_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X1_B25:J12	YAPC	REP.A026_YAPC_24H_X1_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J07	YAPC	REP.A026_YAPC_24H_X2_B25	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J08	YAPC	REP.A026_YAPC_24H_X2_B25	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J09	YAPC	REP.A026_YAPC_24H_X2_B25	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J10	YAPC	REP.A026_YAPC_24H_X2_B25	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J11	YAPC	REP.A026_YAPC_24H_X2_B25	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X2_B25:J12	YAPC	REP.A026_YAPC_24H_X2_B25	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J07	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J07	BRD-K91263825-003-21-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J08	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J08	BRD-K91263825-003-21-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J09	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J09	BRD-K91263825-003-21-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J10	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J10	BRD-K91263825-003-21-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J11	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J11	BRD-K91263825-003-21-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004543	N06AA10	nortriptyline	BRD-K91263825	1	7	REP.A026_YAPC_24H_X3.L2_B27:J12	YAPC	REP.A026_YAPC_24H_X3.L2_B27	J12	BRD-K91263825-003-21-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D13	YAPC	REP.A013_YAPC_24H_X1_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D14	YAPC	REP.A013_YAPC_24H_X1_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D15	YAPC	REP.A013_YAPC_24H_X1_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D16	YAPC	REP.A013_YAPC_24H_X1_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D17	YAPC	REP.A013_YAPC_24H_X1_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X1_B22:D18	YAPC	REP.A013_YAPC_24H_X1_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D13	YAPC	REP.A013_YAPC_24H_X2_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D14	YAPC	REP.A013_YAPC_24H_X2_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D15	YAPC	REP.A013_YAPC_24H_X2_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D16	YAPC	REP.A013_YAPC_24H_X2_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D17	YAPC	REP.A013_YAPC_24H_X2_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X2_B22:D18	YAPC	REP.A013_YAPC_24H_X2_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D13	YAPC	REP.A013_YAPC_24H_X3_B22	D13	BRD-K37991163-003-13-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D14	YAPC	REP.A013_YAPC_24H_X3_B22	D14	BRD-K37991163-003-13-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D15	YAPC	REP.A013_YAPC_24H_X3_B22	D15	BRD-K37991163-003-13-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D16	YAPC	REP.A013_YAPC_24H_X3_B22	D16	BRD-K37991163-003-13-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D17	YAPC	REP.A013_YAPC_24H_X3_B22	D17	BRD-K37991163-003-13-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004691	N06AB05	paroxetine	BRD-K37991163	1	7	REP.A013_YAPC_24H_X3_B22:D18	YAPC	REP.A013_YAPC_24H_X3_B22	D18	BRD-K37991163-003-13-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L01	YAPC	REP.A013_YAPC_24H_X1_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L02	YAPC	REP.A013_YAPC_24H_X1_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L03	YAPC	REP.A013_YAPC_24H_X1_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L04	YAPC	REP.A013_YAPC_24H_X1_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L05	YAPC	REP.A013_YAPC_24H_X1_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X1_B22:L06	YAPC	REP.A013_YAPC_24H_X1_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L01	YAPC	REP.A013_YAPC_24H_X2_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L02	YAPC	REP.A013_YAPC_24H_X2_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L03	YAPC	REP.A013_YAPC_24H_X2_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L04	YAPC	REP.A013_YAPC_24H_X2_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L05	YAPC	REP.A013_YAPC_24H_X2_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X2_B22:L06	YAPC	REP.A013_YAPC_24H_X2_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L01	YAPC	REP.A013_YAPC_24H_X3_B22	L01	BRD-K42098891-003-20-5	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L02	YAPC	REP.A013_YAPC_24H_X3_B22	L02	BRD-K42098891-003-20-5	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L03	YAPC	REP.A013_YAPC_24H_X3_B22	L03	BRD-K42098891-003-20-5	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L04	YAPC	REP.A013_YAPC_24H_X3_B22	L04	BRD-K42098891-003-20-5	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L05	YAPC	REP.A013_YAPC_24H_X3_B22	L05	BRD-K42098891-003-20-5	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100004976	N06AA11	protriptyline	BRD-K42098891	1	7	REP.A013_YAPC_24H_X3_B22:L06	YAPC	REP.A013_YAPC_24H_X3_B22	L06	BRD-K42098891-003-20-5	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I01	YAPC	REP.A023_YAPC_24H_X1_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I02	YAPC	REP.A023_YAPC_24H_X1_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I03	YAPC	REP.A023_YAPC_24H_X1_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I04	YAPC	REP.A023_YAPC_24H_X1_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I05	YAPC	REP.A023_YAPC_24H_X1_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X1_B23:I06	YAPC	REP.A023_YAPC_24H_X1_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I01	YAPC	REP.A023_YAPC_24H_X2_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I02	YAPC	REP.A023_YAPC_24H_X2_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I03	YAPC	REP.A023_YAPC_24H_X2_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I04	YAPC	REP.A023_YAPC_24H_X2_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I05	YAPC	REP.A023_YAPC_24H_X2_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X2_B23:I06	YAPC	REP.A023_YAPC_24H_X2_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I01	YAPC	REP.A023_YAPC_24H_X3_B23	I01	BRD-K70464547-003-01-2	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I02	YAPC	REP.A023_YAPC_24H_X3_B23	I02	BRD-K70464547-003-01-2	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I03	YAPC	REP.A023_YAPC_24H_X3_B23	I03	BRD-K70464547-003-01-2	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I04	YAPC	REP.A023_YAPC_24H_X3_B23	I04	BRD-K70464547-003-01-2	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I05	YAPC	REP.A023_YAPC_24H_X3_B23	I05	BRD-K70464547-003-01-2	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005203	N06AB06	sertraline	BRD-K70464547	1	7	REP.A023_YAPC_24H_X3_B23:I06	YAPC	REP.A023_YAPC_24H_X3_B23	I06	BRD-K70464547-003-01-2	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X1_B23:G07	YAPC	REP.A022_YAPC_24H_X1_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X1_B23:G08	YAPC	REP.A022_YAPC_24H_X1_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X1_B23:G09	YAPC	REP.A022_YAPC_24H_X1_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X1_B23:G10	YAPC	REP.A022_YAPC_24H_X1_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X1_B23:G11	YAPC	REP.A022_YAPC_24H_X1_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G07	YAPC	REP.A022_YAPC_24H_X2_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G08	YAPC	REP.A022_YAPC_24H_X2_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G09	YAPC	REP.A022_YAPC_24H_X2_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G10	YAPC	REP.A022_YAPC_24H_X2_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G11	YAPC	REP.A022_YAPC_24H_X2_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X2_B23:G12	YAPC	REP.A022_YAPC_24H_X2_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G07	YAPC	REP.A022_YAPC_24H_X3_B23	G07	BRD-K70778732-003-26-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G08	YAPC	REP.A022_YAPC_24H_X3_B23	G08	BRD-K70778732-003-26-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G09	YAPC	REP.A022_YAPC_24H_X3_B23	G09	BRD-K70778732-003-26-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G10	YAPC	REP.A022_YAPC_24H_X3_B23	G10	BRD-K70778732-003-26-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G11	YAPC	REP.A022_YAPC_24H_X3_B23	G11	BRD-K70778732-003-26-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005533	N06AX05	trazodone	BRD-K70778732	1	7	REP.A022_YAPC_24H_X3_B23:G12	YAPC	REP.A022_YAPC_24H_X3_B23	G12	BRD-K70778732-003-26-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X1_B27:A19	YAPC	REP.A004_YAPC_24H_X1_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X1_B27:A20	YAPC	REP.A004_YAPC_24H_X1_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X1_B27:A21	YAPC	REP.A004_YAPC_24H_X1_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X1_B27:A22	YAPC	REP.A004_YAPC_24H_X1_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X1_B27:A23	YAPC	REP.A004_YAPC_24H_X1_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A19	YAPC	REP.A004_YAPC_24H_X2_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A20	YAPC	REP.A004_YAPC_24H_X2_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A21	YAPC	REP.A004_YAPC_24H_X2_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A22	YAPC	REP.A004_YAPC_24H_X2_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A23	YAPC	REP.A004_YAPC_24H_X2_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X2_B27:A24	YAPC	REP.A004_YAPC_24H_X2_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A19	YAPC	REP.A004_YAPC_24H_X3_B27	A19	BRD-A19195498-050-14-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A20	YAPC	REP.A004_YAPC_24H_X3_B27	A20	BRD-A19195498-050-14-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A21	YAPC	REP.A004_YAPC_24H_X3_B27	A21	BRD-A19195498-050-14-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A22	YAPC	REP.A004_YAPC_24H_X3_B27	A22	BRD-A19195498-050-14-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A23	YAPC	REP.A004_YAPC_24H_X3_B27	A23	BRD-A19195498-050-14-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005584	N06AA06	trimipramine	BRD-A19195498	1	7	REP.A004_YAPC_24H_X3_B27:A24	YAPC	REP.A004_YAPC_24H_X3_B27	A24	BRD-A19195498-050-14-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D07	YAPC	REP.A016_YAPC_24H_X1_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D08	YAPC	REP.A016_YAPC_24H_X1_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D09	YAPC	REP.A016_YAPC_24H_X1_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D10	YAPC	REP.A016_YAPC_24H_X1_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D11	YAPC	REP.A016_YAPC_24H_X1_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X1_B23:D12	YAPC	REP.A016_YAPC_24H_X1_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D07	YAPC	REP.A016_YAPC_24H_X2_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D08	YAPC	REP.A016_YAPC_24H_X2_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D09	YAPC	REP.A016_YAPC_24H_X2_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D10	YAPC	REP.A016_YAPC_24H_X2_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D11	YAPC	REP.A016_YAPC_24H_X2_B23	D11	BRD-A51714012-003-13-6	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X2_B23:D12	YAPC	REP.A016_YAPC_24H_X2_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X3_B23:D07	YAPC	REP.A016_YAPC_24H_X3_B23	D07	BRD-A51714012-003-13-6	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X3_B23:D08	YAPC	REP.A016_YAPC_24H_X3_B23	D08	BRD-A51714012-003-13-6	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X3_B23:D09	YAPC	REP.A016_YAPC_24H_X3_B23	D09	BRD-A51714012-003-13-6	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X3_B23:D10	YAPC	REP.A016_YAPC_24H_X3_B23	D10	BRD-A51714012-003-13-6	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005656	N06AX16	venlafaxine	BRD-A51714012	1	7	REP.A016_YAPC_24H_X3_B23:D12	YAPC	REP.A016_YAPC_24H_X3_B23	D12	BRD-A51714012-003-13-6	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X1_B24:O07	YAPC	REP.A010_YAPC_24H_X1_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X1_B24:O08	YAPC	REP.A010_YAPC_24H_X1_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X1_B24:O09	YAPC	REP.A010_YAPC_24H_X1_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X1_B24:O10	YAPC	REP.A010_YAPC_24H_X1_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X1_B24:O12	YAPC	REP.A010_YAPC_24H_X1_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O07	YAPC	REP.A010_YAPC_24H_X2_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O08	YAPC	REP.A010_YAPC_24H_X2_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O09	YAPC	REP.A010_YAPC_24H_X2_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O10	YAPC	REP.A010_YAPC_24H_X2_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O11	YAPC	REP.A010_YAPC_24H_X2_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X2_B24:O12	YAPC	REP.A010_YAPC_24H_X2_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O07	YAPC	REP.A010_YAPC_24H_X3_B24	O07	BRD-A15202882-003-02-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O08	YAPC	REP.A010_YAPC_24H_X3_B24	O08	BRD-A15202882-003-02-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O09	YAPC	REP.A010_YAPC_24H_X3_B24	O09	BRD-A15202882-003-02-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O10	YAPC	REP.A010_YAPC_24H_X3_B24	O10	BRD-A15202882-003-02-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O11	YAPC	REP.A010_YAPC_24H_X3_B24	O11	BRD-A15202882-003-02-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100055480	N06AX17	milnacipran	BRD-A15202882	1	7	REP.A010_YAPC_24H_X3_B24:O12	YAPC	REP.A010_YAPC_24H_X3_B24	O12	BRD-A15202882-003-02-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L13	YAPC	REP.A023_YAPC_24H_X1_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L14	YAPC	REP.A023_YAPC_24H_X1_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L15	YAPC	REP.A023_YAPC_24H_X1_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L16	YAPC	REP.A023_YAPC_24H_X1_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L17	YAPC	REP.A023_YAPC_24H_X1_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X1_B23:L18	YAPC	REP.A023_YAPC_24H_X1_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L13	YAPC	REP.A023_YAPC_24H_X2_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L14	YAPC	REP.A023_YAPC_24H_X2_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L15	YAPC	REP.A023_YAPC_24H_X2_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L16	YAPC	REP.A023_YAPC_24H_X2_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L17	YAPC	REP.A023_YAPC_24H_X2_B23	L17	BRD-K71103788-003-12-0	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X2_B23:L18	YAPC	REP.A023_YAPC_24H_X2_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X3_B23:L13	YAPC	REP.A023_YAPC_24H_X3_B23	L13	BRD-K71103788-003-12-0	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X3_B23:L14	YAPC	REP.A023_YAPC_24H_X3_B23	L14	BRD-K71103788-003-12-0	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X3_B23:L15	YAPC	REP.A023_YAPC_24H_X3_B23	L15	BRD-K71103788-003-12-0	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X3_B23:L16	YAPC	REP.A023_YAPC_24H_X3_B23	L16	BRD-K71103788-003-12-0	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100060834	N06AX21	duloxetine	BRD-K71103788	1	7	REP.A023_YAPC_24H_X3_B23:L18	YAPC	REP.A023_YAPC_24H_X3_B23	L18	BRD-K71103788-003-12-0	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F19	YAPC	REP.A013_YAPC_24H_X1_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F20	YAPC	REP.A013_YAPC_24H_X1_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F21	YAPC	REP.A013_YAPC_24H_X1_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F22	YAPC	REP.A013_YAPC_24H_X1_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F23	YAPC	REP.A013_YAPC_24H_X1_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X1_B22:F24	YAPC	REP.A013_YAPC_24H_X1_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F19	YAPC	REP.A013_YAPC_24H_X2_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F20	YAPC	REP.A013_YAPC_24H_X2_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F21	YAPC	REP.A013_YAPC_24H_X2_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F22	YAPC	REP.A013_YAPC_24H_X2_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F23	YAPC	REP.A013_YAPC_24H_X2_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X2_B22:F24	YAPC	REP.A013_YAPC_24H_X2_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F19	YAPC	REP.A013_YAPC_24H_X3_B22	F19	BRD-M39350793-334-01-1	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F20	YAPC	REP.A013_YAPC_24H_X3_B22	F20	BRD-M39350793-334-01-1	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F21	YAPC	REP.A013_YAPC_24H_X3_B22	F21	BRD-M39350793-334-01-1	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F22	YAPC	REP.A013_YAPC_24H_X3_B22	F22	BRD-M39350793-334-01-1	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F23	YAPC	REP.A013_YAPC_24H_X3_B22	F23	BRD-M39350793-334-01-1	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100065856	N06AX18	reboxetine	BRD-M39350793	1	7	REP.A013_YAPC_24H_X3_B22:F24	YAPC	REP.A013_YAPC_24H_X3_B22	F24	BRD-M39350793-334-01-1	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L01	YAPC	REP.A021_YAPC_24H_X1_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L02	YAPC	REP.A021_YAPC_24H_X1_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L03	YAPC	REP.A021_YAPC_24H_X1_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L04	YAPC	REP.A021_YAPC_24H_X1_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L05	YAPC	REP.A021_YAPC_24H_X1_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X1_B23:L06	YAPC	REP.A021_YAPC_24H_X1_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L01	YAPC	REP.A021_YAPC_24H_X2_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L02	YAPC	REP.A021_YAPC_24H_X2_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L03	YAPC	REP.A021_YAPC_24H_X2_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L04	YAPC	REP.A021_YAPC_24H_X2_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L05	YAPC	REP.A021_YAPC_24H_X2_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X2_B23:L06	YAPC	REP.A021_YAPC_24H_X2_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L01	YAPC	REP.A021_YAPC_24H_X3_B23	L01	BRD-K84698278-001-03-4	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L02	YAPC	REP.A021_YAPC_24H_X3_B23	L02	BRD-K84698278-001-03-4	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L03	YAPC	REP.A021_YAPC_24H_X3_B23	L03	BRD-K84698278-001-03-4	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L04	YAPC	REP.A021_YAPC_24H_X3_B23	L04	BRD-K84698278-001-03-4	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L05	YAPC	REP.A021_YAPC_24H_X3_B23	L05	BRD-K84698278-001-03-4	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100082148	N06AX22	agomelatine	BRD-K84698278	1	7	REP.A021_YAPC_24H_X3_B23:L06	YAPC	REP.A021_YAPC_24H_X3_B23	L06	BRD-K84698278-001-03-4	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N01	YAPC	REP.A026_YAPC_24H_X1_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N02	YAPC	REP.A026_YAPC_24H_X1_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N03	YAPC	REP.A026_YAPC_24H_X1_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N04	YAPC	REP.A026_YAPC_24H_X1_B25	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N05	YAPC	REP.A026_YAPC_24H_X1_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X1_B25:N06	YAPC	REP.A026_YAPC_24H_X1_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X2_B25:N01	YAPC	REP.A026_YAPC_24H_X2_B25	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X2_B25:N02	YAPC	REP.A026_YAPC_24H_X2_B25	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X2_B25:N03	YAPC	REP.A026_YAPC_24H_X2_B25	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X2_B25:N05	YAPC	REP.A026_YAPC_24H_X2_B25	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X2_B25:N06	YAPC	REP.A026_YAPC_24H_X2_B25	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N01	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N01	BRD-A98845662-036-03-7	10.0	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N02	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N02	BRD-A98845662-036-03-7	3.33333	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N03	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N03	BRD-A98845662-036-03-7	1.11111	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N04	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N04	BRD-A98845662-036-03-7	0.37037	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N05	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N05	BRD-A98845662-036-03-7	0.123457	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100125017	N06AX23	desvenlafaxine	BRD-A98845662	1	7	REP.A026_YAPC_24H_X3.L2_B27:N06	YAPC	REP.A026_YAPC_24H_X3.L2_B27	N06	BRD-A98845662-036-03-7	0.0411523	um	trt_cp	24.0	h	cell line	YAPC	-666	-666	tumor	pancreas	pancreatic carcinoma	adherent	-666	DSMZ	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N07	A549	LJP008_A549_24H_X1_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N08	A549	LJP008_A549_24H_X1_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N09	A549	LJP008_A549_24H_X1_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N10	A549	LJP008_A549_24H_X1_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N11	A549	LJP008_A549_24H_X1_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X1_F1B19:N12	A549	LJP008_A549_24H_X1_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N07	A549	LJP008_A549_24H_X2_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N08	A549	LJP008_A549_24H_X2_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N09	A549	LJP008_A549_24H_X2_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N10	A549	LJP008_A549_24H_X2_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N11	A549	LJP008_A549_24H_X2_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X2_F1B19:N12	A549	LJP008_A549_24H_X2_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N07	A549	LJP008_A549_24H_X3_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N08	A549	LJP008_A549_24H_X3_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N09	A549	LJP008_A549_24H_X3_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N10	A549	LJP008_A549_24H_X3_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N11	A549	LJP008_A549_24H_X3_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X3_F1B19:N12	A549	LJP008_A549_24H_X3_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N07	A549	LJP008_A549_24H_X4_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N08	A549	LJP008_A549_24H_X4_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N09	A549	LJP008_A549_24H_X4_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N10	A549	LJP008_A549_24H_X4_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N11	A549	LJP008_A549_24H_X4_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X4_F1B19:N12	A549	LJP008_A549_24H_X4_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N07	A549	LJP008_A549_24H_X5_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N08	A549	LJP008_A549_24H_X5_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N09	A549	LJP008_A549_24H_X5_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N10	A549	LJP008_A549_24H_X5_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N11	A549	LJP008_A549_24H_X5_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X5_F1B19:N12	A549	LJP008_A549_24H_X5_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N07	A549	LJP008_A549_24H_X6_F1B19	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N08	A549	LJP008_A549_24H_X6_F1B19	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N09	A549	LJP008_A549_24H_X6_F1B19	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N10	A549	LJP008_A549_24H_X6_F1B19	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N11	A549	LJP008_A549_24H_X6_F1B19	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_A549_24H_X6_F1B19:N12	A549	LJP008_A549_24H_X6_F1B19	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	A549	-666	-666	tumor	lung	non small cell lung cancer| carcinoma	adherent	CCL-185	ATCC	58	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N07	ASC.C	LJP008_ASC.C_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N08	ASC.C	LJP008_ASC.C_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N09	ASC.C	LJP008_ASC.C_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N10	ASC.C	LJP008_ASC.C_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N11	ASC.C	LJP008_ASC.C_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X1_B21:N12	ASC.C	LJP008_ASC.C_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N07	ASC.C	LJP008_ASC.C_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N08	ASC.C	LJP008_ASC.C_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N09	ASC.C	LJP008_ASC.C_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N10	ASC.C	LJP008_ASC.C_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N11	ASC.C	LJP008_ASC.C_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X2_B21:N12	ASC.C	LJP008_ASC.C_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N07	ASC.C	LJP008_ASC.C_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N08	ASC.C	LJP008_ASC.C_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N09	ASC.C	LJP008_ASC.C_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N10	ASC.C	LJP008_ASC.C_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N11	ASC.C	LJP008_ASC.C_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC.C_24H_X3_B21:N12	ASC.C	LJP008_ASC.C_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	HPA-v	Sciencell	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N07	CD34	LJP008_CD34_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N08	CD34	LJP008_CD34_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N09	CD34	LJP008_CD34_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N10	CD34	LJP008_CD34_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N11	CD34	LJP008_CD34_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X1_B21:N12	CD34	LJP008_CD34_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N07	CD34	LJP008_CD34_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N08	CD34	LJP008_CD34_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N09	CD34	LJP008_CD34_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N10	CD34	LJP008_CD34_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N11	CD34	LJP008_CD34_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X2_B21:N12	CD34	LJP008_CD34_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N07	CD34	LJP008_CD34_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N08	CD34	LJP008_CD34_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N09	CD34	LJP008_CD34_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N10	CD34	LJP008_CD34_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N11	CD34	LJP008_CD34_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_CD34_24H_X3_B21:N12	CD34	LJP008_CD34_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	CD34	-666	-666	normal	bone	bone marrow	suspension	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N07	HCC515	LJP008_HCC515_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N08	HCC515	LJP008_HCC515_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N09	HCC515	LJP008_HCC515_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N10	HCC515	LJP008_HCC515_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N11	HCC515	LJP008_HCC515_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X1_B20:N12	HCC515	LJP008_HCC515_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N07	HCC515	LJP008_HCC515_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N08	HCC515	LJP008_HCC515_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N09	HCC515	LJP008_HCC515_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N10	HCC515	LJP008_HCC515_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N11	HCC515	LJP008_HCC515_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X2_B20:N12	HCC515	LJP008_HCC515_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N07	HCC515	LJP008_HCC515_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N08	HCC515	LJP008_HCC515_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N09	HCC515	LJP008_HCC515_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N10	HCC515	LJP008_HCC515_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N11	HCC515	LJP008_HCC515_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HCC515_24H_X3_B20:N12	HCC515	LJP008_HCC515_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HCC515	-666	-666	normal	lung	carcinoma	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N07	HEPG2	LJP008_HEPG2_24H_X1_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N08	HEPG2	LJP008_HEPG2_24H_X1_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N09	HEPG2	LJP008_HEPG2_24H_X1_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N10	HEPG2	LJP008_HEPG2_24H_X1_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N11	HEPG2	LJP008_HEPG2_24H_X1_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X1_B20:N12	HEPG2	LJP008_HEPG2_24H_X1_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N07	HEPG2	LJP008_HEPG2_24H_X2_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N08	HEPG2	LJP008_HEPG2_24H_X2_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N09	HEPG2	LJP008_HEPG2_24H_X2_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N10	HEPG2	LJP008_HEPG2_24H_X2_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N11	HEPG2	LJP008_HEPG2_24H_X2_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X2_B20:N12	HEPG2	LJP008_HEPG2_24H_X2_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N07	HEPG2	LJP008_HEPG2_24H_X3_B20	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N08	HEPG2	LJP008_HEPG2_24H_X3_B20	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N09	HEPG2	LJP008_HEPG2_24H_X3_B20	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N10	HEPG2	LJP008_HEPG2_24H_X3_B20	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N11	HEPG2	LJP008_HEPG2_24H_X3_B20	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HEPG2_24H_X3_B20:N12	HEPG2	LJP008_HEPG2_24H_X3_B20	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HEPG2	-666	-666	tumor	liver	hepatocellular carcinoma	adherent	HB-8065	ATCC	15	M	Caucasian
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N07	HME1	LJP008_HME1_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N08	HME1	LJP008_HME1_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N09	HME1	LJP008_HME1_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N10	HME1	LJP008_HME1_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N11	HME1	LJP008_HME1_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X1_B21:N12	HME1	LJP008_HME1_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N07	HME1	LJP008_HME1_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N08	HME1	LJP008_HME1_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N09	HME1	LJP008_HME1_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N10	HME1	LJP008_HME1_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N11	HME1	LJP008_HME1_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X2_B21:N12	HME1	LJP008_HME1_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N07	HME1	LJP008_HME1_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N08	HME1	LJP008_HME1_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N09	HME1	LJP008_HME1_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N10	HME1	LJP008_HME1_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N11	HME1	LJP008_HME1_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HME1_24H_X3_B21:N12	HME1	LJP008_HME1_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HME1	-666	immortalized normal	normal	breast	-666	adherent	CRL-4010	-666	-666	M	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N07	HUVEC	LJP008_HUVEC_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N08	HUVEC	LJP008_HUVEC_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N09	HUVEC	LJP008_HUVEC_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N10	HUVEC	LJP008_HUVEC_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N11	HUVEC	LJP008_HUVEC_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X1_B21:N12	HUVEC	LJP008_HUVEC_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N07	HUVEC	LJP008_HUVEC_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N08	HUVEC	LJP008_HUVEC_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N09	HUVEC	LJP008_HUVEC_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N10	HUVEC	LJP008_HUVEC_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N11	HUVEC	LJP008_HUVEC_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X2_B21:N12	HUVEC	LJP008_HUVEC_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N07	HUVEC	LJP008_HUVEC_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N08	HUVEC	LJP008_HUVEC_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N09	HUVEC	LJP008_HUVEC_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N10	HUVEC	LJP008_HUVEC_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N11	HUVEC	LJP008_HUVEC_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_HUVEC_24H_X3_B21:N12	HUVEC	LJP008_HUVEC_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	cell line	HUVEC	-666	immortalized normal	normal	vascular system	normal endothelial cell|umbilical cord	adherent	IFO50271	JCRB	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N07	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N08	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N09	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N10	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N11	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X1_B21:N12	NPC.TAK	LJP008_NPC.TAK_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N07	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N08	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N09	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N10	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N11	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X2_B21:N12	NPC.TAK	LJP008_NPC.TAK_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N07	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N08	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N09	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N10	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N11	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.TAK_24H_X3_B21:N12	NPC.TAK	LJP008_NPC.TAK_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N07	SKL.C	LJP008_SKL.C_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N08	SKL.C	LJP008_SKL.C_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N09	SKL.C	LJP008_SKL.C_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N10	SKL.C	LJP008_SKL.C_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N11	SKL.C	LJP008_SKL.C_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X2_B21:N12	SKL.C	LJP008_SKL.C_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N07	SKL.C	LJP008_SKL.C_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N08	SKL.C	LJP008_SKL.C_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N09	SKL.C	LJP008_SKL.C_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N10	SKL.C	LJP008_SKL.C_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N11	SKL.C	LJP008_SKL.C_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X3_B21:N12	SKL.C	LJP008_SKL.C_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N07	SKL.C	LJP008_SKL.C_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N08	SKL.C	LJP008_SKL.C_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N09	SKL.C	LJP008_SKL.C_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N10	SKL.C	LJP008_SKL.C_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N11	SKL.C	LJP008_SKL.C_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL.C_24H_X1_B21:N12	SKL.C	LJP008_SKL.C_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N07	ASC	LJP008_ASC_24H_X1.A2_B22	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N08	ASC	LJP008_ASC_24H_X1.A2_B22	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N09	ASC	LJP008_ASC_24H_X1.A2_B22	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N10	ASC	LJP008_ASC_24H_X1.A2_B22	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N11	ASC	LJP008_ASC_24H_X1.A2_B22	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X1.A2_B22:N12	ASC	LJP008_ASC_24H_X1.A2_B22	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N07	ASC	LJP008_ASC_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N08	ASC	LJP008_ASC_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N09	ASC	LJP008_ASC_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N10	ASC	LJP008_ASC_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N11	ASC	LJP008_ASC_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X2_B21:N12	ASC	LJP008_ASC_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N07	ASC	LJP008_ASC_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N08	ASC	LJP008_ASC_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N09	ASC	LJP008_ASC_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N10	ASC	LJP008_ASC_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N11	ASC	LJP008_ASC_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_ASC_24H_X3_B21:N12	ASC	LJP008_ASC_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	ASC	-666	-666	primary	adipose	normal primary adipocyte stem cells	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N07	NEU	LJP008_NEU_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N08	NEU	LJP008_NEU_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N09	NEU	LJP008_NEU_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N10	NEU	LJP008_NEU_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N11	NEU	LJP008_NEU_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X1_B21:N12	NEU	LJP008_NEU_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N07	NEU	LJP008_NEU_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N08	NEU	LJP008_NEU_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N09	NEU	LJP008_NEU_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N10	NEU	LJP008_NEU_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N11	NEU	LJP008_NEU_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X2_B21:N12	NEU	LJP008_NEU_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N07	NEU	LJP008_NEU_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N08	NEU	LJP008_NEU_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N09	NEU	LJP008_NEU_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N10	NEU	LJP008_NEU_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N11	NEU	LJP008_NEU_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NEU_24H_X3_B21:N12	NEU	LJP008_NEU_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NEU	-666	terminally differentiated to be neurons	normal	-666	-666	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N07	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N08	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N09	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N10	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N11	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X1_B21:N12	NPC.CAS9	LJP008_NPC.CAS9_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N07	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N08	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N09	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N10	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N11	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X2_B21:N12	NPC.CAS9	LJP008_NPC.CAS9_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N07	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N08	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N09	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N10	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N11	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC.CAS9_24H_X3_B21:N12	NPC.CAS9	LJP008_NPC.CAS9_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	NPC	NPC that were genetically modified to stably express Cas9 protein	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N07	NPC	LJP008_NPC_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N08	NPC	LJP008_NPC_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N09	NPC	LJP008_NPC_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N10	NPC	LJP008_NPC_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N11	NPC	LJP008_NPC_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X1_B21:N12	NPC	LJP008_NPC_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N07	NPC	LJP008_NPC_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N08	NPC	LJP008_NPC_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N09	NPC	LJP008_NPC_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N10	NPC	LJP008_NPC_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N11	NPC	LJP008_NPC_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X2_B21:N12	NPC	LJP008_NPC_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N07	NPC	LJP008_NPC_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N08	NPC	LJP008_NPC_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N09	NPC	LJP008_NPC_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N10	NPC	LJP008_NPC_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N11	NPC	LJP008_NPC_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_NPC_24H_X3_B21:N12	NPC	LJP008_NPC_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	differentiated	NPC	-666	differentiated from iPSC, but not terminally differentiated	primary	central nervous system	normal stem fibroblast-derived iPScs	adherent	-666	-666	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N07	SKL	LJP008_SKL_24H_X1_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N08	SKL	LJP008_SKL_24H_X1_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N09	SKL	LJP008_SKL_24H_X1_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N10	SKL	LJP008_SKL_24H_X1_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N11	SKL	LJP008_SKL_24H_X1_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X1_B21:N12	SKL	LJP008_SKL_24H_X1_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N07	SKL	LJP008_SKL_24H_X2_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N08	SKL	LJP008_SKL_24H_X2_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N09	SKL	LJP008_SKL_24H_X2_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N10	SKL	LJP008_SKL_24H_X2_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N11	SKL	LJP008_SKL_24H_X2_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X2_B21:N12	SKL	LJP008_SKL_24H_X2_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N07	SKL	LJP008_SKL_24H_X3_B21	N07	BRD-K47029922-003-09-1	10.0	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N08	SKL	LJP008_SKL_24H_X3_B21	N08	BRD-K47029922-003-09-1	3.33	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N09	SKL	LJP008_SKL_24H_X3_B21	N09	BRD-K47029922-003-09-1	1.11	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N10	SKL	LJP008_SKL_24H_X3_B21	N10	BRD-K47029922-003-09-1	0.37	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N11	SKL	LJP008_SKL_24H_X3_B21	N11	BRD-K47029922-003-09-1	0.12	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
CID100005530	N06AF04	tranylcypromine	BRD-K47029922	1	19	LJP008_SKL_24H_X3_B21:N12	SKL	LJP008_SKL_24H_X3_B21	N12	BRD-K47029922-003-09-1	0.04	um	trt_cp	24.0	h	primary	SKL	-666	-666	primary	muscle	normal primary skeletal muscle cells	adherent	CC-2561	LONZA	-666	-666	-666
